(	O
5	O
-	O
TTTGAATTCAGATCCCCCTATGCAAGG	O
-	O
3	O
-	O
TTTAAGCTTTAACTGTCGACTTCGCGCG	O
-	O
3	O
'')	O
and	O
gltBR	O
(	O
5	O
''-	O
TTTGGATCCTGATGCCGTCATTTTGTGC	O
-	O
3	O
'	O
15	O
1767	O
).	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
conflicts	O
interest	O
with	O
the	O
contents	O
this	O
article	O
.	O
The	O
atomic	O
coordinates	O
and	O
structure	O
factors	O
(	O
code	O
5LQD	O
)	O
have	O
been	O
deposited	O
in	O
the	O
Protein	O
Data	O
Bank	O
(	O
http	O
://	O
wwpdb	O
.	O
/).	O
M	O
.	O
J	O
.	O
Bibb	O
and	O
M	O
.	O
J	O
.	O
Buttner	O
unpublished	O
data	O
.	O
PDB	O
Protein	O
Data	O
Bank	O
IPTG	B-Chemical
isopropyl	B-Chemical
?ý	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
thiogalactopyranoside	I-Chemical
.	O
The	O
abbreviations	O
used	O
are	O
:	O
References	O
LC	O
-	O
MS	O
/	O
MS	O
Analysis	O
Unravels	O
Deep	O
Manganese	O
Superoxide	O
Dismutase	O
in	O
Kidney	O
Cancer	O
Manganese	O
superoxide	O
dismutase	O
(	O
MNSOD	O
)	O
is	O
the	O
major	O
scavengers	O
reactive	B-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
in	O
mitochondria	O
with	O
pivotal	O
regulatory	O
role	O
in	O
ischemic	O
disorders	O
inflammation	O
and	O
cancer	O
.	O
Here	O
we	O
report	O
modification	O
MNSOD	O
in	O
human	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
by	O
the	O
shotgun	O
method	O
using	O
data	O
-	O
dependent	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
).	O
While	O
5816	O
and	O
5571	O
proteins	O
were	O
identified	O
in	O
cancer	O
and	O
adjacent	O
tissues	O
respectively	O
208	O
proteins	O
were	O
found	O
to	O
be	O
up	O
-	O
down	O
-	O
regulated	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O
category	O
interaction	O
network	O
and	O
Western	O
blotting	O
suggested	O
a	O
close	O
correlation	O
between	O
RCC	O
-	O
mediated	O
proteins	O
and	O
such	O
as	O
MNSOD	O
.	O
Markedly	O
modifications	O
MNSOD	O
were	O
identified	O
at	O
histidine	B-Chemical
(	O
H54	O
and	O
H55	O
)	O
tyrosine	B-Chemical
(	O
Y58	O
)	O
tryptophan	B-Chemical
(	O
W147	O
W149	O
W205	O
and	O
W210	O
)	O
and	O
asparagine	B-Chemical
(	O
N206	O
and	O
N209	O
)	O
residues	O
additional	O
to	O
methionine	B-Chemical
.	O
These	O
insults	O
were	O
located	O
at	O
three	O
hotspots	O
near	O
the	O
hydrophobic	O
pocket	O
the	O
manganese	B-Chemical
binding	O
site	O
which	O
the	O
Y58	O
W147	O
and	O
W149	O
was	O
up	O
-	O
regulated	O
around	O
three	O
folds	O
and	O
the	O
H54	O
and	O
H55	O
was	O
detected	O
in	O
the	O
cancer	O
tissues	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O
When	O
normalized	O
to	O
MNSOD	O
expression	O
levels	O
relative	O
MNSOD	O
enzymatic	O
activity	O
was	O
decreased	O
in	O
cancer	O
tissues	O
suggesting	O
impairment	O
MNSOD	O
enzymatic	O
activity	O
in	O
kidney	O
cancer	O
due	O
to	O
modifications	O
.	O
Thus	O
LC	O
-	O
MS	O
/	O
MS	O
analysis	O
revealed	O
multiple	O
modifications	O
MNSOD	O
at	O
different	O
amino	B-Chemical
acid	I-Chemical
residues	O
that	O
might	O
mediate	O
the	O
regulation	O
the	O
superoxide	B-Chemical
radicals	O
mitochondrial	O
ROS	B-Chemical
scavenging	O
and	O
MNSOD	O
activity	O
in	O
kidney	O
cancer	O
.	O
1	O
.	O
Introduction	O
Superoxide	O
dismutases	O
(	O
SODs	O
)	O
are	O
the	O
ubiquitous	O
superfamily	O
antioxidant	O
metalloenzymes	O
that	O
convert	O
the	O
superoxide	B-Chemical
anion	I-Chemical
(	O
ƒ??)	I-Chemical
into	O
and	O
hydrogen	B-Chemical
peroxide	I-Chemical
(	O
H2O2	B-Chemical
)	O
when	O
cells	O
are	O
exposed	O
to	O
.	O
These	O
enzymes	O
are	O
the	O
major	O
scavengers	O
reactive	B-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
the	O
natural	O
side	O
products	O
during	O
the	O
process	O
aerobic	O
cells	O
respiration	O
in	O
physiological	O
and	O
pathological	O
conditions	O
[	O
1	O
].	O
Three	O
forms	O
superoxide	O
dismutases	O
namely	O
Cu	O
/	O
ZnSOD	O
(	O
SOD1	O
/	O
3	O
in	O
humans	O
)	O
Fe	O
/	O
MNSOD	O
(	O
also	O
called	O
MNSOD	O
SOD2	O
in	O
humans	O
)	O
and	O
NiSOD	O
(	O
found	O
in	O
bacteria	O
)	O
are	O
identified	O
[	O
2	O
].	O
Among	O
them	O
MNSOD	O
is	O
the	O
primary	O
mitochondrial	O
ROS	B-Chemical
scavenging	O
enzyme	O
that	O
catalyzes	O
the	O
conversion	O
superoxide	B-Chemical
to	O
H2O2	B-Chemical
which	O
is	O
subsequently	O
transformed	O
to	O
water	B-Chemical
by	O
catalase	O
and	O
peroxidases	O
[	O
1	O
3	O
].	O
MNSOD	O
is	O
essential	O
for	O
the	O
survival	O
all	O
aerobic	O
from	O
bacteria	O
to	O
humans	O
under	O
physiological	O
conditions	O
[	O
1	O
4	O
].	O
Posttranslational	O
modifications	O
(	O
PTMs	O
)	O
play	O
a	O
major	O
role	O
in	O
regulating	O
MNSOD	O
activities	O
interactions	O
and	O
localization	O
[	O
1	O
].	O
Protein	O
modification	O
a	O
major	O
class	O
PTM	O
is	O
caused	O
by	O
nitrative	O
disruption	O
amino	B-Chemical
acid	I-Chemical
residues	O
.	O
protein	O
modification	O
has	O
been	O
described	O
during	O
aging	O
and	O
various	O
pathological	O
conditions	O
and	O
serves	O
as	O
a	O
useful	O
biomarker	O
for	O
assessing	O
stress	O
processes	O
in	O
aging	O
and	O
disease	O
conditions	O
[	O
4	O
].	O
Protein	O
can	O
lead	O
to	O
hydroxylation	O
aromatic	O
groups	O
and	O
aliphatic	O
amino	B-Chemical
acid	I-Chemical
side	O
chains	O
nitration	O
aromatic	B-Chemical
amino	I-Chemical
acid	I-Chemical
residues	O
sulfoxidation	O
methionine	B-Chemical
residues	O
[	O
5	O
].	O
Some	O
specific	O
enzymes	O
such	O
as	O
tyrosine	O
hydroxylase	O
(	O
TH	O
)	O
facilitate	O
the	O
process	O
in	O
vivo	O
[	O
6	O
].	O
Aromatic	B-Chemical
amino	I-Chemical
acid	I-Chemical
side	O
chains	O
such	O
as	O
tyrosine	B-Chemical
(	O
Tyr	B-Chemical
Y	O
)	O
and	O
tryptophan	B-Chemical
(	O
Trp	B-Chemical
W	O
)	O
are	O
more	O
susceptible	O
to	O
free	O
radical	O
incursion	O
leading	O
to	O
specific	O
modification	O
the	O
aromatic	O
ring	O
.	O
For	O
example	O
tyrosine	B-Chemical
(	O
Tyr	B-Chemical
)	O
yields	O
greater	O
3	 B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylalanine	I-Chemical
(	I-Chemical
DOPA	I-Chemical
)	I-Chemical
and	I-Chemical
less	I-Chemical
2	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
isomer	I-Chemical
[	O
7	O
].	O
Protein	O
can	O
lead	O
to	O
diverse	O
functional	O
consequences	O
such	O
as	O
loss	O
enzymatic	O
and	O
binding	O
activities	O
increased	O
susceptibility	O
to	O
aggregation	O
proteolysis	O
and	O
altered	O
immunogenicity	O
[	O
8	O
].	O
it	O
is	O
believed	O
that	O
protein	O
is	O
central	O
to	O
functional	O
deficit	O
the	O
target	O
proteins	O
[	O
9	O
].	O
In	O
addition	O
to	O
direct	O
damage	O
cells	O
could	O
undergo	O
nitrative	O
damage	O
through	O
reactive	B-Chemical
nitrogen	I-Chemical
species	I-Chemical
(	O
RNS	B-Chemical
)	O
pathway	O
which	O
with	O
the	O
redox	O
-	O
sensitive	O
amino	B-Chemical
acid	I-Chemical
residues	O
including	O
tyrosine	B-Chemical
and	O
tryptophan	B-Chemical
[	O
10	O
].	O
Nitration	O
tyrosine	B-Chemical
58	O
(	O
Y58	O
Y34	O
when	O
the	O
24	O
amino	B-Chemical
acids	I-Chemical
transit	O
peptide	O
is	O
cleaved	O
)	O
MNSOD	O
has	O
been	O
detected	O
by	O
crystal	O
structures	O
and	O
mutation	O
analysis	O
[	O
1	O
11	O
].	O
Previous	O
data	O
showed	O
that	O
human	O
MNSOD	O
Y58	O
was	O
exclusively	O
nitrated	O
to	O
3	B-Chemical
-	I-Chemical
nitrotyrosine	I-Chemical
(	O
3	B-Chemical
-	I-Chemical
NT	I-Chemical
)	O
to	O
inactivate	O
its	O
enzymatic	O
activity	O
and	O
nitration	O
Y58	O
alone	O
was	O
sufficient	O
for	O
inactivation	O
MNSOD	O
enzymatic	O
activity	O
[	O
1	O
].	O
Similar	O
to	O
nitration	O
acetylation	O
MNSOD	O
was	O
shown	O
to	O
impair	O
its	O
enzymatic	O
activity	O
.	O
Recent	O
evidence	O
suggests	O
the	O
presence	O
multiple	O
MNSOD	O
acetylation	O
sites	O
lysine	B-Chemical
(	O
Lys	B-Chemical
K	O
)	O
such	O
as	O
53	O
68	O
89	O
122	O
130	O
[	O
12	O
].	O
It	O
was	O
also	O
shown	O
that	O
SIRT3	O
could	O
deacetylate	O
MNSOD	O
and	O
enhance	O
its	O
enzymatic	O
activity	O
in	O
vitro	O
[	O
1	O
3	O
13	O
].	O
stress	O
in	O
mitochondria	O
becomes	O
a	O
major	O
source	O
ROS	B-Chemical
.	O
Free	O
radicals	O
from	O
mitochondria	O
interact	O
with	O
surrounding	O
molecules	O
and	O
initiate	O
a	O
cascade	O
signaling	O
pathways	O
leading	O
to	O
modifications	O
cellular	O
.	O
modifications	O
within	O
mitochondrial	O
proteins	O
may	O
contribute	O
to	O
the	O
development	O
carcinogenesis	O
[	O
14	O
].	O
The	O
precise	O
mechanisms	O
by	O
which	O
and	O
nitrative	O
conditions	O
affect	O
MNSOD	O
structure	O
and	O
function	O
remain	O
unclear	O
.	O
While	O
MNSOD	O
is	O
reportedly	O
up	O
-	O
regulated	O
in	O
kidney	O
cancer	O
[	O
15	O
16	O
]	O
its	O
enzymatic	O
activity	O
in	O
tumor	O
areas	O
is	O
similar	O
to	O
adjacent	O
kidney	O
tissues	O
[	O
16	O
17	O
]	O
suggesting	O
that	O
MNSOD	O
enzymatic	O
activity	O
does	O
not	O
necessarily	O
correlate	O
with	O
its	O
protein	O
expression	O
.	O
It	O
was	O
recently	O
shown	O
that	O
stress	O
-	O
mediated	O
MNSOD	O
modifications	O
compromised	O
its	O
enzymatic	O
activity	O
and	O
led	O
to	O
functional	O
deficit	O
[	O
1	O
3	O
18	O
19	O
].	O
In	O
this	O
study	O
we	O
first	O
pinpointed	O
MNSOD	O
as	O
a	O
vital	O
protein	O
in	O
the	O
kidney	O
tissues	O
from	O
clear	O
cell	O
renal	O
cell	O
carcinoma	O
(	O
ccRCC	O
)	O
using	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
)	O
then	O
attempted	O
to	O
identify	O
and	O
quantify	O
crucial	O
sites	O
modifications	O
MNSOD	O
using	O
high	O
resolution	O
LC	O
-	O
MS	O
/	O
MS	O
and	O
Progenesis	O
LC	O
-	O
MS	O
software	O
respectively	O
.	O
The	O
newly	O
identified	O
(	O
to	O
the	O
best	O
knowledge	O
)	O
sites	O
we	O
report	O
may	O
introduce	O
novel	O
perspectives	O
for	O
the	O
refinement	O
MNSOD	O
regulatory	O
mechanisms	O
.	O
Characterization	O
MNSOD	O
modifications	O
may	O
be	O
vital	O
for	O
interpretation	O
previous	O
studies	O
MNSOD	O
in	O
tumor	O
biology	O
and	O
could	O
enhance	O
intervening	O
ability	O
in	O
tumorigenesis	O
.	O
2	O
.	O
Results	O
2	O
.	O
1	O
.	O
Quantitative	O
Proteomic	O
Analysis	O
Suggests	O
the	O
Involvement	O
Anti	O
-	O
Stress	O
Pathway	O
in	O
ccRCC	O
Three	O
pairs	O
tumor	O
and	O
adjacent	O
tissues	O
from	O
ccRCC	O
patients	O
were	O
analyzed	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
.	O
Totally	O
5571	O
and	O
5816	O
non	O
-	O
redundant	O
proteins	O
with	O
FDR	O
<	O
0	O
.	O
1	O
were	O
identified	O
in	O
adjacent	O
and	O
ccRCC	O
tissues	O
respectively	O
(	O
Table	O
S1	O
).	O
Among	O
the	O
identified	O
proteins	O
the	O
average	O
spectral	O
counts	O
three	O
repeats	O
were	O
used	O
to	O
evaluate	O
their	O
expression	O
levels	O
which	O
revealed	O
100	O
up	O
-	O
and	O
108	O
down	O
-	O
regulated	O
proteins	O
for	O
at	O
least	O
1	O
.	O
4	O
folds	O
in	O
ccRCC	O
vs	O
.	O
adjacent	O
tissues	O
with	O
the	O
criteria	O
p	O
<	O
0	O
.	O
5	O
detected	O
in	O
every	O
replicate	O
and	O
the	O
average	O
spectral	O
counts	O
>	O
20	O
(	O
Table	O
S2	O
).	O
According	O
to	O
Database	O
for	O
Annotation	O
Visualization	O
and	O
Integrated	O
Discovery	O
(	O
DAVID	O
)	O
functional	O
annotation	O
33	O
the	O
208	O
dysregulated	O
proteins	O
were	O
related	O
to	O
-	O
reductases	O
(	O
p	O
=	O
2	O
.	O
87	O
??	O
10	O
ƒ??	O
18	O
)	O
(	O
Tables	O
S3	O
and	O
S4	O
).	O
Heatmap	O
analysis	O
(	O
Figure	O
1a	O
)	O
denoted	O
the	O
involvement	O
these	O
in	O
binding	O
with	O
cofactors	O
coenzyme	O
NAD	B-Chemical
NADH	B-Chemical
and	O
/	O
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
).	I-Chemical
Notably	O
MNSOD	O
was	O
among	O
these	O
suggesting	O
that	O
mitochondrial	O
MNSOD	O
was	O
also	O
involved	O
in	O
the	O
electron	O
transport	O
chain	O
for	O
ROS	B-Chemical
removal	O
.	O
Consistent	O
with	O
these	O
category	O
based	O
biological	O
process	O
using	O
Search	O
Tool	O
for	O
the	O
Retrieval	O
Interacting	O
Genes	O
/	O
Proteins	O
(	O
STRING	O
)	O
(	O
Table	O
S5	O
)	O
indicated	O
that	O
the	O
most	O
significant	O
categories	O
was	O
-	O
reduction	O
process	O
(	O
37	O
proteins	O
p	O
=	O
6	O
.	O
49	O
??	O
10	O
ƒ??	O
17	O
)	O
(	O
Table	O
S6	O
).	O
Three	O
main	O
interactive	O
clusters	O
were	O
formed	O
among	O
the	O
37	O
interacting	O
proteins	O
with	O
MNSOD	O
as	O
an	O
important	O
node	O
(	O
Figure	O
1b	O
).	O
Because	O
cancer	O
cells	O
usually	O
demand	O
high	O
ROS	B-Chemical
concentrations	O
to	O
maintain	O
their	O
high	O
proliferation	O
rate	O
[	O
14	O
]	O
these	O
data	O
suggested	O
that	O
-	O
reductases	O
particularly	O
MNSOD	O
played	O
an	O
important	O
role	O
in	O
RCC	O
pathogenesis	O
[	O
16	O
].	O
2	O
.	O
2	O
.	O
Modification	O
MNSOD	O
For	O
a	O
deep	O
post	O
-	O
translational	O
modification	O
analysis	O
MNSOD	O
was	O
excised	O
from	O
SDS	B-Chemical
-	O
PAGE	O
(	O
Figure	O
2a	O
)	O
and	O
analyzed	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
.	O
With	O
a	O
standard	O
search	O
using	O
MASCOT	O
and	O
SEQUEST	O
18	O
high	O
confident	O
peptides	O
MNSOD	O
were	O
identified	O
which	O
covered	O
76	O
%	O
the	O
sequence	O
(	O
Figure	O
2b	O
).	O
Next	O
the	O
MS	O
/	O
MS	O
data	O
were	O
searched	O
again	O
with	O
an	O
modification	O
search	O
algorithm	O
[	O
20	O
]	O
to	O
identify	O
the	O
peptides	O
MNSOD	O
containing	O
at	O
any	O
possible	O
amino	B-Chemical
acids	I-Chemical
with	O
a	O
delta	O
mass	O
+	O
16	O
Da	O
(	O
Table	O
1	O
).	O
Totally	O
168	O
+	O
16	O
modification	O
events	O
were	O
counted	O
81	O
which	O
at	O
tryptophan	B-Chemical
(	O
W	O
)	O
27	O
at	O
glycine	B-Chemical
(	O
G	O
)	O
24	O
at	O
tyrosine	B-Chemical
(	O
Y	O
)	O
14	O
at	O
histidine	B-Chemical
(	O
H	O
)	O
13	O
at	O
asparagine	B-Chemical
(	O
N	O
)	O
7	O
at	O
alanine	B-Chemical
(	O
A	O
)	O
and	O
2	O
at	O
valine	B-Chemical
(	O
V	O
).	O
To	O
confirm	O
whether	O
these	O
+	O
16	O
modifications	O
were	O
due	O
to	O
restricted	O
search	O
with	O
dynamic	O
(+	O
15	O
.	O
995	O
Da	O
)	O
was	O
performed	O
using	O
MASCOT	O
and	O
SEQUEST	O
.	O
High	O
confident	O
modifications	O
were	O
confirmed	O
at	O
tryptophan	B-Chemical
(	O
W	O
)	O
tyrosine	B-Chemical
(	O
Y	O
)	O
histidine	B-Chemical
(	O
H	O
)	O
and	O
asparagine	B-Chemical
(	O
N	O
)	O
residues	O
MNSOD	O
(	O
Table	O
2	O
).	O
Markedly	O
these	O
sites	O
were	O
located	O
in	O
three	O
hotspots	O
including	O
hotspot	O
1	O
(	O
H54	O
H55	O
Y58	O
)	O
hotspot	O
2	O
(	O
W147	O
W149	O
)	O
and	O
hotspot	O
3	O
(	O
W205	O
N206	O
N209	O
W210	O
).	O
Additionally	O
the	O
known	O
nitration	O
(+	O
44	O
.	O
985	O
Da	O
)	O
at	O
tyrosine	B-Chemical
(	O
Y58	O
)	O
was	O
also	O
identified	O
in	O
the	O
kidney	O
tissues	O
(	O
Table	O
2	O
).	O
2	O
.	O
3	O
.	O
Tryptophan	B-Chemical
at	O
W147	O
/	O
W149	O
and	O
W205	O
/	O
W210	O
MNSOD	O
half	O
the	O
events	O
MNSOD	O
at	O
tryptophan	B-Chemical
.	O
Four	O
potentially	O
sites	O
W147	O
/	O
W149	O
and	O
W205	O
/	O
W210	O
were	O
identified	O
in	O
two	O
hotspots	O
near	O
the	O
C	O
-	O
terminus	O
.	O
In	O
the	O
hotspot	O
around	O
the	O
residues	O
from	O
200	O
to	O
212	O
(	O
hotspot	O
3	O
)	O
two	O
the	O
tryptophan	B-Chemical
residues	O
were	O
found	O
in	O
the	O
peptide	O
AIW205NVINW210ENVTER	O
.	O
The	O
W210	O
(	O
Figure	O
S1a	O
)	O
was	O
identified	O
by	O
the	O
unmodified	O
b4	O
ƒ??	O
7	O
ions	O
and	O
the	O
mass	O
shift	O
the	O
b8	O
ƒ??	O
13	O
ions	O
supported	O
by	O
the	O
unmodified	O
y2	O
ƒ??	O
6	O
and	O
the	O
modified	O
y7	O
ƒ??	O
12	O
ions	O
which	O
has	O
been	O
reported	O
before	O
[	O
21	O
].	O
Similarly	O
at	O
W205	O
(	O
Figure	O
S1b	O
)	O
was	O
identified	O
by	O
the	O
unmodified	O
y3	O
ƒ??	O
9	O
11	O
ions	O
followed	O
by	O
the	O
modified	O
y12	O
ion	O
;	O
it	O
was	O
supported	O
by	O
the	O
shifted	O
b5	O
7	O
ƒ??	O
8	O
10	O
ƒ??	O
11	O
ions	O
.	O
The	O
tryptophan	B-Chemical
residues	O
were	O
found	O
in	O
the	O
peptide	O
LTAASVGVQGSGW147GW149LGFNK	O
in	O
hotspot	O
2	O
.	O
The	O
tryptophan	B-Chemical
at	O
W147	O
(	O
Figure	O
S1c	O
)	O
was	O
uncovered	O
by	O
the	O
unmodified	O
y4	O
ƒ??	O
5	O
7	O
and	O
modified	O
y8	O
ƒ??	O
12	O
14	O
ions	O
which	O
was	O
supported	O
by	O
the	O
unmodified	O
b6	O
8	O
ƒ??	O
9	O
11	O
and	O
modified	O
b16	O
19	O
ions	O
.	O
Double	O
at	O
W147	O
and	O
W149	O
in	O
a	O
different	O
MS	O
/	O
MS	O
profile	O
the	O
same	O
peptide	O
(	O
Figure	O
S1d	O
)	O
was	O
identified	O
by	O
the	O
unmodified	O
b6	O
8	O
ƒ??	O
9	O
11	O
ions	O
and	O
double	O
mass	O
shifts	O
15	O
.	O
99	O
Da	O
in	O
the	O
b15	O
ƒ??	O
19	O
ions	O
.	O
Markedly	O
these	O
identified	O
tryptophan	B-Chemical
at	O
W147	O
W149	O
W205	O
and	O
W210	O
were	O
located	O
in	O
the	O
hotspots	O
that	O
were	O
reported	O
to	O
be	O
important	O
for	O
the	O
enzymatic	O
activity	O
MNSOD	O
[	O
2	O
].	O
Notably	O
tryptophan	O
hydroxylase	O
(	O
TPH	O
)	O
a	O
well	O
characterized	O
enzyme	O
in	O
mammals	O
was	O
shown	O
to	O
convert	O
tryptophan	B-Chemical
to	O
5	B-Chemical
-	I-Chemical
hydroxytryptophan	I-Chemical
the	O
precursor	O
for	O
the	O
neurotransmitter	O
serotonin	B-Chemical
and	O
melatonin	B-Chemical
[	O
22	O
]	O
although	O
it	O
was	O
unclear	O
whether	O
TPH	O
was	O
involved	O
in	O
tryptophan	B-Chemical
in	O
proteins	O
.	O
2	O
.	O
4	O
.	O
Asparagine	B-Chemical
at	O
N206	O
and	O
N209	O
MNSOD	O
The	O
asparagine	B-Chemical
residue	O
in	O
proteins	O
might	O
be	O
to	O
form	O
beta	B-Chemical
-	I-Chemical
hydroxyl	I-Chemical
asparagine	I-Chemical
[	O
23	O
].	O
We	O
identified	O
two	O
asparagine	B-Chemical
sites	O
at	O
N206	O
and	O
N209	O
in	O
MNSOD	O
and	O
the	O
two	O
asparagine	B-Chemical
residues	O
were	O
found	O
in	O
the	O
peptide	O
AIWN206VIN209WENVTER	O
which	O
was	O
located	O
in	O
the	O
C	O
-	O
terminal	O
.	O
Notably	O
this	O
modification	O
was	O
in	O
combination	O
with	O
modification	O
:	O
double	O
at	O
W205N206	O
and	O
N209W210	O
in	O
the	O
same	O
peptide	O
(	O
Table	O
2	O
).	O
The	O
N206	O
in	O
the	O
peptide	O
(	O
Figure	O
S1e	O
)	O
was	O
identified	O
by	O
the	O
unmodified	O
y3	O
ƒ??	O
10	O
ions	O
and	O
the	O
double	O
mass	O
shifts	O
15	O
.	O
99	O
Da	O
in	O
the	O
y12	O
ion	O
and	O
it	O
was	O
further	O
supported	O
by	O
the	O
double	O
mass	O
shifts	O
15	O
.	O
99	O
Da	O
in	O
the	O
ions	O
after	O
b4	O
.	O
The	O
N209	O
(	O
Figure	O
S1f	O
)	O
was	O
identified	O
by	O
the	O
first	O
shift	O
between	O
the	O
b4	O
ƒ??	O
6	O
ions	O
and	O
b7	O
ion	O
and	O
the	O
W210	O
identified	O
by	O
the	O
second	O
shift	O
15	O
.	O
99	O
Da	O
between	O
the	O
b7	O
ion	O
and	O
b8	O
ƒ??	O
13	O
ions	O
;	O
the	O
double	O
asparagine	B-Chemical
/	O
tryptophan	B-Chemical
residues	O
were	O
confirmed	O
by	O
the	O
unmodified	O
y3	O
ƒ??	O
6	O
ions	O
and	O
double	O
mass	O
shifts	O
15	O
.	O
99	O
Da	O
in	O
the	O
y8	O
ƒ??	O
12	O
ions	O
.	O
Therefore	O
we	O
concluded	O
that	O
the	O
asparagine	B-Chemical
residues	O
at	O
N206	O
and	O
N209	O
were	O
hotspots	O
for	O
that	O
could	O
be	O
spontaneously	O
synchronously	O
with	O
tryptophan	B-Chemical
.	O
2	O
.	O
5	O
.	O
Histidine	B-Chemical
at	O
H54	O
and	O
H55	O
MNSOD	O
Histidine	B-Chemical
in	O
proteins	O
are	O
commonly	O
found	O
in	O
cells	O
undergoing	O
redox	O
-	O
mediated	O
histidine	B-Chemical
to	O
2	B-Chemical
-	I-Chemical
-	I-Chemical
histidine	I-Chemical
.	O
The	O
product	O
has	O
been	O
suggested	O
as	O
a	O
biological	O
marker	O
for	O
modified	O
proteins	O
[	O
24	O
].	O
In	O
this	O
study	O
we	O
identified	O
two	O
histidine	B-Chemical
residues	O
at	O
H54	O
and	O
H55	O
in	O
MNSOD	O
.	O
The	O
histidine	B-Chemical
at	O
H54	O
in	O
the	O
peptide	O
H	O
(	O
54	O
)	O
HAAYVNNLNVTEEK	O
(	O
Figure	O
S1g	O
)	O
was	O
identified	O
by	O
the	O
mass	O
shifts	O
at	O
b2	O
ƒ??	O
14	O
ions	O
which	O
was	O
supported	O
by	O
the	O
unmodified	O
y2	O
ƒ??	O
14	O
ions	O
followed	O
by	O
the	O
total	O
mass	O
shift	O
.	O
The	O
double	O
histidine	B-Chemical
at	O
H54	O
and	O
H55	O
in	O
the	O
peptide	O
H54H55AAYVNNLNVTEEK	O
(	O
Figure	O
S1h	O
)	O
was	O
identified	O
by	O
double	O
mass	O
shifts	O
at	O
b11	O
13	O
ions	O
which	O
was	O
supported	O
by	O
the	O
unmodified	O
y4	O
6	O
ƒ??	O
13	O
ions	O
followed	O
by	O
32	O
Da	O
shift	O
the	O
total	O
mass	O
.	O
The	O
two	O
histidine	B-Chemical
residues	O
were	O
located	O
in	O
the	O
first	O
hotspot	O
for	O
which	O
was	O
also	O
reported	O
previously	O
in	O
human	O
medulloblastoma	O
cells	O
[	O
21	O
].	O
2	O
.	O
6	O
.	O
Tyrosine	B-Chemical
at	O
Y58	O
MNSOD	O
Tyrosine	B-Chemical
could	O
be	O
to	O
form	O
3	B-Chemical
-	I-Chemical
hydroxyl	I-Chemical
tyrosine	I-Chemical
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylalanine	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
)	O
by	O
tyrosine	O
hydroxylase	O
(	O
TH	O
)	O
[	O
6	O
10	O
];	O
however	O
it	O
was	O
unclear	O
whether	O
TH	O
the	O
tyrosine	B-Chemical
residue	O
in	O
proteins	O
.	O
The	O
tyrosine	B-Chemical
at	O
Y58	O
was	O
identified	O
because	O
the	O
mass	O
shift	O
15	O
.	O
99	O
Da	O
was	O
absent	O
in	O
the	O
y4	O
ƒ??	O
10	O
ions	O
but	O
present	O
in	O
the	O
y11	O
ƒ??	O
14	O
ions	O
in	O
the	O
MS	O
/	O
MS	O
profile	O
the	O
peptide	O
HHAAY58VNNLNVTEEK	O
(	O
Figure	O
S1i	O
);	O
it	O
was	O
further	O
confirmed	O
by	O
the	O
absence	O
the	O
extra	O
mass	O
in	O
the	O
b2	O
4	O
ions	O
and	O
presence	O
in	O
the	O
b5	O
ƒ??	O
14	O
ions	O
.	O
2	O
.	O
7	O
.	O
at	O
H54	O
H55	O
Y58	O
W147	O
and	O
W149	O
MNSOD	O
Is	O
Up	O
-	O
Regulated	O
in	O
ccRCC	O
The	O
peak	O
areas	O
were	O
commonly	O
considered	O
proportional	O
to	O
the	O
amounts	O
the	O
peptide	O
.	O
In	O
this	O
study	O
the	O
level	O
an	O
residue	O
was	O
measured	O
by	O
the	O
areas	O
all	O
peptide	O
fragments	O
containing	O
the	O
residue	O
.	O
In	O
comparison	O
with	O
unoxidized	O
the	O
relative	O
level	O
residues	O
at	O
H54	O
H55	O
Y58	O
W147	O
W149	O
W205	O
N206	O
N209	O
and	O
W210	O
were	O
calculated	O
as	O
0	O
.	O
12	O
0	O
.	O
12	O
0	O
.	O
73	O
0	O
.	O
9530	O
0	O
.	O
6171	O
0	O
.	O
6938	O
0	O
.	O
5298	O
0	O
.	O
5298	O
and	O
0	O
.	O
6938	O
respectively	O
in	O
kidney	O
tissues	O
(	O
Figure	O
3a	O
Table	O
S7	O
).	O
Apparently	O
the	O
basal	O
levels	O
in	O
MNSOD	O
might	O
indicate	O
a	O
managed	O
balance	O
between	O
formation	O
and	O
neutralization	O
ROS	B-Chemical
in	O
vivo	O
.	O
Note	O
that	O
abundances	O
W205	O
and	O
N206	O
were	O
identical	O
to	O
W210	O
and	O
N209	O
because	O
they	O
were	O
from	O
two	O
identical	O
peptides	O
with	O
the	O
same	O
abundance	O
but	O
different	O
pattern	O
.	O
The	O
abundances	O
H54	O
and	O
H55	O
were	O
similar	O
because	O
they	O
came	O
from	O
a	O
low	O
abundant	O
single	O
peptide	O
(	O
H54	O
)	O
and	O
a	O
high	O
abundant	O
double	O
peptide	O
(	O
H54	O
and	O
H55	O
)	O
so	O
that	O
their	O
total	O
abundances	O
were	O
mainly	O
contributed	O
by	O
the	O
high	O
abundant	O
peptide	O
.	O
Markedly	O
at	O
H54	O
and	O
H55	O
found	O
in	O
kidney	O
cancer	O
tissues	O
(	O
p	O
<	O
0	O
.	O
5	O
n	O
=	O
4	O
)	O
and	O
at	O
Y58	O
W147	O
and	O
W149	O
increased	O
2	O
.	O
63	O
3	O
.	O
26	O
and	O
3	O
.	O
13	O
-	O
fold	O
(	O
p	O
<	O
0	O
.	O
5	O
n	O
=	O
4	O
)	O
in	O
kidney	O
cancer	O
tissues	O
respectively	O
in	O
comparison	O
with	O
those	O
in	O
adjacent	O
non	O
-	O
cancer	O
tissues	O
the	O
same	O
patient	O
(	O
Figure	O
3b	O
).	O
While	O
at	O
N206	O
and	O
N209	O
decreased	O
1	O
.	O
54	O
-	O
fold	O
(	O
p	O
<	O
0	O
.	O
5	O
n	O
=	O
4	O
)	O
and	O
at	O
W205	O
and	O
W210	O
decreased	O
1	O
.	O
40	O
-	O
fold	O
(	O
p	O
<	O
0	O
.	O
5	O
n	O
=	O
4	O
)	O
in	O
kidney	O
cancer	O
tissues	O
.	O
Thus	O
these	O
data	O
suggested	O
that	O
at	O
certain	O
amino	B-Chemical
acid	I-Chemical
positions	O
MNSOD	O
could	O
be	O
dysregulated	O
in	O
kidney	O
cancer	O
.	O
2	O
.	O
8	O
.	O
The	O
Relative	O
MNSOD	O
Enzymatic	O
Activity	O
Is	O
Attenuated	O
in	O
ccRCC	O
Western	O
blotting	O
analysis	O
four	O
individual	O
ccRCC	O
and	O
adjacent	O
tissue	O
lysates	O
showed	O
a	O
significant	O
increase	O
MNSOD	O
expression	O
in	O
ccRCC	O
(	O
p	O
<	O
0	O
.	O
5	O
Figure	O
4a	O
).	O
Then	O
MNSOD	O
enzymatic	O
activity	O
was	O
measured	O
from	O
ccRCC	O
and	O
adjacent	O
kidney	O
tissue	O
lysates	O
using	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
activity	O
kit	O
.	O
When	O
normalized	O
by	O
MNSOD	O
expression	O
level	O
the	O
relative	O
enzymatic	O
activity	O
MNSOD	O
was	O
decreased	O
in	O
ccRCC	O
in	O
comparison	O
with	O
adjacent	O
tissues	O
(	O
p	O
<	O
0	O
.	O
5	O
Figure	O
4b	O
)	O
although	O
the	O
total	O
activity	O
was	O
similar	O
.	O
This	O
suggested	O
that	O
modification	O
MNSOD	O
might	O
impair	O
its	O
enzymatic	O
activity	O
.	O
3	O
.	O
Discussion	O
MNSOD	O
is	O
highly	O
expressed	O
in	O
kidney	O
and	O
is	O
reportedly	O
up	O
-	O
regulated	O
in	O
ccRCC	O
[	O
15	O
16	O
]	O
the	O
most	O
common	O
subtype	O
RCC	O
in	O
adults	O
.	O
Label	O
-	O
free	O
quantitative	O
proteomics	O
approach	O
which	O
is	O
based	O
the	O
number	O
acquired	O
spectra	O
for	O
each	O
protein	O
the	O
ion	O
intensities	O
identical	O
peptides	O
has	O
become	O
a	O
popular	O
alternative	O
to	O
assess	O
relative	O
amount	O
peptides	O
proteins	O
[	O
25	O
].	O
In	O
this	O
study	O
label	O
-	O
free	O
quantification	O
was	O
performed	O
to	O
compare	O
a	O
number	O
proteins	O
in	O
kidney	O
tissues	O
and	O
208	O
proteins	O
were	O
found	O
to	O
meet	O
the	O
criteria	O
for	O
dysregulation	O
between	O
ccRCC	O
and	O
adjacent	O
tissues	O
.	O
Among	O
them	O
MNSOD	O
a	O
crucial	O
protein	O
regulating	O
ROS	B-Chemical
was	O
pinpointed	O
as	O
an	O
important	O
target	O
by	O
STRING	O
and	O
DAVID	O
bioinformatics	O
tools	O
.	O
It	O
was	O
followed	O
by	O
ion	O
intensity	O
-	O
based	O
quantification	O
to	O
compare	O
peptides	O
MNSOD	O
between	O
ccRCC	O
and	O
adjacent	O
tissues	O
.	O
Using	O
MNSOD	O
protein	O
bands	O
from	O
4	O
pairs	O
kidney	O
samples	O
shotgun	O
proteomics	O
and	O
search	O
algorithm	O
this	O
approach	O
revealed	O
9	O
modification	O
sites	O
at	O
4	O
different	O
amino	B-Chemical
acid	I-Chemical
residues	O
endogenous	O
MNSOD	O
protein	O
(	O
Table	O
2	O
).	O
Modified	O
sites	O
involved	O
two	O
histidine	B-Chemical
(	O
H54	O
and	O
H55	O
)	O
tyrosine	B-Chemical
(	O
Y58	O
)	O
four	O
tryptophan	B-Chemical
(	O
W147	O
W149	O
W205	O
and	O
W210	O
)	O
and	O
two	O
asparagine	B-Chemical
(	O
N206	O
and	O
N209	O
)	O
and	O
most	O
the	O
residues	O
clustered	O
at	O
the	O
C	O
-	O
terminus	O
.	O
Consistent	O
with	O
findings	O
it	O
was	O
recently	O
reported	O
that	O
MNSOD	O
could	O
be	O
at	O
H54	O
H55	O
and	O
W210	O
in	O
medulloblastoma	O
cells	O
[	O
21	O
].	O
Notably	O
three	O
hotspots	O
at	O
amino	B-Chemical
acid	I-Chemical
residues	O
54	O
ƒ??	O
58	O
147	O
ƒ??	O
149	O
and	O
205	O
ƒ??	O
210	O
were	O
and	O
multiple	O
incidents	O
simultaneously	O
in	O
the	O
nearby	O
positions	O
such	O
as	O
W147W149	O
and	O
N209W210	O
.	O
data	O
revealed	O
that	O
MNSOD	O
could	O
be	O
at	O
tryptophan	B-Chemical
/	O
asparagine	B-Chemical
residues	O
while	O
tryptophan	B-Chemical
and	O
asparagine	B-Chemical
hydroxylation	O
were	O
previously	O
reported	O
to	O
alter	O
the	O
structure	O
and	O
/	O
function	O
the	O
protein	O
[	O
26	O
27	O
].	O
These	O
demonstrated	O
that	O
mitochondrial	O
MNSOD	O
was	O
not	O
upregulated	O
in	O
kidney	O
cancer	O
but	O
it	O
was	O
also	O
deeply	O
at	O
several	O
hotspots	O
.	O
Based	O
three	O
-	O
dimensional	O
structure	O
(	O
1LUV	O
.	O
pdb	O
)	O
the	O
catalytic	O
core	O
(	O
active	O
site	O
)	O
MNSOD	O
is	O
located	O
between	O
the	O
N	O
-	O
terminal	O
helices	O
and	O
the	O
C	O
-	O
terminal	O
?ñ	O
/	O
?ý	O
domain	O
coordinating	O
in	O
a	O
strained	O
trigonal	O
bipyramidal	O
geometry	O
by	O
the	O
side	O
chains	O
His50	B-Chemical
His98	B-Chemical
Asp183	B-Chemical
and	O
His187	B-Chemical
and	O
the	O
Mn	B-Chemical
ion	O
in	O
the	O
active	O
metal	O
ion	O
(	O
Figure	O
2b	O
and	O
Figure	O
4c	O
)	O
[	O
3	O
28	O
].	O
The	O
residues	O
near	O
the	O
active	O
site	O
were	O
known	O
to	O
affect	O
the	O
enzymatic	O
activity	O
the	O
stability	O
sites	O
involving	O
His54	B-Chemical
Tyr58	B-Chemical
and	O
Trp147	B-Chemical
[	O
28	O
29	O
30	O
].	O
The	O
hydrophobic	O
side	O
chains	O
that	O
surrounded	O
the	O
metal	O
-	O
ligand	O
cluster	O
including	O
His51	B-Chemical
His54	B-Chemical
His55	B-Chemical
Tyr58	B-Chemical
Phe101	B-Chemical
Trp102	B-Chemical
Trp149	B-Chemical
Tyr190	B-Chemical
and	O
Tyr200	B-Chemical
could	O
also	O
be	O
altered	O
[	O
31	O
].	O
Therefore	O
modifications	O
these	O
residues	O
in	O
and	O
around	O
the	O
MNSOD	O
active	O
site	O
were	O
believed	O
to	O
affect	O
the	O
catalytic	O
activity	O
[	O
32	O
].	O
In	O
this	O
study	O
we	O
found	O
that	O
the	O
residues	O
were	O
close	O
to	O
the	O
active	O
site	O
located	O
in	O
the	O
hydrophobic	O
side	O
chains	O
which	O
surrounded	O
the	O
manganese	B-Chemical
-	O
ligand	O
cluster	O
and	O
formed	O
a	O
hydrophobic	O
pocket	O
the	O
surface	O
proteins	O
.	O
These	O
included	O
the	O
residues	O
His54	B-Chemical
(	O
H54	O
)	O
His55	B-Chemical
(	O
H55	O
)	O
Tyr58	B-Chemical
(	O
Y58	O
)	O
Trp147	B-Chemical
(	O
W147	O
)	O
and	O
Trp149	B-Chemical
(	O
W149	O
)	O
(	O
Figure	O
4	O
)	O
[	O
2	O
5	O
6	O
9	O
31	O
].	O
These	O
are	O
supported	O
by	O
previous	O
reports	O
demonstrating	O
that	O
mutations	O
and	O
modifications	O
close	O
to	O
the	O
active	O
site	O
significantly	O
affect	O
the	O
structural	O
stability	O
as	O
well	O
as	O
the	O
catalytic	O
activity	O
MNSOD	O
[	O
33	O
].	O
In	O
addition	O
the	O
relative	O
enzymatic	O
activity	O
when	O
normalized	O
by	O
MNSOD	O
expression	O
was	O
decreased	O
in	O
ccRCC	O
in	O
comparison	O
with	O
the	O
adjacent	O
tissues	O
.	O
We	O
therefore	O
speculated	O
that	O
the	O
newly	O
identified	O
modification	O
may	O
initially	O
affect	O
the	O
structure	O
then	O
compromise	O
the	O
catalytic	O
activity	O
MNSOD	O
and	O
thereby	O
contribute	O
to	O
ccRCC	O
formation	O
and	O
development	O
.	O
Using	O
MS	O
we	O
found	O
that	O
human	O
endogenous	O
mitochondrial	O
MNSOD	O
can	O
undergo	O
modifications	O
at	O
histidine	B-Chemical
tyrosine	B-Chemical
tryptophan	B-Chemical
and	O
asparagine	B-Chemical
residues	O
.	O
To	O
knowledge	O
we	O
report	O
for	O
the	O
first	O
time	O
that	O
human	O
MNSOD	O
can	O
be	O
at	O
tyrosine	B-Chemical
and	O
asparagine	B-Chemical
residues	O
.	O
Although	O
MNSOD	O
at	O
H54	O
H55	O
and	O
W210	O
was	O
reported	O
in	O
medulloblastoma	O
cells	O
[	O
21	O
]	O
the	O
extent	O
and	O
its	O
modification	O
patterns	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O
Asparagine	B-Chemical
hydroxylation	O
ankyrin	O
repeat	O
domain	O
(	O
ARD	O
)	O
ankyrin	O
R	O
by	O
factor	O
-	O
inhibiting	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
FIH	O
)	O
altered	O
the	O
structure	O
and	O
function	O
the	O
erythrocyte	O
cytoskeletal	O
ankyrin	O
protein	O
[	O
27	O
]	O
and	O
tyrosine	B-Chemical
affected	O
mouse	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
(	O
BMMSCs	O
)	O
proliferation	O
and	O
differentiation	O
[	O
26	O
]	O
but	O
little	O
is	O
known	O
about	O
asparagine	B-Chemical
and	O
tyrosine	B-Chemical
in	O
MNSOD	O
.	O
Label	O
-	O
free	O
quantification	O
demonstrated	O
a	O
significant	O
increase	O
at	O
H54	O
H55	O
Y58	O
W147	O
and	O
W149	O
in	O
ccRCC	O
comparing	O
with	O
adjacent	O
tissues	O
(	O
Figure	O
3b	O
).	O
As	O
protein	O
usually	O
altered	O
the	O
enzymatic	O
activity	O
[	O
8	O
]	O
we	O
speculated	O
that	O
the	O
H54	O
H55	O
Y58	O
W147	O
and	O
W149	O
mediated	O
MNSOD	O
activity	O
and	O
thereby	O
contributed	O
to	O
ccRCC	O
initiation	O
.	O
It	O
also	O
accounts	O
for	O
the	O
inconsistency	O
enzymatic	O
activity	O
and	O
MNSOD	O
expression	O
in	O
ccRCC	O
versus	O
adjacent	O
tissues	O
.	O
Cancer	O
cells	O
produce	O
greater	O
amount	O
ROS	B-Chemical
than	O
their	O
corresponding	O
normal	O
cells	O
thus	O
more	O
MNSOD	O
aggregates	O
in	O
ccRCC	O
to	O
scavenge	O
ROS	B-Chemical
.	O
However	O
increased	O
ROS	B-Chemical
also	O
inhibits	O
MNSOD	O
activity	O
via	O
mechanisms	O
in	O
ccRCC	O
.	O
suggest	O
that	O
in	O
addition	O
to	O
MNSOD	O
in	O
cancer	O
cells	O
MNSOD	O
might	O
also	O
contribute	O
to	O
ROS	B-Chemical
regulation	O
by	O
mediation	O
MNSOD	O
activity	O
[	O
34	O
].	O
4	O
.	O
Materials	O
and	O
Methods	O
4	O
.	O
1	O
.	O
Sample	O
Preparation	O
and	O
Protein	O
Extraction	O
Kidney	O
cancer	O
tissues	O
(	O
ccRCC	O
)	O
and	O
adjacent	O
morphologically	O
normal	O
kidney	O
cortex	O
(	O
adjacent	O
tissues	O
)	O
were	O
collected	O
from	O
7	O
cancer	O
patients	O
with	O
nephrectomy	O
(	O
5	O
males	O
and	O
2	O
females	O
age	O
from	O
46	O
to	O
75	O
Fuhrman	O
nuclear	O
grading	O
with	O
2	O
G1	O
+	O
2	O
G2	O
+	O
2	O
G3	O
+	O
1	O
G4	O
TNM	O
staging	O
with	O
2	O
T1	O
+	O
3	O
T2	O
+	O
2	O
T3	O
)	O
in	O
full	O
compliance	O
with	O
Institutional	O
Ethics	O
Review	O
Board	O
ƒ??	O
s	O
guidance	O
.	O
All	O
procedures	O
were	O
consistent	O
with	O
the	O
National	O
Institutes	O
Health	O
Guide	O
and	O
approved	O
by	O
the	O
institutional	O
board	O
with	O
patients	O
ƒ??	O
written	O
consent	O
.	O
This	O
study	O
was	O
evaluated	O
and	O
approved	O
by	O
the	O
Ethics	O
Committee	O
Shandong	O
Provincial	O
Hospital	O
Affiliated	O
to	O
Shandong	O
University	O
.	O
Frozen	O
tissues	O
were	O
homogenized	O
in	O
RIPA	O
lysis	O
buffer	O
(	O
Millipore	O
Billerica	O
MA	O
USA	O
)	O
including	O
the	O
protease	O
inhibitor	O
cocktail	O
(	O
Roche	O
Basel	O
Switzerland	O
).	O
Protein	O
concentration	O
was	O
determined	O
using	O
BCA	O
protein	O
assay	O
(	O
Biyuntian	O
Beijing	O
China	O
).	O
Total	O
proteins	O
the	O
ccRCC	O
and	O
adjacent	O
tissues	O
from	O
3	O
patients	O
(	O
TNM	O
staging	O
with	O
1	O
T1	O
+	O
1	O
T2	O
+	O
1	O
T3	O
)	O
were	O
subjected	O
to	O
quantitative	O
proteomic	O
analysis	O
and	O
those	O
from	O
4	O
patients	O
(	O
TNM	O
staging	O
with	O
1	O
T1	O
+	O
2	O
T2	O
+	O
1	O
T3	O
)	O
were	O
used	O
for	O
PTMs	O
and	O
MNSOD	O
enzymatic	O
activity	O
analyses	O
.	O
4	O
.	O
2	O
.	O
Liquid	O
Chromatography	O
Tandem	O
Mass	O
Spectrometry	O
For	O
quantitative	O
proteomic	O
analysis	O
~	O
100	O
?¬g	O
total	O
proteins	O
from	O
the	O
tumor	O
and	O
adjacent	O
tissues	O
were	O
separated	O
sodium	B-Chemical
dodecyl	I-Chemical
sulfate	I-Chemical
polyacrylamide	I-Chemical
gel	O
electrophoresis	O
(	O
SDS	B-Chemical
-	O
PAGE	O
)	O
roughly	O
divided	O
into	O
10	O
slices	O
according	O
to	O
molecular	O
weights	O
and	O
digested	O
with	O
trypsin	O
as	O
described	O
previously	O
[	O
35	O
].	O
The	O
extracted	O
peptides	O
from	O
each	O
gel	O
band	O
were	O
desalted	O
by	O
ZipTip	O
(	O
Millipore	O
)	O
and	O
subjected	O
to	O
peptide	O
fractionation	O
using	O
an	O
EASY	O
-	O
nLC	O
II	O
system	O
(	O
Thermo	O
Scientific	O
Waltham	O
MA	O
USA	O
).	O
The	O
gradient	O
-	O
eluted	O
peptides	O
were	O
analyzed	O
by	O
a	O
Velos	O
Pro	O
ion	O
trap	O
mass	O
spectrometer	O
(	O
Thermo	O
Scientific	O
).	O
The	O
liquid	O
chromatography	O
column	O
(	O
150	O
mm	O
??	O
??	O
0	O
.	O
75	O
mm	O
)	O
was	O
packed	O
with	O
3	O
?¬m	O
100	O
??	O
PepMap	O
C18	O
(	O
Thermo	O
Scientific	O
).	O
Samples	O
were	O
analyzed	O
using	O
120	O
min	O
linear	O
gradient	O
5	O
%ƒ??	O
35	O
%	O
acetonitrile	B-Chemical
in	O
0	O
.	O
1	O
%	O
formic	B-Chemical
acid	I-Chemical
with	O
a	O
flow	O
rate	O
300	O
nL	O
/	O
min	O
(	O
solvent	O
A	O
:	O
0	O
.	O
1	O
%	O
formic	B-Chemical
acid	I-Chemical
in	O
water	B-Chemical
solvent	O
B	O
:	O
0	O
.	O
1	O
%	O
formic	B-Chemical
acid	I-Chemical
in	O
acetonitrile	B-Chemical
)	O
and	O
the	O
mass	O
spectrometer	O
was	O
in	O
a	O
data	O
-	O
dependent	O
mode	O
in	O
which	O
MS	O
/	O
MS	O
fragmentation	O
was	O
performed	O
using	O
the	O
20	O
most	O
intense	O
peaks	O
every	O
full	O
MS	O
scan	O
.	O
MS	O
/	O
MS	O
spectra	O
were	O
searched	O
against	O
the	O
human	O
protein	O
database	O
(	O
UniProtKB	O
;	O
88	O
295	O
entries	O
)	O
using	O
SEQUEST	O
HT	O
which	O
is	O
part	O
the	O
Proteome	O
Discoverer	O
1	O
.	O
4	O
data	O
analysis	O
package	O
(	O
Thermo	O
Scientific	O
San	O
Jose	O
CA	O
USA	O
).	O
Trypsin	O
(	O
full	O
cleavage	O
)	O
was	O
specified	O
as	O
cleavage	O
enzyme	O
allowing	O
up	O
to	O
two	O
missing	O
cleavages	O
.	O
MS	O
/	O
MS	O
spectra	O
were	O
searched	O
with	O
a	O
maximum	O
allowed	O
deviation	O
1	O
Da	O
for	O
the	O
precursor	O
mass	O
and	O
0	O
.	O
8	O
Da	O
for	O
fragment	O
masses	O
.	O
Methionine	B-Chemical
was	O
selected	O
as	O
a	O
dynamic	O
modification	O
and	O
the	O
FALSE	O
discovery	O
rate	O
(	O
FDR	O
)	O
was	O
1	O
%.	O
For	O
deep	O
PTMs	O
analysis	O
total	O
proteins	O
from	O
the	O
tumor	O
and	O
adjacent	O
tissues	O
were	O
separated	O
SDS	B-Chemical
-	O
PAGE	O
and	O
the	O
~	O
22	O
kDa	O
bands	O
corresponding	O
to	O
MNSOD	O
were	O
excised	O
.	O
Proteins	O
in	O
the	O
gel	O
slices	O
were	O
digested	O
with	O
trypsin	O
and	O
peptides	O
were	O
recovered	O
with	O
C18	O
ZipTip	O
.	O
The	O
extracted	O
and	O
desalted	O
peptides	O
were	O
subjected	O
to	O
peptide	O
fractionation	O
by	O
liquid	O
chromatography	O
an	O
EASY	O
-	O
nLC	O
1000	O
system	O
(	O
Thermo	O
Scientific	O
)	O
equipped	O
with	O
a	O
long	O
C18	O
column	O
(	O
300	O
mm	O
??	O
??	O
0	O
.	O
75	O
mm	O
3	O
?¬m	O
particles	O
).	O
Samples	O
were	O
fractionated	O
with	O
120	O
min	O
linear	O
gradient	O
5	O
%ƒ??	O
35	O
%	O
acetonitrile	B-Chemical
/	O
0	O
.	O
1	O
%	O
formic	B-Chemical
acid	I-Chemical
at	O
a	O
flow	O
rate	O
300	O
nL	O
/	O
min	O
(	O
solvent	O
A	O
:	O
0	O
.	O
1	O
%	O
formic	B-Chemical
acid	I-Chemical
in	O
water	O
solvent	O
B	O
:	O
0	O
.	O
1	O
%	O
formic	B-Chemical
acid	I-Chemical
in	O
acetonitrile	B-Chemical
).	O
The	O
MS	O
and	O
MS	O
/	O
MS	O
spectra	O
were	O
acquired	O
by	O
a	O
LTQ	O
-	O
Elite	O
mass	O
spectrometer	O
(	O
Thermo	O
Scientific	O
)	O
in	O
a	O
data	O
-	O
dependent	O
mode	O
in	O
which	O
MS	O
/	O
MS	O
fragmentation	O
the	O
20	O
most	O
intense	O
peaks	O
were	O
acquired	O
for	O
every	O
full	O
MS	O
scan	O
.	O
MS	O
/	O
MS	O
spectra	O
were	O
searched	O
against	O
the	O
human	O
protein	O
database	O
using	O
MASCOT	O
and	O
SEQUEST	O
.	O
Trypsin	O
(	O
full	O
cleavage	O
)	O
was	O
specified	O
as	O
cleavage	O
enzyme	O
allowing	O
up	O
to	O
two	O
missing	O
cleavages	O
.	O
MS	O
/	O
MS	O
spectra	O
were	O
searched	O
with	O
a	O
maximum	O
allowed	O
deviation	O
10	O
ppm	O
for	O
the	O
precursor	O
mass	O
and	O
0	O
.	O
6	O
Da	O
for	O
fragment	O
masses	O
.	O
The	O
various	O
amino	B-Chemical
acid	I-Chemical
residues	O
including	O
methionine	B-Chemical
was	O
selected	O
as	O
dynamic	O
modification	O
and	O
the	O
FALSE	O
discovery	O
rate	O
(	O
FDR	O
)	O
was	O
1	O
%.	O
For	O
nitration	O
tyrosine	B-Chemical
was	O
selected	O
as	O
dynamic	O
modification	O
.	O
The	O
thresholds	O
for	O
the	O
accepted	O
MS	O
/	O
MS	O
spectra	O
(	O
peptides	O
)	O
were	O
Ions	O
Score	O
38	O
for	O
MASCOT	O
XCorr	O
1	O
.	O
22	O
??	O
charges	O
for	O
SEQUEST	O
[	O
36	O
].	O
All	O
modification	O
site	O
assignments	O
were	O
confirmed	O
by	O
manual	O
spectrum	O
interpretation	O
.	O
For	O
modification	O
search	O
a	O
multi	O
-	O
blind	O
spectral	O
alignment	O
algorithm	O
termed	O
MODification	O
via	O
alignment	O
MODa	O
[	O
20	O
]	O
was	O
used	O
.	O
Amino	B-Chemical
acid	I-Chemical
residues	O
with	O
a	O
delta	O
mass	O
+	O
16	O
Da	O
and	O
probability	O
higher	O
than	O
95	O
%	O
were	O
retained	O
for	O
potential	O
modifications	O
.	O
4	O
.	O
3	O
.	O
Label	O
-	O
Free	O
Quantification	O
To	O
quantitatively	O
compare	O
the	O
protein	O
abundances	O
between	O
ccRCC	O
and	O
adjacent	O
tissues	O
spectral	O
count	O
was	O
performed	O
[	O
37	O
].	O
This	O
method	O
compares	O
the	O
number	O
identified	O
MS	O
/	O
MS	O
spectra	O
from	O
the	O
same	O
protein	O
in	O
each	O
the	O
multiple	O
data	O
sets	O
.	O
For	O
normalization	O
the	O
spectral	O
counts	O
each	O
protein	O
were	O
divided	O
by	O
the	O
total	O
spectral	O
counts	O
all	O
proteins	O
from	O
the	O
same	O
sample	O
.	O
To	O
estimate	O
the	O
levels	O
at	O
each	O
residue	O
the	O
intensities	O
all	O
peptide	O
fragments	O
containing	O
the	O
residue	O
were	O
measured	O
[	O
38	O
]	O
by	O
Progenesis	O
LC	O
-	O
MS	O
software	O
(	O
version	O
4	O
.	O
1	O
Nonlinear	O
Dynamics	O
Newcastle	O
UK	O
).	O
For	O
quantification	O
ratio	O
the	O
residues	O
the	O
abundance	O
residue	O
was	O
divided	O
by	O
the	O
abundance	O
unoxidized	O
residue	O
in	O
every	O
four	O
pairs	O
tissue	O
samples	O
as	O
shown	O
in	O
Table	O
S7	O
.	O
4	O
.	O
4	O
.	O
Pathway	O
and	O
Network	O
Analyses	O
Dysregulated	O
Proteins	O
in	O
ccRCC	O
The	O
dysregulated	O
proteins	O
were	O
chosen	O
based	O
the	O
criteria	O
p	O
<	O
0	O
.	O
5	O
presence	O
in	O
every	O
replicate	O
average	O
spectral	O
counts	O
>	O
20	O
and	O
fold	O
change	O
ratio	O
1	O
.	O
4	O
(	O
up	O
down	O
)	O
in	O
ccRCC	O
comparing	O
with	O
adjacent	O
tissues	O
.	O
For	O
identifying	O
enriched	O
signaling	O
networks	O
and	O
diseases	O
categories	O
the	O
dysregulated	O
proteins	O
were	O
subjected	O
to	O
bioinformatics	O
tools	O
:	O
STRING	O
(	O
available	O
:	O
)	O
and	O
DAVID	O
functional	O
annotation	O
tool	O
(	O
available	O
:	O
)	O
[	O
39	O
].	O
The	O
STRING	O
database	O
version	O
10	O
and	O
medium	O
confidence	O
(	O
0	O
.	O
4000	O
)	O
were	O
used	O
and	O
active	O
interaction	O
sources	O
included	O
all	O
default	O
settings	O
such	O
as	O
text	O
mining	O
experiments	O
database	O
co	O
-	O
expression	O
neighborhood	O
gene	O
fusion	O
co	O
-	O
.	O
For	O
DAVID	O
functional	O
annotation	O
DAVID	O
database	O
version	O
6	O
.	O
8	O
was	O
used	O
.	O
4	O
.	O
5	O
.	O
Western	O
Blotting	O
(	O
WB	O
)	O
Analysis	O
Samples	O
were	O
separated	O
SDS	B-Chemical
-	O
PAGE	O
gel	O
.	O
After	O
electrophoresis	O
the	O
proteins	O
were	O
transferred	O
to	O
nitrocellulose	O
(	O
NC	O
)	O
membranes	O
blocked	O
then	O
probed	O
with	O
primary	O
antibodies	O
against	O
MNSOD	O
(	O
1	O
:	O
750	O
Santa	O
Cruz	O
Dallas	O
TX	O
USA	O
)	O
and	O
Tubulin	O
(	O
1	O
:	O
10	O
0	O
Sigma	O
-	O
Aldrich	O
St	O
.	O
Louis	O
MO	O
USA	O
).	O
Proteins	O
were	O
detected	O
using	O
fluorescence	O
conjugated	O
secondary	O
antibody	O
.	O
The	O
membranes	O
were	O
scanned	O
with	O
infrared	O
imaging	O
system	O
(	O
Li	O
-	O
Cor	O
Lincoln	O
NE	O
USA	O
).	O
4	O
.	O
6	O
.	O
MNSOD	O
Enzymatic	O
Activity	O
Assay	O
Commercial	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
activity	O
kit	O
(	O
Jiancheng	O
biotechnology	O
Nanjing	O
China	O
)	O
was	O
used	O
to	O
measure	O
MNSOD	O
enzymatic	O
activity	O
from	O
kidney	O
tissue	O
lysates	O
according	O
to	O
manufacturer	O
ƒ??	O
s	O
instructions	O
and	O
based	O
modified	O
method	O
as	O
previously	O
reported	O
[	O
16	O
].	O
Total	O
SOD	O
activity	O
was	O
assayed	O
by	O
the	O
inhibition	O
xantine	O
/	O
xantine	O
mediated	O
reduction	O
cytochrome	O
c	O
and	O
MNSOD	O
activity	O
was	O
determined	O
with	O
addition	O
3	O
mM	O
KCN	B-Chemical
to	O
inhibit	O
Cu	O
/	O
ZnSOD	O
.	O
4	O
.	O
7	O
.	O
Data	O
Analysis	O
The	O
SPSS	O
17	O
.	O
0	O
software	O
(	O
SPSS	O
Inc	O
.	O
Chicago	O
IL	O
USA	O
)	O
was	O
used	O
for	O
statistical	O
analysis	O
.	O
p	O
<	O
0	O
.	O
5	O
was	O
considered	O
statistically	O
significant	O
.	O
Statistical	O
analyses	O
between	O
two	O
groups	O
were	O
performed	O
using	O
a	O
Student	O
ƒ??	O
s	O
t	O
-	O
test	O
whereas	O
comparisons	O
involving	O
multiple	O
groups	O
were	O
performed	O
with	O
a	O
two	O
-	O
way	O
ANOVA	O
test	O
.	O
5	O
.	O
Conclusions	O
study	O
suggests	O
that	O
MNSOD	O
could	O
be	O
highly	O
susceptible	O
to	O
modifications	O
in	O
ccRCC	O
.	O
The	O
newly	O
identified	O
modification	O
sites	O
particularly	O
those	O
in	O
the	O
C	O
-	O
terminus	O
hydrophobic	O
pocket	O
may	O
be	O
developed	O
as	O
biomarkers	O
molecular	O
targets	O
to	O
study	O
ROS	B-Chemical
regulatory	O
mechanisms	O
ease	O
the	O
interpretation	O
previous	O
MNSOD	O
data	O
in	O
tumor	O
biology	O
and	O
enhance	O
intervening	O
ability	O
in	O
tumorigenesis	O
[	O
18	O
19	O
].	O
Supplementary	O
Materials	O
Supplementary	O
materials	O
can	O
be	O
found	O
at	O
.	O
Author	O
Contributions	O
Jiaju	O
Lu	O
and	O
Jing	O
-	O
Hua	O
Yang	O
conceived	O
and	O
designed	O
the	O
experiments	O
;	O
Zuohui	O
Zhao	O
Ruirui	O
Jing	O
and	O
Cuiling	O
Li	O
performed	O
the	O
experiments	O
;	O
Fengqin	O
Wang	O
and	O
Han	O
-	O
Pil	O
Choi	O
analyzed	O
the	O
data	O
;	O
Xin	O
Lu	O
contributed	O
to	O
sample	O
collection	O
;	O
Zuohui	O
Zhao	O
Jing	O
-	O
Hua	O
Yang	O
Kazem	O
M	O
.	O
Azadzoi	O
and	O
Han	O
-	O
Pil	O
Choi	O
wrote	O
the	O
manuscript	O
and	O
contributed	O
to	O
the	O
revision	O
manuscript	O
.	O
Conflicts	O
Interest	O
The	O
authors	O
declare	O
no	O
conflict	O
interest	O
.	O
References	O
Quantitative	O
proteomic	O
analysis	O
revealed	O
the	O
importance	O
anti	O
-	O
stress	O
pathway	O
in	O
ccRCC	O
.	O
(	O
a	O
)	O
The	O
heatmap	O
showed	O
the	O
33	O
(	O
by	O
DAVID	O
)	O
were	O
involved	O
in	O
binding	O
cofactor	O
coenzyme	O
NAD	B-Chemical
NADH	B-Chemical
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
).	I-Chemical
1	O
:	O
NAD	B-Chemical
binding	O
site	O
;	O
2	O
:	O
NAD	B-Chemical
NADH	B-Chemical
binding	O
;	O
3	O
:	O
nucleotide	B-Chemical
phosphate	I-Chemical
-	O
binding	O
region	O
;	O
4	O
:	O
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
)-	I-Chemical
binding	O
domain	O
;	O
5	O
:	O
NAD	B-Chemical
;	O
6	O
:	O
coenzyme	O
binding	O
;	O
7	O
:	O
cofactor	O
binding	O
;	O
8	O
:	O
reduction	O
;	O
9	O
:	O
.	O
Red	O
arrow	O
showed	O
the	O
candidate	O
protein	O
(	O
MNSOD	O
SOD2	O
).	O
Green	O
area	O
:	O
gene	O
-	O
term	O
association	O
positively	O
reported	O
light	O
blue	O
area	O
:	O
gene	O
term	O
association	O
not	O
reported	O
yet	O
;	O
(	O
b	O
)	O
visualization	O
protein	O
ƒ??	O
protein	O
interactions	O
the	O
37	O
-	O
reduction	O
related	O
proteins	O
in	O
ccRCC	O
using	O
STRING	O
analysis	O
(	O
confidence	O
mode	O
).	O
37	O
-	O
reduction	O
related	O
proteins	O
were	O
input	O
into	O
STRING	O
software	O
and	O
they	O
formed	O
three	O
main	O
clusters	O
(	O
33	O
connected	O
proteins	O
were	O
shown	O
and	O
the	O
clusters	O
were	O
divided	O
by	O
dotted	O
lines	O
)	O
among	O
which	O
MNSOD	O
(	O
SOD2	O
red	O
arrow	O
)	O
were	O
participated	O
in	O
the	O
network	O
and	O
were	O
chosen	O
to	O
be	O
validated	O
later	O
.	O
The	O
solid	O
lines	O
represented	O
interactions	O
between	O
proteins	O
and	O
thickness	O
the	O
solid	O
lines	O
denoted	O
the	O
confidence	O
level	O
associated	O
with	O
each	O
interactions	O
.	O
LC	O
-	O
MS	O
/	O
MS	O
coverage	O
MNSOD	O
.	O
(	O
a	O
)	O
Whole	O
cell	O
lysates	O
from	O
kidney	O
tissues	O
were	O
separated	O
by	O
SDS	B-Chemical
-	O
PAGE	O
and	O
stained	O
by	O
Coomassie	B-Chemical
Blue	I-Chemical
(	O
arrow	O
indicated	O
MNSOD	O
).	O
The	O
gel	O
image	O
is	O
the	O
representative	O
4	O
pairs	O
tumor	O
and	O
adjacent	O
tissues	O
used	O
for	O
PTMs	O
analysis	O
.	O
A	O
:	O
adjacent	O
;	O
T	O
:	O
tumor	O
;	O
(	O
b	O
)	O
CID	O
-	O
based	O
sequence	O
coverage	O
MNSOD	O
.	O
After	O
Coomassie	O
Blue	O
staining	O
the	O
22	O
kDa	O
protein	O
bands	O
corresponding	O
to	O
MNSOD	O
were	O
cut	O
from	O
the	O
gel	O
and	O
digested	O
and	O
peptides	O
were	O
analyzed	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
LTQ	O
-	O
mass	O
spectrometer	O
(	O
MS	O
).	O
The	O
underlined	O
amino	B-Chemical
acids	I-Chemical
(	O
bold	O
letters	O
)	O
were	O
identified	O
by	O
Proteome	O
Discoverer	O
1	O
.	O
4	O
(	O
MASCOT	O
and	O
SEQUEST	O
)	O
which	O
covered	O
76	O
.	O
13	O
%	O
sequence	O
MNSOD	O
.	O
Signal	O
:	O
the	O
signal	O
peptide	O
;	O
?ñ	O
:	O
the	O
?ñ	O
-	O
helices	O
;	O
?ý	O
:	O
the	O
?ý	O
-	O
sheets	O
subscript	O
numbers	O
represent	O
numbers	O
;	O
solid	O
arrows	O
:	O
metal	O
(	O
Mn2	B-Chemical
+)	I-Chemical
binding	O
sites	O
.	O
Quantification	O
the	O
residues	O
MNSOD	O
.	O
(	O
a	O
)	O
The	O
average	O
ratios	O
the	O
to	O
unoxidized	O
residues	O
in	O
tumor	O
+	O
adjacent	O
tissues	O
.	O
Abundances	O
the	O
modified	O
and	O
unmodified	O
peptide	O
fragments	O
containing	O
the	O
nine	O
and	O
unoxidized	O
residues	O
(	O
H54	O
H55	O
Y58	O
W147	O
W149	O
W205	O
N206	O
N209	O
and	O
W210	O
)	O
were	O
used	O
to	O
calculate	O
the	O
ratios	O
(	O
Table	O
S7	O
).	O
Three	O
hotspots	O
are	O
indicated	O
;	O
(	O
b	O
)	O
comparison	O
the	O
modification	O
between	O
tumor	O
and	O
adjacent	O
tissues	O
.	O
The	O
relative	O
ratios	O
to	O
unoxidized	O
residues	O
at	O
histidine	B-Chemical
54	O
(	O
H54	O
)	O
55	O
(	O
H55	O
)	O
and	O
tyrosine	B-Chemical
58	O
(	O
Y58	O
)	O
were	O
low	O
both	O
in	O
ccRCC	O
tumor	O
tissues	O
and	O
adjacent	O
tissues	O
but	O
dramatically	O
increased	O
in	O
tumor	O
comparing	O
with	O
adjacent	O
tissues	O
(	O
the	O
left	O
panel	O
*	O
p	O
<	O
0	O
.	O
3	O
n	O
=	O
4	O
)	O
(	O
Table	O
S7	O
).	O
The	O
relative	O
ratios	O
at	O
tryptophan	B-Chemical
147	O
(	O
W147	O
)	O
and	O
149	O
(	O
W149	O
)	O
were	O
also	O
increased	O
significantly	O
in	O
tumor	O
but	O
the	O
relative	O
ratios	O
at	O
tryptophan	B-Chemical
205	O
(	O
W205	O
)	O
asparagine	B-Chemical
206	O
(	O
N206	O
)	O
asparagine	B-Chemical
209	O
(	O
N209	O
)	O
and	O
tryptophan	B-Chemical
210	O
(	O
W210	O
)	O
were	O
decreased	O
slightly	O
in	O
tumor	O
(	O
the	O
right	O
panel	O
*	O
p	O
<	O
0	O
.	O
3	O
n	O
=	O
4	O
)	O
(	O
Table	O
S7	O
).	O
MNSOD	O
expression	O
enzymatic	O
activity	O
and	O
the	O
potential	O
hotspots	O
MNSOD	O
.	O
(	O
a	O
)	O
The	O
expression	O
MNSOD	O
in	O
adjacent	O
(	O
A	O
)	O
and	O
ccRCC	O
(	O
T	O
)	O
tissues	O
.	O
Four	O
individual	O
ccRCC	O
and	O
adjacent	O
tissue	O
lysates	O
were	O
separated	O
by	O
SDS	B-Chemical
-	O
PAGE	O
and	O
the	O
expression	O
MNSOD	O
was	O
detected	O
by	O
Western	O
blotting	O
.	O
Tubulin	O
served	O
as	O
the	O
loading	O
control	O
(*	O
p	O
<	O
0	O
.	O
5	O
n	O
=	O
4	O
);	O
(	O
b	O
)	O
MNSOD	O
enzymatic	O
activity	O
in	O
adjacent	O
(	O
A	O
)	O
and	O
ccRCC	O
(	O
T	O
)	O
tissues	O
.	O
Superoxide	O
dismutase	O
(	O
SOD	O
)	O
activity	O
kit	O
was	O
used	O
to	O
measure	O
MNSOD	O
enzymatic	O
activity	O
.	O
The	O
relative	O
MNSOD	O
enzymatic	O
activity	O
was	O
normalized	O
by	O
MNSOD	O
expression	O
(*	O
p	O
<	O
0	O
.	O
5	O
n	O
=	O
4	O
);	O
(	O
c	O
)	O
the	O
potential	O
hotspots	O
in	O
three	O
dimensional	O
structure	O
MNSOD	O
.	O
The	O
ribbon	O
structure	O
MNSOD	O
subunit	O
(	O
1LUV	O
.	O
pdb	O
)	O
is	O
depicted	O
with	O
the	O
two	O
separate	O
polypeptide	O
chains	O
.	O
The	O
active	O
sites	O
(	O
manganese	B-Chemical
ions	O
Mn	B-Chemical
)	O
are	O
depicted	O
as	O
solid	O
spheres	O
and	O
the	O
modification	O
sites	O
(	O
H54	O
H55	O
Y58	O
W147	O
W149	O
W205	O
N206	O
N209	O
W210	O
)	O
are	O
indicated	O
as	O
red	O
dashed	O
arrows	O
.	O
The	O
3D	O
structure	O
shows	O
the	O
three	O
hotspots	O
(	O
hotspot	O
1	O
(	O
H54	O
H55	O
Y58	O
)	O
hotspot	O
2	O
(	O
W147	O
W149	O
)	O
and	O
hotspot	O
3	O
(	O
W205	O
N206	O
N209	O
W210	O
))	O
are	O
distributed	O
in	O
the	O
surface	O
homotetrameric	O
MNSOD	O
and	O
point	O
to	O
protein	O
internal	O
which	O
composite	O
a	O
hydrophobic	O
side	O
chain	O
and	O
affect	O
the	O
molecular	O
structure	O
MNSOD	O
.	O
The	O
colors	O
in	O
the	O
ribbon	O
structure	O
MNSOD	O
subunit	O
are	O
the	O
automatically	O
displayed	O
colors	O
according	O
to	O
1LUV	O
.	O
pdb	O
.	O
Frequency	O
+	O
16	O
modification	O
events	O
MNSOD	O
at	O
different	O
amino	B-Chemical
acid	I-Chemical
residues	O
*.	O
*	O
Note	O
:	O
total	O
counts	O
the	O
peptide	O
with	O
a	O
delta	O
mass	O
+	O
16	O
Da	O
at	O
the	O
indicated	O
amino	B-Chemical
acids	I-Chemical
.	O
The	O
modified	O
(	O
and	O
nitrated	O
)	O
amino	B-Chemical
acid	I-Chemical
residues	O
in	O
MNSOD	O
a	O
.	O
a	O
The	O
modified	O
peptides	O
in	O
MNSOD	O
(	O
P04179	O
SODM_HUMAN	O
)	O
which	O
were	O
identified	O
by	O
MASCOT	O
and	O
SEQUEST	O
.	O
See	O
Figure	O
S1	O
for	O
mass	O
spectra	O
containing	O
b	O
and	O
y	O
ions	O
.	O
b	O
Precursor	O
mass	O
accuracy	O
<	O
10	O
ppm	O
.	O
c	O
Modified	O
peptide	O
sequences	O
.	O
:	O
no	O
:	O
nitration	O
.	O
The	O
peptide	O
sequences	O
with	O
bold	O
letters	O
indicate	O
novel	O
/	O
nitrated	O
residues	O
.	O
d	O
Ions	O
Score	O
(>	O
38	O
)	O
by	O
MASCOT	O
XCorr	O
(>	O
1	O
.	O
22	O
??	O
charges	O
)	O
by	O
SEQUEST	O
.	O
e	O
Asn	B-Chemical
combined	O
with	O
Trp	B-Chemical
.	O
Neuropeptide	O
S	O
(	O
NPS	O
)	O
variants	O
modify	O
the	O
signaling	O
and	O
risk	O
effects	O
NPS	O
Receptor	O
1	O
(	O
NPSR1	O
)	O
variants	O
in	O
asthma	O
Single	O
nucleotide	B-Chemical
polymorphisms	O
(	O
SNPs	O
)	O
close	O
to	O
the	O
gain	O
-	O
-	O
function	O
substitution	O
Asn	B-Chemical
(	O
107	O
)	O
Ile	B-Chemical
(	O
rs324981	O
A	O
>	O
T	O
)	O
in	O
Neuropeptide	O
S	O
Receptor	O
1	O
(	O
NPSR1	O
)	O
have	O
been	O
associated	O
with	O
asthma	O
.	O
Furthermore	O
a	O
functional	O
SNP	O
(	O
rs4751440	O
G	O
>	O
C	O
)	O
in	O
Neuropeptide	O
S	O
(	O
NPS	O
)	O
encodes	O
a	O
Val	B-Chemical
(	O
6	O
)	O
Leu	B-Chemical
substitution	O
the	O
mature	O
peptide	O
that	O
results	O
in	O
reduced	O
bioactivity	O
.	O
We	O
sought	O
to	O
examine	O
the	O
effects	O
different	O
combinations	O
these	O
NPS	O
and	O
NPSR1	O
variants	O
downstream	O
signaling	O
and	O
genetic	O
risk	O
asthma	O
.	O
In	O
transfected	O
cells	O
the	O
magnitude	O
NPSR1	O
-	O
induced	O
activation	O
cAMP	B-Chemical
/	O
PKA	O
signal	O
transduction	O
pathways	O
and	O
downstream	O
gene	O
expression	O
was	O
dependent	O
the	O
combination	O
the	O
NPS	O
and	O
NPSR1	O
variants	O
with	O
NPS	O
-	O
Val	O
(	O
6	O
)/	O
NPSR1	O
-	O
Ile	O
(	O
107	O
)	O
resulting	O
in	O
strongest	O
and	O
NPS	O
-	O
Leu	O
(	O
6	O
)/	O
NPSR1	O
-	O
Asn	O
(	O
107	O
)	O
in	O
weakest	O
effects	O
respectively	O
.	O
two	O
copies	O
the	O
NPS	O
-	O
Leu	O
(	O
6	O
)	O
(	O
rs4751440	O
)	O
were	O
associated	O
with	O
physician	O
-	O
diagnosed	O
childhood	O
asthma	O
(	O
:	O
0	O
.	O
67	O
95	O
%	O
CI	O
0	O
.	O
49	O
ƒ??	O
0	O
.	O
92	O
p	O
=	O
0	O
.	O
1	O
)	O
and	O
together	O
with	O
two	O
linked	O
NPS	O
variants	O
(	O
rs1931704	O
and	O
rs10830123	O
)	O
formed	O
a	O
protective	O
haplotype	O
(	O
p	O
=	O
0	O
.	O
8	O
)	O
in	O
the	O
Swedish	O
birth	O
cohort	O
BAMSE	O
(	O
2033	O
children	O
).	O
NPS	O
rs10830123	O
showed	O
epistasis	O
with	O
NPSR1	O
rs324981	O
encoding	O
Asn	B-Chemical
(	O
107	O
)	O
Ile	B-Chemical
(	O
p	O
=	O
0	O
.	O
9	O
)	O
in	O
BAMSE	O
and	O
with	O
the	O
linked	O
NPSR1	O
rs17199659	O
(	O
p	O
=	O
0	O
.	O
5	O
)	O
in	O
the	O
German	O
MAGIC	O
/	O
ISAAC	O
II	O
cohort	O
(	O
1454	O
children	O
).	O
In	O
conclusion	O
NPS	O
variants	O
modify	O
asthma	O
risk	O
and	O
should	O
be	O
considered	O
in	O
genetic	O
association	O
studies	O
NPSR1	O
with	O
asthma	O
and	O
complex	O
diseases	O
.	O
Introduction	O
Neuropeptide	O
S	O
(	O
NPS	O
)	O
affects	O
multiple	O
neuroendocrine	O
behavioral	O
and	O
inflammatory	O
responses	O
via	O
its	O
G	O
protein	O
-	O
coupled	O
cell	O
surface	O
receptor	O
NPSR1	O
(	O
Neuropeptide	O
S	O
Receptor	O
1	O
)	O
[	O
1	O
ƒ??	O
4	O
].	O
NPSR1	O
was	O
identified	O
as	O
a	O
susceptibility	O
gene	O
for	O
asthma	O
and	O
related	O
traits	O
by	O
positional	O
cloning	O
and	O
the	O
associations	O
NPSR1	O
single	O
nucleotide	B-Chemical
polymorphisms	O
(	O
SNPs	O
)	O
with	O
asthma	O
have	O
been	O
replicated	O
in	O
ethnically	O
diverse	O
populations	O
[	O
5	O
ƒ??	O
12	O
]	O
and	O
marginally	O
supported	O
by	O
a	O
large	O
-	O
scale	O
genome	O
-	O
wide	O
association	O
study	O
(	O
GWAS	O
)	O
[	O
13	O
].	O
In	O
addition	O
NPSR1	O
SNPs	O
have	O
shown	O
genetic	O
associations	O
with	O
inflammatory	O
phenotypes	O
such	O
as	O
inflammatory	O
bowel	O
disease	O
[	O
14	O
]	O
and	O
rheumatoid	O
arthritis	O
[	O
15	O
16	O
].	O
However	O
the	O
NPSR1	O
locus	O
has	O
shown	O
allelic	O
heterogeneity	O
with	O
different	O
markers	O
(	O
tag	O
SNPs	O
intronic	O
markers	O
and	O
haplotypes	O
)	O
showing	O
associations	O
depending	O
the	O
study	O
design	O
and	O
population	O
being	O
studied	O
.	O
We	O
have	O
previously	O
shown	O
that	O
several	O
susceptibility	O
alleles	O
low	O
-	O
to	O
-	O
moderate	O
-	O
effects	O
in	O
NPSR1	O
may	O
modify	O
the	O
asthma	O
risk	O
and	O
show	O
epistasis	O
depending	O
the	O
carrier	O
status	O
for	O
variants	O
in	O
genes	O
belonging	O
to	O
common	O
biological	O
pathways	O
[	O
17	O
].	O
These	O
effects	O
may	O
not	O
be	O
uncovered	O
by	O
SNP	O
arrays	O
which	O
are	O
suitable	O
for	O
detection	O
common	O
polymorphisms	O
but	O
cannot	O
detect	O
the	O
effects	O
less	O
frequent	O
coding	O
mutations	O
and	O
low	O
frequency	O
functional	O
SNPs	O
.	O
The	O
functional	O
NPSR1	O
SNP	O
rs324981	O
(	O
A	O
>	O
T	O
)	O
encoding	O
a	O
substitution	O
Asn	O
(	O
107	O
)	O
Ile	O
in	O
the	O
putative	O
ligand	O
-	O
binding	O
pocket	O
NPSR1	O
[	O
5	O
]	O
has	O
shown	O
associations	O
with	O
neuropsychiatric	O
phenotypes	O
such	O
as	O
panic	O
disorders	O
[	O
18	O
ƒ??	O
20	O
]	O
psychological	O
stress	O
[	O
21	O
]	O
and	O
fear	O
responses	O
[	O
22	O
23	O
].	O
A	O
GWAS	O
circadian	O
sleep	O
parameters	O
found	O
an	O
association	O
between	O
rs324981	O
and	O
regular	O
bedtime	O
[	O
24	O
]	O
and	O
another	O
study	O
showed	O
that	O
the	O
same	O
SNP	O
was	O
associated	O
with	O
sleep	O
and	O
rest	O
duration	O
[	O
25	O
].	O
In	O
cell	O
models	O
the	O
change	O
Asn	B-Chemical
(	O
107	O
)	O
to	O
Ile	B-Chemical
(	O
107	O
)	O
results	O
in	O
10	O
-	O
fold	O
increase	O
in	O
NPS	O
-	O
mediated	O
intracellular	O
signaling	O
[	O
26	O
]	O
and	O
changes	O
in	O
genome	O
-	O
wide	O
transcriptional	O
profiles	O
[	O
27	O
].	O
In	O
addition	O
the	O
NPSR1	O
SNP	O
rs324981	O
has	O
been	O
associated	O
with	O
airway	O
hyperresponsiveness	O
to	O
methacholine	B-Chemical
in	O
a	O
Chinese	O
population	O
[	O
8	O
].	O
Non	O
-	O
coding	O
functional	O
SNPs	O
have	O
also	O
been	O
detected	O
in	O
NPSR1	O
for	O
instance	O
rs2530547	O
which	O
affects	O
luciferase	O
expression	O
in	O
gene	O
reporter	O
assays	O
and	O
NPSR1	O
mRNA	O
levels	O
in	O
human	O
leukocytes	O
[	O
27	O
].	O
By	O
changing	O
the	O
levels	O
expression	O
in	O
this	O
receptor	O
they	O
may	O
ultimately	O
also	O
affect	O
signaling	O
and	O
are	O
hypothesized	O
to	O
affect	O
neuroinflammatory	O
phenotypes	O
[	O
28	O
].	O
Thereby	O
associations	O
with	O
individual	O
NPSR1	O
SNPs	O
needs	O
to	O
be	O
evaluated	O
in	O
the	O
context	O
gene	O
-	O
gene	O
interactions	O
because	O
a	O
combination	O
functional	O
polymorphisms	O
may	O
ultimately	O
determine	O
receptor	O
properties	O
and	O
/	O
expression	O
levels	O
[	O
27	O
].	O
A	O
functional	O
SNP	O
rs4751440	O
in	O
NPS	O
encodes	O
a	O
Val	O
(	O
6	O
)	O
Leu	B-Chemical
substitution	O
in	O
the	O
mature	O
NPS	O
peptide	O
that	O
results	O
in	O
lower	O
bioactivity	O
[	O
29	O
].	O
We	O
hypothesized	O
that	O
the	O
interaction	O
functional	O
NPS	O
and	O
NPSR1	O
SNPs	O
might	O
lead	O
to	O
either	O
strong	O
minimal	O
downstream	O
signaling	O
depending	O
the	O
genotype	O
combination	O
both	O
loci	O
.	O
The	O
aims	O
this	O
study	O
were	O
:	O
1	O
)	O
To	O
clarify	O
the	O
potential	O
functional	O
crosstalk	O
between	O
NPS	O
and	O
NPSR1	O
variants	O
;	O
2	O
)	O
to	O
identify	O
the	O
impact	O
putative	O
NPS	O
risk	O
alleles	O
the	O
susceptibility	O
to	O
asthma	O
;	O
and	O
3	O
)	O
to	O
evaluate	O
potential	O
gene	O
-	O
gene	O
interaction	O
effects	O
(	O
epistasis	O
)	O
between	O
NPS	O
and	O
NPSR1	O
polymorphisms	O
asthma	O
.	O
Results	O
Biological	O
interaction	O
NPS	O
and	O
NPSR1	O
variants	O
can	O
lead	O
to	O
either	O
strong	O
minimal	O
downstream	O
signaling	O
NPS	O
is	O
known	O
to	O
activate	O
NPSR1	O
by	O
increasing	O
cAMP	B-Chemical
production	O
[	O
30	O
31	O
].	O
To	O
compare	O
the	O
bioactivities	O
the	O
two	O
NPS	O
variants	O
we	O
measured	O
the	O
dose	O
-	O
responses	O
NPSR1	O
-	O
Ile	O
(	O
107	O
)	O
and	O
NPSR1	O
-	O
Asn	O
(	O
107	O
)	O
coding	O
variants	O
to	O
either	O
wildtype	O
NPS	O
-	O
Val	O
(	O
6	O
)	O
alternative	O
NPS	O
-	O
Leu	O
(	O
6	O
)	O
in	O
a	O
luciferase	O
assay	O
dependent	O
the	O
activation	O
a	O
cAMP	B-Chemical
-	O
response	O
element	O
(	O
CRE	O
).	O
This	O
assay	O
was	O
used	O
since	O
elevation	O
the	O
intracellular	O
cAMP	B-Chemical
levels	O
activates	O
cAMP	B-Chemical
response	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
via	O
phosphorylation	O
protein	O
kinase	O
A	O
(	O
PKA	O
).	O
Activated	O
CREB	O
binds	O
to	O
CRE	O
and	O
induces	O
the	O
expression	O
downstream	O
target	O
genes	O
the	O
cAMP	B-Chemical
/	O
PKA	O
signaling	O
pathway	O
.	O
Because	O
the	O
low	O
endogenous	O
expression	O
levels	O
NPSR1	O
in	O
majority	O
the	O
available	O
cell	O
lines	O
[	O
26	O
29	O
]	O
we	O
first	O
used	O
HEK293	O
cells	O
with	O
forced	O
NPSR1	O
expression	O
as	O
a	O
model	O
for	O
ligand	O
-	O
receptor	O
interactions	O
.	O
This	O
approach	O
allowed	O
comparisons	O
between	O
the	O
present	O
and	O
previous	O
studies	O
[	O
26	O
29	O
].	O
HEK293	O
cells	O
were	O
transiently	O
co	O
-	O
transfected	O
with	O
the	O
two	O
NPSR1	O
variants	O
along	O
with	O
a	O
CRE	O
-	O
responsive	O
firefly	O
luciferase	O
construct	O
and	O
a	O
construct	O
constitutively	O
expressing	O
Renilla	O
luciferase	O
.	O
Firefly	O
and	O
Renilla	O
luciferase	O
activity	O
was	O
measured	O
3	O
h	O
after	O
stimulation	O
with	O
serial	O
dilutions	O
NPS	O
(	O
10	O
pM	O
-	O
100	O
?¬M	O
).	O
As	O
shown	O
in	O
Fig	O
1	O
wildtype	O
NPS	O
ƒ??	O
Val	O
(	O
6	O
)	O
peptide	O
stimulated	O
CRE	O
ƒ??	O
dependent	O
luciferase	O
activity	O
at	O
50	O
ƒ??	O
fold	O
lower	O
concentrations	O
than	O
the	O
NPS	O
ƒ??	O
Leu	O
(	O
6	O
)	O
peptide	O
in	O
NPSR1	O
ƒ??	O
Ile	O
(	O
107	O
)	O
cells	O
(	O
pEC	O
50	O
:	O
8	O
.	O
4	O
?ñ	O
0	O
.	O
2	O
and	O
6	O
.	O
7	O
?ñ	O
0	O
.	O
2	O
p	O
=	O
0	O
.	O
4	O
respectively	O
)	O
and	O
at	O
15	O
-	O
fold	O
lower	O
concentrations	O
in	O
NPSR1	O
ƒ??	O
Asn	O
(	O
107	O
)	O
cells	O
(	O
pEC	O
50	O
:	O
6	O
.	O
1	O
?ñ	O
0	O
.	O
3	O
and	O
4	O
.	O
9	O
?ñ	O
0	O
.	O
1	O
p	O
=	O
0	O
.	O
3	O
respectively	O
).	O
NPS	O
variants	O
and	O
CRE	O
luciferase	O
activity	O
.	O
Dose	O
-	O
response	O
curves	O
NPS	O
-	O
Val	O
(	O
6	O
)	O
'	O
s	O
protocol	O
.	O
The	O
mRNA	O
expression	O
was	O
measured	O
with	O
qRT	O
-	O
PCR	O
using	O
either	O
SYBR	O
Green	O
(	O
for	O
NR4A1	O
FOS	O
IER3	O
and	O
EGR1	O
the	O
primer	O
sequences	O
are	O
given	O
in	O
S5	O
Table	O
)	O
TaqMAN	O
assay	O
(	O
Hs00601975	O
for	O
CXCL2	O
Hs00601975	O
Hs01011368	O
for	O
CCL20	O
Hs01036497	O
for	O
NPSR1	O
and	O
Pre	O
-	O
Developed	O
TaqMAN	O
Assay	O
Reagents	O
Part	O
No	O
.	O
4310884	O
for	O
GAPDH	O
;	O
Applied	O
Biosystems	O
).	O
The	O
PCR	O
assays	O
were	O
performed	O
in	O
a	O
total	O
volume	O
10	O
?¬l	O
using	O
7500	O
Fast	O
Real	O
-	O
Time	O
PCR	O
system	O
(	O
Applied	O
Biosystems	O
)	O
with	O
the	O
following	O
reaction	O
conditions	O
:	O
50	O
?ø	O
C	O
for	O
2	O
min	O
and	O
94	O
?ø	O
C	O
for	O
10	O
min	O
;	O
followed	O
by	O
45	O
cycles	O
92	O
?ø	O
C	O
for	O
14	O
s	O
and	O
1	O
min	O
at	O
60	O
?ø	O
C	O
.	O
A	O
dissociation	O
stage	O
was	O
added	O
to	O
the	O
SYBR	O
Green	O
reactions	O
to	O
confirm	O
primer	O
specificity	O
.	O
Results	O
are	O
shown	O
as	O
relative	O
expression	O
compared	O
with	O
unstimulated	O
cells	O
and	O
GAPDH	O
(	O
Applied	O
Biosystems	O
)	O
was	O
used	O
as	O
an	O
endogenous	O
control	O
.	O
Samples	O
were	O
normalized	O
to	O
GAPDH	O
(	O
in	O
SH	O
-	O
SY5Y	O
cells	O
)	O
to	O
GAPDH	O
and	O
NPSR1	O
in	O
to	O
control	O
for	O
the	O
efficiency	O
the	O
transient	O
transfections	O
(	O
in	O
HEK293	O
cells	O
).	O
The	O
variation	O
in	O
NPSR1	O
expression	O
(	O
Ct	O
values	O
)	O
between	O
cells	O
transfected	O
with	O
the	O
NPSR1	O
-	O
Asn	O
(	O
107	O
)	O
and	O
NPSR1	O
-	O
Ile	O
(	O
107	O
)	O
was	O
within	O
cycle	O
.	O
Expression	O
levels	O
mRNA	O
in	O
each	O
sample	O
were	O
determined	O
by	O
the	O
comparative	O
CT	O
method	O
relative	O
quantification	O
and	O
expressed	O
in	O
fold	O
-	O
changes	O
relative	O
to	O
the	O
chosen	O
reference	O
sample	O
.	O
Study	O
populations	O
Genetic	O
association	O
analyses	O
were	O
conducted	O
in	O
the	O
prospective	O
Swedish	O
birth	O
-	O
cohort	O
BAMSE	O
(	O
Children	O
Allergy	O
Milieu	O
Stockholm	O
an	O
Epidemiological	O
study	O
)	O
which	O
is	O
an	O
unselected	O
population	O
-	O
based	O
Swedish	O
birth	O
cohort	O
designed	O
to	O
assess	O
risk	O
factors	O
for	O
allergic	O
diseases	O
in	O
childhood	O
.	O
This	O
prospective	O
study	O
4	O
89	O
children	O
has	O
been	O
described	O
in	O
detail	O
elsewhere	O
[	O
38	O
39	O
].	O
At	O
age	O
8	O
all	O
children	O
were	O
invited	O
to	O
clinical	O
testing	O
and	O
blood	O
samples	O
were	O
.	O
After	O
exclusion	O
samples	O
with	O
too	O
little	O
blood	O
incomplete	O
questionnaire	O
data	O
lack	O
parental	O
consent	O
to	O
genetic	O
analysis	O
there	O
were	O
2033	O
samples	O
with	O
DNA	O
extracted	O
for	O
genetic	O
studies	O
(	O
which	O
262	O
were	O
asthmatics	O
).	O
All	O
samples	O
were	O
analyzed	O
coded	O
.	O
The	O
study	O
was	O
approved	O
by	O
the	O
Regional	O
Ethical	O
Committee	O
Karolinska	O
Institutet	O
Stockholm	O
Sweden	O
.	O
Written	O
informed	O
consent	O
was	O
from	O
the	O
parents	O
and	O
/	O
legal	O
guardians	O
.	O
Replication	O
studies	O
were	O
carried	O
in	O
1454	O
children	O
from	O
the	O
Multicenter	O
Asthma	O
Genetic	O
in	O
Childhood	O
(	O
MAGIC	O
)	O
study	O
(	O
mean	O
age	O
11	O
y	O
)	O
and	O
the	O
cross	O
sectional	O
International	O
Study	O
Asthma	O
and	O
Allergies	O
in	O
Childhood	O
phase	O
II	O
(	O
ISAAC	O
II	O
)	O
study	O
(	O
age	O
9	O
ƒ??	O
11	O
y	O
)	O
[	O
50	O
ƒ??	O
52	O
].	O
From	O
both	O
populations	O
all	O
samples	O
which	O
had	O
been	O
part	O
the	O
first	O
GWAS	O
asthma	O
[	O
50	O
]	O
and	O
for	O
which	O
we	O
had	O
imputation	O
data	O
available	O
were	O
selected	O
for	O
this	O
study	O
.	O
After	O
quality	O
control	O
(	O
QC	O
)	O
1	O
454	O
samples	O
(	O
763	O
asthmatics	O
and	O
683	O
controls	O
)	O
remained	O
for	O
analysis	O
.	O
All	O
study	O
methods	O
were	O
approved	O
by	O
the	O
local	O
ethics	O
committees	O
and	O
written	O
informed	O
consent	O
was	O
from	O
all	O
parents	O
children	O
included	O
in	O
this	O
study	O
.	O
To	O
control	O
for	O
population	O
stratification	O
all	O
children	O
were	O
German	O
descent	O
.	O
Considering	O
that	O
previous	O
studies	O
have	O
detected	O
marginal	O
genetic	O
differences	O
between	O
Swedes	O
and	O
Germans	O
and	O
that	O
GWAS	O
data	O
supported	O
that	O
within	O
Europe	O
Germans	O
and	O
Swedes	O
are	O
most	O
closely	O
related	O
[	O
53	O
]	O
it	O
can	O
be	O
assumed	O
that	O
the	O
Swedish	O
BAMSE	O
and	O
the	O
German	O
ISAAC	O
/	O
MAGICS	O
were	O
comparable	O
.	O
Phenotype	O
assessment	O
Information	O
the	O
clinical	O
was	O
from	O
questionnaires	O
filled	O
by	O
the	O
parents	O
except	O
for	O
atopic	O
sensitization	O
which	O
was	O
assessed	O
from	O
plasma	O
samples	O
.	O
In	O
BAMSE	O
Asthma	O
ever	O
up	O
to	O
8	O
years	O
was	O
defined	O
as	O
a	O
physician	O
-	O
diagnosed	O
asthma	O
between	O
3	O
mo	O
after	O
birth	O
and	O
up	O
to	O
8	O
y	O
age	O
[	O
54	O
].	O
Atopic	O
sensitization	O
was	O
considered	O
present	O
if	O
a	O
child	O
had	O
levels	O
allergen	O
-	O
specific	O
IgE	O
>	O
0	O
.	O
35	O
kU	O
/	O
L	O
to	O
Phadiatop	O
a	O
mixture	O
cat	O
dog	O
horse	O
birch	O
timothy	O
mugwort	O
Dermatophagoides	O
pteronyssinus	O
and	O
Cladosporium	O
allergens	O
at	O
8	O
y	O
age	O
(	O
ImmunoCAP	O
Thermo	O
Fisher	O
Scientific	O
Phadia	O
AB	O
Uppsala	O
Sweden	O
).	O
In	O
MAGIC	O
the	O
assessed	O
variables	O
included	O
asthma	O
and	O
allergy	O
which	O
were	O
diagnosed	O
by	O
a	O
pediatric	O
pulmonologist	O
according	O
to	O
clinical	O
guidelines	O
and	O
measures	O
such	O
as	O
lung	O
function	O
tests	O
clinical	O
examination	O
and	O
allergy	O
testing	O
[	O
51	O
55	O
].	O
In	O
ISAAC	O
II	O
children	O
were	O
classified	O
as	O
having	O
asthma	O
if	O
parents	O
reported	O
a	O
physician	O
ƒ??	O
s	O
diagnosis	O
asthma	O
at	O
least	O
spastic	O
asthmatic	O
bronchitis	O
more	O
than	O
in	O
self	O
-	O
administered	O
questionnaires	O
[	O
56	O
57	O
].	O
The	O
populations	O
the	O
Swedish	O
BAMSE	O
and	O
the	O
German	O
ISAAC	O
/	O
MAGICS	O
are	O
assumed	O
to	O
be	O
comparable	O
because	O
in	O
both	O
the	O
definition	O
the	O
phenotype	O
ƒ?	O
asthma	O
ƒ?	O
was	O
based	O
a	O
physician	O
-	O
diagnosis	O
and	O
the	O
age	O
range	O
the	O
children	O
was	O
comparable	O
(	O
8	O
years	O
in	O
BAMSE	O
vs	O
.	O
10	O
years	O
in	O
ISAAC	O
/	O
MAGICS	O
)	O
[	O
58	O
].	O
SNP	O
selection	O
genotyping	O
and	O
quality	O
control	O
In	O
BAMSE	O
the	O
NPS	O
and	O
NPSR1	O
polymorphisms	O
were	O
genotyped	O
by	O
using	O
the	O
iPLEX	O
chemistry	O
the	O
SEQUENOM	O
platform	O
at	O
the	O
Mutation	O
Analysis	O
Facility	O
(	O
Karolinska	O
Institutet	O
)	O
with	O
the	O
exception	O
rs4751440	O
which	O
was	O
genotyped	O
by	O
a	O
TaqMan	O
SNP	O
Genotyping	O
Assay	O
in	O
an	O
ABI	O
Prism	O
7500	O
Fast	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
)	O
according	O
to	O
manufacturer	O
'	O
s	O
exact	O
test	O
.	O
Full	O
model	O
associations	O
were	O
evaluated	O
using	O
the	O
Cochran	O
-	O
Armitage	O
trend	O
test	O
and	O
genotypic	O
dominant	O
and	O
recessive	O
models	O
.	O
The	O
genotypic	O
and	O
dominant	O
/	O
recessive	O
tests	O
were	O
conducted	O
if	O
there	O
was	O
a	O
minimum	O
number	O
five	O
per	O
cell	O
either	O
in	O
the	O
2	O
-	O
by	O
-	O
3	O
2	O
-	O
by	O
-	O
2	O
tables	O
.	O
Since	O
we	O
tested	O
32	O
individual	O
SNPs	O
it	O
was	O
expected	O
at	O
least	O
1	O
.	O
6	O
SNPs	O
to	O
be	O
significant	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
due	O
to	O
chance	O
.	O
Epistasis	O
was	O
evaluated	O
using	O
the	O
ƒ??	O
epistasis	O
command	O
in	O
PLINK	O
.	O
All	O
pairwise	O
SNP	O
combinations	O
were	O
tested	O
in	O
the	O
case	O
-	O
control	O
datasets	O
.	O
Allelic	O
by	O
allelic	O
epistasis	O
between	O
NPS	O
and	O
NPSR1	O
SNPs	O
were	O
calculated	O
by	O
logistic	O
regression	O
.	O
The	O
allele	O
dosage	O
each	O
SNP	O
(	O
A	O
and	O
B	O
)	O
was	O
modeled	O
in	O
the	O
form	O
Y	O
~	O
?ý0	O
+	O
?ý1	O
.	O
A	O
+	O
?ý2	O
.	O
B	O
+	O
?ý3	O
.	O
AB	O
+	O
e	O
and	O
the	O
test	O
for	O
interaction	O
based	O
the	O
coefficient	O
?ý3	O
.	O
In	O
the	O
equation	O
Y	O
represents	O
the	O
presence	O
asthma	O
as	O
a	O
function	O
the	O
intercept	O
(	O
?ý0	O
)	O
and	O
the	O
coeffients	O
the	O
different	O
alleles	O
and	O
e	O
the	O
residual	O
error	O
.	O
Supporting	O
information	O
References	O
HSP90	O
inhibitors	O
potentiate	O
PGF2?ñ	B-Chemical
-	O
induced	O
IL	O
-	O
6	O
synthesis	O
via	O
p38	O
MAP	O
kinase	O
in	O
Heat	O
shock	O
protein	O
90	O
(	O
HSP90	O
)	O
that	O
is	O
ubiquitously	O
expressed	O
in	O
various	O
tissues	O
is	O
recognized	O
to	O
be	O
a	O
major	O
molecular	O
chaperone	O
.	O
We	O
have	O
previously	O
reported	O
that	O
prostaglandin	B-Chemical
F2?ñ	I-Chemical
(	O
PGF2?ñ	B-Chemical
)	O
a	O
potent	O
bone	O
remodeling	O
mediator	O
stimulates	O
the	O
synthesis	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
through	O
p44	O
/	O
p42	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
and	O
p38	O
MAP	O
kinase	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
and	O
that	O
Rho	O
-	O
kinase	O
acts	O
at	O
a	O
point	O
upstream	O
p38	O
MAP	O
kinase	O
.	O
In	O
the	O
present	O
study	O
we	O
investigated	O
the	O
involvement	O
HSP90	O
in	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
and	O
the	O
underlying	O
mechanism	O
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O
Geldanamycin	B-Chemical
an	O
inhibitor	O
HSP90	O
significantly	O
amplified	O
both	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
and	O
the	O
mRNA	O
expression	O
levels	O
.	O
In	O
addition	O
HSP90	O
inhibitors	O
17	B-Chemical
-	I-Chemical
allylamino	I-Chemical
-	I-Chemical
17demethoxy	I-Chemical
-	I-Chemical
geldanamycin	I-Chemical
(	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
)	O
and	O
17	B-Chemical
-	I-Chemical
dimethylamino	I-Chemical
-	I-Chemical
ethylamino	I-Chemical
-	I-Chemical
17	I-Chemical
-	I-Chemical
demethoxy	I-Chemical
-	I-Chemical
geldanamycin	I-Chemical
(	O
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
)	O
and	O
enhanced	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
.	O
Geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
and	O
markedly	O
strengthened	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
p38	O
MAP	O
kinase	O
.	O
Geldanamycin	B-Chemical
and	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
did	O
not	O
affect	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
p44	O
/	O
p42	O
MAP	O
kinase	O
and	O
myosin	O
phosphatase	O
targeting	O
subunit	O
(	O
MYPT	O
-	O
1	O
)	O
a	O
substrate	O
Rho	O
-	O
kinase	O
and	O
the	O
protein	O
levels	O
RhoA	O
and	O
Rho	O
-	O
kinase	O
.	O
In	O
addition	O
HSP90	O
-	O
siRNA	O
enhanced	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
p38	O
MAP	O
kinase	O
.	O
Furthermore	O
SB203580	B-Chemical
an	O
inhibitor	O
p38	O
MAP	O
kinase	O
significantly	O
suppressed	O
the	O
amplification	O
by	O
geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
.	O
results	O
strongly	O
suggest	O
that	O
HSP90	O
negatively	O
regulates	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
in	O
and	O
that	O
the	O
effect	O
HSP90	O
is	O
exerted	O
through	O
regulating	O
p38	O
MAP	O
kinase	O
activation	O
.	O
Introduction	O
Heat	O
shock	O
proteins	O
(	O
HSPs	O
)	O
are	O
induced	O
in	O
response	O
to	O
biological	O
stress	O
such	O
as	O
heat	O
stress	O
and	O
chemical	O
stress	O
[	O
1	O
].	O
HSPs	O
which	O
are	O
generally	O
recognized	O
as	O
molecular	O
chaperones	O
facilitate	O
the	O
refolding	O
nonnative	O
proteins	O
assist	O
in	O
their	O
elimination	O
via	O
the	O
chaperone	O
-	O
mediated	O
autophagy	O
the	O
ubiquitin	O
proteasome	O
system	O
.	O
HSPs	O
have	O
recently	O
been	O
classified	O
into	O
seven	O
families	O
named	O
HSPH	O
(	O
HSP110	O
)	O
HSPC	O
(	O
HSP90	O
)	O
HSPA	O
(	O
HSP70	O
)	O
HSPD	O
/	O
E	O
(	O
HSP60	O
/	O
HSP10	O
)	O
CCT	O
(	O
TRiC	O
)	O
DNAJ	O
(	O
HSP40	O
)	O
and	O
HSPB	O
(	O
small	O
HSP	O
)	O
[	O
1	O
2	O
].	O
Among	O
them	O
HSP90	O
(	O
HSPC	O
)	O
abundantly	O
express	O
in	O
a	O
variety	O
type	O
unstressed	O
cells	O
and	O
represents	O
1	O
ƒ??	O
2	O
%	O
total	O
cellular	O
proteins	O
which	O
increases	O
to	O
4	O
ƒ??	O
6	O
%	O
under	O
the	O
stress	O
conditions	O
[	O
2	O
].	O
HSP90	O
consists	O
three	O
domains	O
such	O
as	O
N	O
-	O
terminal	O
domains	O
middle	O
domains	O
and	O
C	O
-	O
terminal	O
domains	O
and	O
acts	O
as	O
an	O
ATP	B-Chemical
-	O
dependent	O
chaperone	O
[	O
3	O
].	O
It	O
has	O
been	O
shown	O
that	O
HSP90	O
is	O
in	O
many	O
types	O
cancers	O
and	O
that	O
HSP90	O
-	O
dependent	O
client	O
proteins	O
are	O
involved	O
in	O
a	O
variety	O
pathways	O
[	O
4	O
5	O
].	O
Therefore	O
inhibition	O
HSP90	O
functions	O
has	O
become	O
as	O
the	O
leading	O
strategies	O
for	O
anticancer	O
chemotherapeutics	O
[	O
4	O
5	O
].	O
In	O
previous	O
study	O
[	O
6	O
]	O
we	O
have	O
demonstrated	O
that	O
HSP90	O
inhibitors	O
such	O
as	O
geldanamycin	B-Chemical
[	O
7	O
]	O
17	B-Chemical
-	I-Chemical
allylamino	I-Chemical
-	I-Chemical
17demethoxy	I-Chemical
-	I-Chemical
geldanamycin	I-Chemical
(	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
)	O
[	O
8	O
]	O
and	O
17	B-Chemical
-	I-Chemical
dimethylamino	I-Chemical
-	I-Chemical
ethylamino	I-Chemical
-	I-Chemical
17	I-Chemical
-	I-Chemical
demethoxy	I-Chemical
-	I-Chemical
geldanamycin	I-Chemical
(	O
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
)	O
[	O
9	O
]	O
cause	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
desensitization	O
in	O
human	O
pancreatic	O
cancer	O
cells	O
and	O
that	O
the	O
activation	O
p38	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
induced	O
by	O
HSP90	O
inhibitors	O
regulates	O
the	O
desensitization	O
EGFR	O
via	O
its	O
phosphorylation	O
at	O
Ser1046	B-Chemical
/	O
7	O
.	O
HSP90	O
inhibitors	O
by	O
interfering	O
the	O
N	O
-	O
terminal	O
domain	O
ATP	B-Chemical
binding	O
site	O
HSP90	O
cause	O
the	O
destabilization	O
and	O
eventual	O
degradation	O
HSP90	O
client	O
proteins	O
and	O
then	O
lead	O
to	O
inhibit	O
ATP	B-Chemical
-	O
dependent	O
HSP90	O
chaperone	O
activity	O
[	O
10	O
].	O
Regarding	O
the	O
MAP	O
kinase	O
superfamily	O
it	O
is	O
generally	O
recognized	O
that	O
p44	O
/	O
p42	O
MAP	O
kinase	O
p38	O
MAP	O
kinase	O
and	O
stress	O
-	O
activated	O
protein	O
kinase	O
/	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
play	O
central	O
roles	O
in	O
a	O
variety	O
cellular	O
functions	O
including	O
proliferation	O
differentiation	O
and	O
survival	O
[	O
11	O
].	O
Therefore	O
HSP90	O
is	O
considered	O
to	O
act	O
as	O
a	O
pivotal	O
modulator	O
various	O
cellular	O
functions	O
via	O
MAP	O
kinases	O
such	O
as	O
p38	O
MAP	O
kinase	O
.	O
Bone	O
metabolism	O
is	O
strictly	O
regulated	O
by	O
two	O
types	O
antagonistic	O
functional	O
cells	O
;	O
and	O
[	O
12	O
].	O
Bone	O
tissue	O
is	O
continuously	O
regenerated	O
through	O
a	O
process	O
so	O
called	O
bone	O
remodeling	O
[	O
13	O
].	O
To	O
maintain	O
an	O
adequate	O
bone	O
quality	O
and	O
the	O
quantity	O
bone	O
formation	O
and	O
bone	O
resorption	O
are	O
tightly	O
coordinated	O
.	O
The	O
disruption	O
bone	O
remodeling	O
process	O
causes	O
metabolic	O
bone	O
diseases	O
such	O
as	O
fracture	O
healing	O
distress	O
.	O
With	O
regard	O
to	O
HSP90	O
inhibitor	O
-	O
effects	O
bone	O
metabolism	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
reportedly	O
stimulates	O
formation	O
and	O
promotes	O
bone	O
metastasis	O
in	O
bone	O
metastasis	O
a	O
breast	O
cancer	O
cell	O
line	O
[	O
14	O
].	O
In	O
addition	O
it	O
has	O
been	O
shown	O
that	O
geldanamycin	B-Chemical
induces	O
autophagy	O
and	O
apoptosis	O
cells	O
[	O
15	O
].	O
However	O
the	O
exact	O
roles	O
HSP90	O
in	O
bone	O
metabolism	O
have	O
not	O
yet	O
been	O
fully	O
clarified	O
.	O
Interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
is	O
a	O
multifunctional	O
cytokine	O
which	O
belongs	O
to	O
the	O
glycoprotein	O
130	O
(	O
gp130	O
)	O
cytokine	O
family	O
and	O
has	O
important	O
physiological	O
effects	O
a	O
variety	O
cell	O
functions	O
such	O
as	O
the	O
promotion	O
B	O
-	O
cell	O
differentiation	O
the	O
T	O
-	O
cell	O
activation	O
and	O
the	O
induction	O
acute	O
-	O
phase	O
proteins	O
[	O
16	O
17	O
].	O
It	O
has	O
been	O
recognized	O
that	O
IL	O
-	O
6	O
stimulates	O
bone	O
resorption	O
and	O
induces	O
formation	O
[	O
17	O
]	O
and	O
IL	O
-	O
6	O
reportedly	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
process	O
bone	O
fracture	O
repair	O
[	O
18	O
].	O
Thus	O
accumulating	O
evidence	O
suggests	O
that	O
IL	O
-	O
6	O
is	O
an	O
modulator	O
and	O
influence	O
bone	O
formation	O
under	O
the	O
condition	O
increased	O
bone	O
turnover	O
[	O
19	O
].	O
the	O
hand	O
prostaglandins	B-Chemical
(	O
PGs	B-Chemical
)	O
modulate	O
various	O
bone	O
cell	O
functions	O
as	O
autacoids	O
.	O
Among	O
them	O
PGF2?ñ	B-Chemical
which	O
has	O
been	O
conventionally	O
recognized	O
as	O
a	O
potent	O
bone	O
-	O
resorptive	O
agent	O
[	O
20	O
]	O
is	O
currently	O
recognized	O
as	O
a	O
bone	O
remodeling	O
mediator	O
[	O
21	O
].	O
It	O
has	O
been	O
previously	O
reported	O
that	O
PGF2?ñ	B-Chemical
induced	O
IL	O
-	O
6	O
production	O
in	O
-	O
enriched	O
cultured	O
neonatal	O
mouse	O
calvaria	O
resulting	O
in	O
bone	O
resorption	O
[	O
20	O
22	O
].	O
We	O
have	O
previously	O
shown	O
that	O
PGF2?ñ	B-Chemical
stimulates	O
the	O
synthesis	O
IL	O
-	O
6	O
through	O
p44	O
/	O
p42	O
MAP	O
kinase	O
and	O
p38	O
MAP	O
kinase	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
[	O
23	O
24	O
].	O
Thus	O
it	O
is	O
probable	O
that	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
IL	O
-	O
6	O
synthesis	O
is	O
not	O
specific	O
for	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
but	O
general	O
phenomena	O
in	O
.	O
However	O
there	O
is	O
no	O
report	O
showing	O
the	O
roles	O
MAP	O
kinases	O
in	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
in	O
as	O
far	O
as	O
we	O
know	O
.	O
In	O
addition	O
we	O
have	O
reported	O
that	O
Rho	O
kinase	O
inhibitors	O
significantly	O
suppress	O
the	O
synthesis	O
IL	O
-	O
6	O
and	O
the	O
phosphorylation	O
p38	O
MAP	O
kinase	O
induced	O
by	O
PGF2?ñ	B-Chemical
without	O
affecting	O
the	O
levels	O
total	O
p38	O
MAP	O
kinase	O
in	O
these	O
cells	O
suggesting	O
that	O
Rho	O
-	O
kinase	O
plays	O
a	O
role	O
in	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
as	O
an	O
upstream	O
regulator	O
p38	O
MAP	O
kinase	O
[	O
25	O
].	O
These	O
findings	O
lead	O
us	O
to	O
speculate	O
that	O
HSP90	O
could	O
regulate	O
the	O
IL	O
-	O
6	O
synthesis	O
stimulated	O
by	O
PGF2?ñ	B-Chemical
in	O
.	O
In	O
the	O
present	O
study	O
we	O
investigated	O
whether	O
HSP90	O
is	O
involved	O
in	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
IL	O
-	O
6	O
synthesis	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
.	O
We	O
herein	O
show	O
that	O
HSP90	O
inhibitors	O
enhance	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
in	O
these	O
cells	O
and	O
that	O
the	O
amplifying	O
effect	O
is	O
exerted	O
through	O
up	O
-	O
regulating	O
p38	O
MAP	O
kinase	O
activation	O
.	O
Materials	O
and	O
methods	O
Materials	O
Geldanamycin	B-Chemical
and	O
PGF2?ñ	B-Chemical
were	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
(	O
St	O
.	O
Louis	O
MO	O
USA	O
).	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
and	O
SB203580	B-Chemical
were	O
from	O
Calbiochem	O
-	O
Novabiochem	O
Co	O
.	O
(	O
La	O
Jolla	O
CA	O
).	O
was	O
purchased	O
from	O
Selleckchem	O
(	O
Houston	O
TX	O
).	O
Mouse	O
interleukin	O
-	O
6	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
kit	O
was	O
purchased	O
from	O
R	O
&	O
D	O
System	O
Inc	O
.	O
(	O
Minneapolis	O
MN	O
).	O
Phospho	O
-	O
specific	O
p44	O
/	O
p42	O
MAP	O
kinase	O
antibodies	O
p44	O
/	O
p42	O
MAP	O
kinase	O
antibodies	O
phospho	O
-	O
specific	O
p38	O
MAP	O
kinase	O
antibodies	O
p38	O
MAP	O
kinase	O
antibodies	O
phospho	O
-	O
specific	O
myosin	O
phosphatase	O
targeting	O
subunit	O
(	O
MYPT	O
-	O
1	O
)	O
antibodies	O
MYPT	O
-	O
1	O
antibodies	O
RhoA	O
antibodies	O
and	O
Rho	O
-	O
kinase	O
(	O
ROCK1	O
)	O
antibodies	O
were	O
from	O
Cell	O
Signaling	O
Technology	O
Inc	O
.	O
(	O
Beverly	O
MA	O
).	O
HSP90	O
antibodies	O
and	O
Glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
antibodies	O
were	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
Inc	O
.	O
(	O
Santa	O
Cruz	O
CA	O
).	O
An	O
ECL	O
Western	O
blotting	O
detection	O
system	O
was	O
from	O
GE	O
Healthcare	O
Life	O
Sciences	O
(	O
Chalfont	O
UK	O
).	O
Control	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
;	O
Silencer	O
Negative	O
Control	O
no	O
.	O
1	O
siRNA	O
)	O
and	O
HSP90	O
-	O
siRNA	O
(	O
Silencer	O
select	O
Pre	O
-	O
designed	O
siRNA	O
s67897	O
and	O
s67898	O
presented	O
as	O
#	O
1	O
and	O
#	O
2	O
)	O
were	O
purchased	O
from	O
Ambion	O
(	O
Austin	O
TX	O
).	O
materials	O
and	O
chemicals	O
were	O
from	O
commercial	O
sources	O
.	O
PGF2?ñ	B-Chemical
was	O
dissolved	O
in	O
ethanol	B-Chemical
.	O
Geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
and	O
SB203580	B-Chemical
were	O
dissolved	O
in	O
dimethyl	B-Chemical
sulfoxide	I-Chemical
.	O
The	O
maximum	O
concentration	O
ethanol	B-Chemical
dimethyl	B-Chemical
sulfoxide	I-Chemical
was	O
0	O
.	O
1	O
%	O
which	O
did	O
not	O
affect	O
the	O
assay	O
for	O
IL	O
-	O
6	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
Western	O
blot	O
analysis	O
.	O
Cell	O
culture	O
Cloned	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
an	O
immortalized	O
cell	O
line	O
which	O
had	O
been	O
derived	O
from	O
newborn	O
mouse	O
calvaria	O
[	O
26	O
]	O
were	O
maintained	O
as	O
previously	O
described	O
[	O
27	O
].	O
Briefly	O
the	O
cells	O
were	O
cultured	O
in	O
?ñ	B-Chemical
-	I-Chemical
minimum	I-Chemical
essential	I-Chemical
medium	I-Chemical
(	O
?ñ	B-Chemical
-	I-Chemical
MEM	I-Chemical
)	O
containing	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
at	O
37	O
?ø	O
C	O
in	O
a	O
humidified	O
atmosphere	O
5	O
%	O
CO2	B-Chemical
/	O
95	O
%	O
air	O
.	O
The	O
cells	O
in	O
early	O
passage	O
until	O
21	O
passages	O
were	O
seeded	O
into	O
35	O
-	O
mm	O
diameter	O
dishes	O
(	O
5	O
x	O
104	O
cells	O
/	O
dish	O
)	O
90	O
-	O
mm	O
diameter	O
dishes	O
(	O
2	O
x	O
105	O
cells	O
/	O
dish	O
)	O
in	O
?ñ	B-Chemical
-	I-Chemical
MEM	I-Chemical
containing	O
10	O
%	O
FBS	O
.	O
After	O
5	O
days	O
the	O
medium	O
was	O
exchanged	O
for	O
?ñ	B-Chemical
-	I-Chemical
MEM	I-Chemical
containing	O
0	O
.	O
3	O
%	O
FBS	O
.	O
The	O
cells	O
were	O
used	O
for	O
experiments	O
after	O
48	O
h	O
.	O
siRNA	O
transfection	O
To	O
knock	O
down	O
HSP90	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
the	O
cells	O
were	O
transfected	O
with	O
HSP90	O
-	O
siRNA	O
negative	O
control	O
siRNA	O
utilizing	O
siLentFect	O
according	O
to	O
the	O
manufacturer	O
ƒ??	O
s	O
protocol	O
.	O
In	O
brief	O
the	O
cells	O
(	O
2	O
x	O
105	O
cells	O
)	O
were	O
seeded	O
into	O
90	O
-	O
mm	O
diameter	O
dishes	O
in	O
?ñ	B-Chemical
-	I-Chemical
MEM	I-Chemical
containing	O
10	O
%	O
FBS	O
and	O
sub	O
-	O
cultured	O
for	O
48	O
h	O
.	O
The	O
cells	O
were	O
then	O
incubated	O
at	O
37	O
?ø	O
C	O
with	O
10	O
nM	O
siRNA	O
-	O
siLentFect	O
complexes	O
(#	O
1	O
)	O
30	O
nM	O
siRNA	O
-	O
siLentFect	O
complexes	O
(#	O
2	O
).	O
After	O
24	O
h	O
the	O
medium	O
was	O
exchanged	O
for	O
?ñ	B-Chemical
-	I-Chemical
MEM	I-Chemical
containing	O
0	O
.	O
3	O
%	O
FBS	O
.	O
The	O
transfected	O
cells	O
were	O
then	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
vehicle	O
in	O
?ñ	B-Chemical
-	I-Chemical
MEM	I-Chemical
containing	O
0	O
.	O
3	O
%	O
FBS	O
for	O
the	O
indicated	O
periods	O
.	O
Assay	O
for	O
IL	O
-	O
6	O
The	O
cultured	O
cells	O
were	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
vehicle	O
in	O
1	O
ml	O
?ñ	B-Chemical
-	I-Chemical
MEM	I-Chemical
containing	O
0	O
.	O
3	O
%	O
FBS	O
for	O
the	O
indicated	O
periods	O
.	O
When	O
indicated	O
cells	O
were	O
pretreated	O
with	O
various	O
doses	O
geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
for	O
60	O
min	O
.	O
The	O
preincubation	O
with	O
30	O
?¬M	O
SB203580	B-Chemical
vehicle	O
was	O
performed	O
for	O
60	O
min	O
prior	O
to	O
the	O
pretreatment	O
.	O
The	O
cells	O
were	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
vehicle	O
in	O
1	O
ml	O
?ñ	B-Chemical
-	I-Chemical
MEM	I-Chemical
containing	O
0	O
.	O
3	O
%	O
FBS	O
for	O
the	O
indicated	O
periods	O
.	O
The	O
conditioned	O
medium	O
was	O
collected	O
at	O
the	O
end	O
incubation	O
and	O
the	O
IL	O
-	O
6	O
concentration	O
in	O
the	O
medium	O
was	O
then	O
measured	O
using	O
the	O
mouse	O
IL	O
-	O
6	O
ELISA	O
kit	O
according	O
to	O
the	O
manufacturer	O
ƒ??	O
s	O
protocol	O
.	O
Reverse	O
transcription	O
-	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
The	O
cultured	O
cells	O
were	O
pretreated	O
with	O
0	O
.	O
3	O
?¬M	O
geldanamycin	B-Chemical
vehicle	O
for	O
60	O
min	O
and	O
then	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
vehicle	O
in	O
?ñ	B-Chemical
-	I-Chemical
MEM	I-Chemical
containing	O
0	O
.	O
3	O
%	O
FBS	O
for	O
3	O
h	O
.	O
Total	O
RNA	O
was	O
isolated	O
and	O
reverse	O
transcribed	O
into	O
complementary	O
DNA	O
using	O
TRIzol	B-Chemical
reagent	O
(	O
Invitrogen	O
;	O
Thermo	O
Fisher	O
Scientific	O
Inc	O
.	O
Heysham	O
Lancashire	O
UK	O
)	O
and	O
Reverse	O
Transcriptase	O
kit	O
(	O
Qiagen	O
Inc	O
.	O
Valencia	O
CA	O
)	O
respectively	O
.	O
RT	O
-	O
qPCR	O
was	O
performed	O
in	O
capillaries	O
using	O
a	O
LightCycler	O
system	O
with	O
the	O
LightCycler	O
FastStart	O
DNA	O
Master	O
SYBR	B-Chemical
Green	I-Chemical
I	I-Chemical
(	O
Roche	O
Diagnostics	O
Basel	O
Switzerland	O
).	O
Sense	O
and	O
antisense	O
primers	O
for	O
mouse	O
IL	O
-	O
6	O
mRNA	O
and	O
GAPDH	O
mRNA	O
were	O
purchased	O
from	O
Takara	O
Bio	O
Inc	O
.	O
(	O
Tokyo	O
Japan	O
)	O
(	O
primer	O
set	O
ID	O
:	O
MA039013	O
RA015380	O
respectively	O
).	O
The	O
amplified	O
products	O
were	O
determined	O
by	O
melting	O
curve	O
analysis	O
and	O
agarose	B-Chemical
electrophoresis	O
.	O
The	O
IL	O
-	O
6	O
mRNA	O
levels	O
were	O
normalized	O
to	O
those	O
GAPDH	O
mRNA	O
.	O
Western	O
blot	O
analysis	O
The	O
cultured	O
cells	O
were	O
pretreated	O
with	O
various	O
doses	O
geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
for	O
60	O
min	O
and	O
then	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
vehicle	O
in	O
?ñ	B-Chemical
-	I-Chemical
MEM	I-Chemical
containing	O
0	O
.	O
3	O
%	O
FBS	O
for	O
the	O
indicated	O
periods	O
.	O
As	O
for	O
the	O
HSP90	O
knockdown	O
cells	O
the	O
cells	O
transfected	O
with	O
siRNA	O
were	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
vehicle	O
in	O
1	O
ml	O
?ñ	B-Chemical
-	I-Chemical
MEM	I-Chemical
containing	O
0	O
.	O
3	O
%	O
FBS	O
for	O
the	O
indicated	O
periods	O
.	O
The	O
cells	O
were	O
then	O
washed	O
twice	O
with	O
phosphate	B-Chemical
-	I-Chemical
buffered	I-Chemical
saline	I-Chemical
and	O
then	O
lysed	O
homogenized	O
and	O
sonicated	O
in	O
a	O
lysis	O
buffer	O
containing	O
62	O
.	O
5	O
mM	O
Tris	B-Chemical
/	O
HCl	B-Chemical
pH	O
6	O
.	O
8	O
2	O
%	O
sodium	B-Chemical
dodecyl	I-Chemical
sulfate	I-Chemical
(	O
SDS	B-Chemical
)	O
50	O
mM	O
dithiothreitol	B-Chemical
and	O
10	O
%	O
glycerol	B-Chemical
.	O
SDS	B-Chemical
-	I-Chemical
polyacrylamide	I-Chemical
gel	O
electrophoresis	O
(	O
PAGE	O
)	O
was	O
performed	O
by	O
the	O
method	O
Laemmli	O
[	O
28	O
]	O
in	O
10	O
%	O
polyacrylamide	B-Chemical
gels	O
.	O
The	O
protein	O
was	O
fractionated	O
and	O
transferred	O
an	O
Immun	O
-	O
Blot	O
PVDF	B-Chemical
membrane	O
(	O
Bio	O
-	O
Rad	O
Hercules	O
CA	O
).	O
The	O
membranes	O
were	O
blocked	O
with	O
5	O
%	O
fat	O
-	O
free	O
dry	O
milk	O
in	O
Tris	B-Chemical
-	I-Chemical
buffered	I-Chemical
saline	I-Chemical
-	I-Chemical
Tween	I-Chemical
(	O
TBS	B-Chemical
-	I-Chemical
T	I-Chemical
;	O
20	O
mM	O
Tris	B-Chemical
-	I-Chemical
HCl	I-Chemical
pH	O
7	O
.	O
6	O
137	O
mM	O
NaCl	B-Chemical
0	O
.	O
1	O
%	O
Tween	B-Chemical
20	I-Chemical
)	O
for	O
1	O
h	O
before	O
incubation	O
with	O
primary	O
antibodies	O
.	O
Western	O
blot	O
analysis	O
was	O
performed	O
as	O
described	O
previously	O
[	O
29	O
]	O
using	O
phospho	O
-	O
specific	O
p44	O
/	O
p42	O
MAP	O
kinase	O
antibodies	O
p44	O
/	O
p42	O
MAP	O
kinase	O
antibodies	O
phospho	O
-	O
specific	O
p38	O
MAP	O
kinase	O
antibodies	O
p38	O
MAP	O
kinase	O
antibodies	O
HSP90	O
antibodies	O
phospho	O
-	O
specific	O
MYPT	O
-	O
1	O
antibodies	O
MYPT	O
-	O
1	O
antibodies	O
RhoA	O
antibodies	O
ROCK1	O
antibodies	O
and	O
GAPDH	O
antibodies	O
as	O
primary	O
antibodies	O
with	O
peroxidase	O
-	O
labeled	O
antibodies	O
raised	O
in	O
goat	O
against	O
rabbit	O
IgG	O
(	O
KPL	O
Inc	O
.	O
Gaithersburg	O
MD	O
)	O
used	O
as	O
secondary	O
antibodies	O
.	O
The	O
primary	O
and	O
secondary	O
antibodies	O
were	O
diluted	O
at	O
1	O
:	O
1000	O
with	O
5	O
%	O
fat	O
-	O
free	O
dry	O
milk	O
in	O
TBS	B-Chemical
-	I-Chemical
T	I-Chemical
.	O
The	O
peroxidase	O
activity	O
the	O
PVDF	B-Chemical
sheet	O
was	O
visualized	O
X	O
-	O
ray	O
film	O
by	O
means	O
the	O
ECL	O
Western	O
blotting	O
detection	O
system	O
.	O
Densitometric	O
analysis	O
A	O
densitometric	O
analysis	O
the	O
Western	O
blots	O
was	O
performed	O
using	O
a	O
scanner	O
and	O
image	O
analysis	O
software	O
program	O
(	O
image	O
J	O
version	O
1	O
.	O
48	O
National	O
Institutes	O
Health	O
Bethesda	O
MD	O
).	O
The	O
phosphorylated	O
protein	O
levels	O
were	O
calculated	O
as	O
follows	O
:	O
the	O
background	O
-	O
subtracted	O
signal	O
intensity	O
each	O
phosphorylation	O
signal	O
was	O
respectively	O
normalized	O
to	O
the	O
total	O
protein	O
signal	O
and	O
plotted	O
as	O
the	O
fold	O
increase	O
in	O
comparison	O
to	O
that	O
the	O
control	O
cells	O
without	O
stimulation	O
.	O
Statistical	O
analysis	O
The	O
data	O
were	O
analyzed	O
by	O
ANOVA	O
followed	O
by	O
Bonferroni	O
method	O
for	O
multiple	O
comparisons	O
between	O
pairs	O
and	O
p	O
<	O
0	O
.	O
5	O
was	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O
All	O
data	O
are	O
presented	O
as	O
the	O
mean	O
?ñ	O
S	O
.	O
E	O
.	O
M	O
.	O
triplicate	O
determinations	O
from	O
three	O
independent	O
cell	O
preparations	O
.	O
Results	O
Effects	O
HSP90	O
inhibitors	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
in	O
MC3T3	O
-	O
E1	O
cells	O
It	O
is	O
recognized	O
that	O
geldanamycin	B-Chemical
a	O
benzoquinone	B-Chemical
ansamycin	I-Chemical
antibiotic	O
binds	O
to	O
the	O
N	O
-	O
terminal	O
domain	O
ATP	B-Chemical
binding	O
site	O
HSP90	O
inhibiting	O
ATP	B-Chemical
-	O
dependent	O
HSP90	O
chaperone	O
activity	O
[	O
7	O
10	O
]	O
and	O
its	O
less	O
toxic	O
derivative	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
and	O
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
also	O
bind	O
specifically	O
to	O
HSP90	O
in	O
a	O
manner	O
similar	O
to	O
geldanamycin	B-Chemical
[	O
8	O
9	O
].	O
In	O
to	O
investigate	O
the	O
involvement	O
HSP90	O
in	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
synthesis	O
IL	O
-	O
6	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
we	O
first	O
examined	O
the	O
effects	O
these	O
HSP90	O
inhibitors	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
.	O
Geldanamycin	B-Chemical
significantly	O
amplified	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
up	O
to	O
48	O
h	O
(	O
Fig	O
1A	O
).	O
In	O
addition	O
the	O
enhancing	O
effect	O
geldanamycin	B-Chemical
was	O
dose	O
-	O
dependent	O
in	O
the	O
range	O
between	O
0	O
.	O
1	O
and	O
1	O
?¬M	O
(	O
Fig	O
1B	O
).	O
The	O
maximum	O
effect	O
geldanamycin	B-Chemical
was	O
at	O
1	O
?¬M	O
which	O
caused	O
an	O
approximately	O
330	O
%	O
increase	O
in	O
the	O
PGF2?ñ	B-Chemical
-	O
effect	O
.	O
Additionally	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
significantly	O
enhanced	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
(	O
Fig	O
2A	O
).	O
The	O
effect	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
(	O
0	O
.	O
1	O
?¬M	O
)	O
the	O
IL	O
-	O
6	O
release	O
caused	O
an	O
approximately	O
150	O
%	O
increase	O
in	O
the	O
PGF2?ñ	B-Chemical
-	O
effect	O
.	O
Furthermore	O
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
significantly	O
amplified	O
the	O
IL	O
-	O
6	O
release	O
(	O
Fig	O
2B	O
).	O
The	O
amplifying	O
effect	O
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
(	O
0	O
.	O
1	O
?¬M	O
)	O
caused	O
an	O
approximately	O
240	O
%	O
increase	O
in	O
the	O
PGF2?ñ	B-Chemical
-	O
effect	O
.	O
Effect	O
geldanamycin	B-Chemical
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O
(	O
A	O
)	O
The	O
cultured	O
cells	O
were	O
pretreated	O
with	O
1	O
?¬M	O
geldanamycin	B-Chemical
(ƒ?ƒ??)	O
vehicle	O
(ƒ?ÿƒ?­)	O
for	O
60	O
min	O
and	O
then	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
(ƒ?ƒ?ÿ)	O
vehicle	O
(ƒ??ƒ?­)	O
for	O
the	O
indicated	O
periods	O
.	O
(	O
B	O
)	O
The	O
cultured	O
cells	O
were	O
pretreated	O
with	O
various	O
doses	O
geldanamycin	B-Chemical
for	O
60	O
min	O
and	O
then	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
(ƒ?)	O
vehicle	O
(ƒ??)	O
for	O
48	O
h	O
.	O
IL	O
-	O
6	O
concentrations	O
in	O
the	O
conditioned	O
medium	O
were	O
determined	O
by	O
ELISA	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
?ñ	O
S	O
.	O
E	O
.	O
M	O
.	O
triplicate	O
determinations	O
from	O
three	O
independent	O
cell	O
preparations	O
.	O
(	O
A	O
)	O
*	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
control	O
.	O
**	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
PGF2?ñ	B-Chemical
alone	O
.	O
(	O
B	O
)	O
*	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
PGF2?ñ	B-Chemical
alone	O
.	O
Effects	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O
The	O
cultured	O
cells	O
were	O
pretreated	O
with	O
1	O
?¬M	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
(	O
A	O
)	O
1	O
?¬M	O
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
(	O
B	O
)	O
vehicle	O
for	O
60	O
min	O
and	O
then	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
vehicle	O
for	O
48	O
h	O
.	O
(	O
C	O
)	O
The	O
cultured	O
cells	O
were	O
pretreated	O
with	O
various	O
doses	O
for	O
60	O
min	O
and	O
then	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
(ƒ?)	O
vehicle	O
(ƒ??)	O
for	O
48	O
h	O
.	O
IL	O
-	O
6	O
concentrations	O
in	O
the	O
conditioned	O
medium	O
were	O
determined	O
by	O
ELISA	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
?ñ	O
S	O
.	O
E	O
.	O
M	O
.	O
triplicate	O
determinations	O
from	O
three	O
independent	O
cell	O
preparations	O
.	O
(	O
A	O
B	O
)	O
*	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
control	O
.	O
(	O
A	O
B	O
)	O
**	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
PGF2?ñ	B-Chemical
alone	O
.	O
(	O
C	O
)	O
*	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
PGF2?ñ	B-Chemical
alone	O
.	O
It	O
is	O
known	O
that	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
and	O
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
belong	O
to	O
geldanamycin	B-Chemical
analogues	O
[	O
30	O
]	O
and	O
is	O
another	O
type	O
HSP90	O
inhibitor	O
different	O
from	O
geldanamycin	B-Chemical
analogues	O
which	O
binds	O
to	O
the	O
N	O
-	O
terminal	O
domain	O
ATP	B-Chemical
binding	O
site	O
HSP90	O
[	O
31	O
].	O
We	O
further	O
examined	O
the	O
effect	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
IL	O
-	O
6	O
release	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
.	O
which	O
by	O
itself	O
had	O
little	O
effect	O
the	O
IL	O
-	O
6	O
release	O
significantly	O
amplified	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
as	O
well	O
as	O
geldanamycin	B-Chemical
analogues	O
(	O
Fig	O
2C	O
).	O
The	O
enhancing	O
effect	O
was	O
dose	O
-	O
dependent	O
in	O
the	O
range	O
between	O
0	O
.	O
1	O
and	O
0	O
.	O
1	O
?¬M	O
.	O
at	O
0	O
.	O
1	O
?¬M	O
caused	O
an	O
approximately	O
300	O
%	O
increase	O
in	O
the	O
PGF2?ñ	B-Chemical
-	O
effect	O
.	O
Effects	O
geldanamycin	B-Chemical
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
expression	O
IL	O
-	O
6	O
mRNA	O
in	O
MC3T3	O
-	O
E1	O
cells	O
In	O
to	O
clarify	O
whether	O
the	O
amplifying	O
effects	O
geldanamycin	B-Chemical
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
is	O
mediated	O
through	O
transcriptional	O
events	O
we	O
next	O
examined	O
the	O
effects	O
geldanamycin	B-Chemical
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
IL	O
-	O
6	O
mRNA	O
expression	O
.	O
We	O
found	O
that	O
geldanamycin	B-Chemical
and	O
which	O
by	O
themselves	O
had	O
little	O
effect	O
the	O
mRNA	O
levels	O
IL	O
-	O
6	O
significantly	O
up	O
-	O
regulated	O
the	O
expression	O
levels	O
mRNA	O
induced	O
by	O
PGF2?ñ	B-Chemical
(	O
Fig	O
3A	O
and	O
Fig	O
3B	O
).	O
Effects	O
geldanamycin	B-Chemical
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
expression	O
levels	O
IL	O
-	O
6	O
mRNA	O
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O
The	O
cultured	O
cells	O
were	O
pretreated	O
with	O
0	O
.	O
3	O
?¬M	O
geldanamycin	B-Chemical
(	O
A	O
)	O
(	O
B	O
)	O
vehicle	O
for	O
60	O
min	O
and	O
then	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
vehicle	O
for	O
3	O
h	O
.	O
The	O
respective	O
total	O
RNA	O
was	O
then	O
isolated	O
and	O
transcribed	O
into	O
cDNA	O
.	O
The	O
expressions	O
IL	O
-	O
6	O
mRNA	O
and	O
GAPDH	O
mRNA	O
were	O
quantified	O
by	O
RT	O
-	O
qPCR	O
.	O
The	O
IL	O
-	O
6	O
mRNA	O
levels	O
were	O
normalized	O
to	O
those	O
GAPDH	O
mRNA	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
?ñ	O
S	O
.	O
E	O
.	O
M	O
.	O
triplicate	O
determinations	O
from	O
three	O
independent	O
cell	O
preparations	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
control	O
.	O
**	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
PGF2?ñ	B-Chemical
alone	O
.	O
Effects	O
HSP90	O
inhibitors	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
p44	O
/	O
p42	O
MAP	O
kinase	O
in	O
MC3T3	O
-	O
E1	O
cells	O
Regarding	O
the	O
intracellular	O
signaling	O
pathway	O
PGF2?ñ	B-Chemical
in	O
we	O
have	O
shown	O
that	O
p44	O
/	O
p42	O
MAP	O
kinase	O
acts	O
as	O
a	O
positive	O
regulator	O
in	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
[	O
23	O
24	O
].	O
Therefore	O
we	O
examined	O
the	O
effects	O
HSP90	O
inhibitors	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
p44	O
/	O
p42	O
MAP	O
kinase	O
in	O
these	O
cells	O
.	O
However	O
geldanamycin	B-Chemical
failed	O
to	O
affect	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
p44	O
/	O
p42	O
MAP	O
kinase	O
(	O
Fig	O
4A	O
).	O
In	O
addition	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
had	O
no	O
effect	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
p44	O
/	O
p42	O
MAP	O
kinase	O
(	O
Fig	O
4B	O
).	O
Effects	O
geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
p44	O
/	O
p42	O
MAP	O
kinase	O
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O
The	O
cultured	O
cells	O
were	O
pretreated	O
with	O
various	O
doses	O
geldanamycin	B-Chemical
(	O
A	O
)	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
(	O
B	O
)	O
for	O
60	O
min	O
and	O
then	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
vehicle	O
for	O
20	O
min	O
.	O
The	O
cell	O
extracts	O
were	O
then	O
subjected	O
to	O
SDS	B-Chemical
-	O
PAGE	O
with	O
subsequent	O
Western	O
blot	O
analysis	O
with	O
antibodies	O
against	O
phospho	O
-	O
specific	O
p44	O
/	O
p42	O
MAP	O
kinase	O
p44	O
/	O
p42	O
MAP	O
kinase	O
.	O
The	O
histogram	O
shows	O
the	O
quantitative	O
representations	O
the	O
levels	O
phosphorylated	O
p44	O
/	O
p42	O
MAP	O
kinase	O
after	O
normalization	O
with	O
respect	O
to	O
p44	O
/	O
p42	O
MAP	O
kinase	O
from	O
laser	O
densitometric	O
analysis	O
.	O
The	O
levels	O
were	O
expressed	O
as	O
the	O
fold	O
increase	O
to	O
the	O
basal	O
levels	O
presented	O
as	O
lane	O
1	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
?ñ	O
S	O
.	O
E	O
.	O
M	O
.	O
triplicate	O
determinations	O
from	O
three	O
independent	O
cell	O
preparations	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
control	O
.	O
N	O
.	O
S	O
.	O
designates	O
no	O
significant	O
difference	O
between	O
the	O
indicated	O
pairs	O
.	O
Effects	O
HSP90	O
inhibitors	O
the	O
phosphorylation	O
p38	O
MAP	O
kinase	O
induced	O
by	O
PGF2?ñ	B-Chemical
in	O
MC3T3	O
-	O
E1	O
cells	O
In	O
previous	O
study	O
[	O
24	O
]	O
we	O
demonstrated	O
that	O
PGF2?ñ	B-Chemical
stimulates	O
IL	O
-	O
6	O
synthesis	O
at	O
least	O
in	O
part	O
through	O
p38	O
MAP	O
kinase	O
in	O
addition	O
to	O
p44	O
/	O
p42	O
MAP	O
kinase	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
.	O
In	O
to	O
clarify	O
whether	O
the	O
activation	O
p38	O
MAP	O
kinase	O
is	O
implicated	O
in	O
the	O
enhancement	O
by	O
HSP90	O
inhibitors	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
IL	O
-	O
6	O
synthesis	O
in	O
MC3T3	O
-	O
E1	O
cells	O
we	O
examined	O
the	O
effects	O
HSP90	O
inhibitors	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
p38	O
MAP	O
kinase	O
.	O
Geldanamycin	B-Chemical
which	O
alone	O
had	O
little	O
effect	O
the	O
p38	O
MAP	O
kinase	O
phosphorylation	O
significantly	O
strengthened	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
p38	O
MAP	O
kinase	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
in	O
the	O
range	O
between	O
0	O
.	O
3	O
and	O
1	O
.	O
0	O
?¬M	O
(	O
Fig	O
5A	O
).	O
Additionally	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
as	O
well	O
as	O
geldanamycin	B-Chemical
which	O
by	O
itself	O
did	O
not	O
affect	O
the	O
p38	O
MAP	O
kinase	O
phosphorylation	O
markedly	O
enhanced	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
p38	O
MAP	O
kinase	O
(	O
Fig	O
5B	O
).	O
The	O
amplifying	O
effect	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
the	O
p38	O
MAP	O
kinase	O
phosphorylation	O
was	O
dose	O
-	O
dependent	O
in	O
the	O
range	O
between	O
0	O
.	O
3	O
and	O
1	O
.	O
0	O
?¬M	O
.	O
Furthermore	O
we	O
found	O
that	O
(	O
1	O
?¬M	O
)	O
as	O
well	O
as	O
geldanamycin	B-Chemical
and	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
which	O
by	O
itself	O
had	O
little	O
effect	O
the	O
p38	O
MAP	O
kinase	O
phosphorylation	O
markedly	O
enhanced	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
p38	O
MAP	O
kinase	O
(	O
Fig	O
5C	O
).	O
Effects	O
geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
the	O
phosphorylation	O
p38	O
MAP	O
kinase	O
induced	O
by	O
PGF2?ñ	B-Chemical
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O
The	O
cultured	O
cells	O
were	O
pretreated	O
with	O
the	O
indicated	O
doses	O
geldanamycin	B-Chemical
(	O
A	O
)	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
(	O
B	O
)	O
(	O
C	O
)	O
for	O
60	O
min	O
and	O
then	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
vehicle	O
for	O
10	O
min	O
.	O
The	O
cell	O
extracts	O
were	O
then	O
subjected	O
to	O
SDS	B-Chemical
-	O
PAGE	O
with	O
subsequent	O
Western	O
blot	O
analysis	O
with	O
antibodies	O
against	O
phospho	O
-	O
specific	O
p38	O
MAP	O
kinase	O
p38	O
MAP	O
kinase	O
.	O
The	O
histogram	O
shows	O
the	O
quantitative	O
representations	O
the	O
levels	O
phosphorylated	O
p38	O
MAP	O
kinase	O
after	O
normalization	O
with	O
respect	O
to	O
p38	O
MAP	O
kinase	O
from	O
laser	O
densitometric	O
analysis	O
.	O
The	O
levels	O
were	O
expressed	O
as	O
the	O
fold	O
increase	O
to	O
the	O
basal	O
levels	O
presented	O
as	O
lane	O
1	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
?ñ	O
S	O
.	O
E	O
.	O
M	O
.	O
triplicate	O
determinations	O
from	O
three	O
independent	O
cell	O
preparations	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
control	O
.	O
**	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
PGF2?ñ	B-Chemical
alone	O
.	O
Effects	O
HSP90	O
inhibitors	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
MYPT	O
-	O
1	O
and	O
the	O
protein	O
levels	O
MYPT	O
-	O
1	O
RhoA	O
and	O
Rho	O
-	O
kinase	O
in	O
MC3T3	O
-	O
E1	O
cells	O
In	O
addition	O
to	O
previous	O
findings	O
in	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
we	O
have	O
demonstrated	O
that	O
Rho	O
-	O
kinase	O
positively	O
regulates	O
at	O
a	O
point	O
upstream	O
p38	O
MAP	O
kinase	O
[	O
25	O
].	O
It	O
is	O
generally	O
recognized	O
that	O
MYPT	O
-	O
1	O
which	O
is	O
a	O
component	O
myosin	O
phosphatase	O
is	O
a	O
substrate	O
Rho	O
-	O
kinase	O
[	O
32	O
33	O
].	O
We	O
next	O
examined	O
the	O
effects	O
HSP90	O
inhibitors	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
MYPT	O
-	O
1	O
and	O
the	O
protein	O
levels	O
MYPT	O
-	O
1	O
RhoA	O
and	O
Rho	O
-	O
kinase	O
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O
Geldanamycin	B-Chemical
failed	O
to	O
affect	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
MYPT	O
-	O
1	O
(	O
Fig	O
6A	O
).	O
We	O
found	O
that	O
the	O
protein	O
levels	O
MYPT	O
-	O
1	O
RhoA	O
Rho	O
-	O
kinase	O
were	O
not	O
affected	O
by	O
geldanamycin	B-Chemical
with	O
without	O
PGF2?ñ	B-Chemical
stimulation	O
(	O
Fig	O
6A	O
).	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
as	O
well	O
as	O
geldanamycin	B-Chemical
had	O
no	O
effect	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
MYPT	O
-	O
1	O
(	O
Fig	O
6B	O
).	O
In	O
addition	O
we	O
confirmed	O
that	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
did	O
not	O
affect	O
the	O
amounts	O
MYPT	O
-	O
1	O
RhoA	O
Rho	O
-	O
kinase	O
(	O
data	O
not	O
shown	O
).	O
Effects	O
geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
the	O
phosphorylation	O
MYPT	O
-	O
1	O
the	O
amounts	O
MYPT	O
-	O
1	O
RhoA	O
and	O
Rho	O
-	O
kinase	O
induced	O
by	O
PGF2?ñ	B-Chemical
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O
The	O
cultured	O
cells	O
were	O
pretreated	O
with	O
various	O
doses	O
geldanamycin	B-Chemical
(	O
A	O
)	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
(	O
B	O
)	O
for	O
60	O
min	O
and	O
then	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
vehicle	O
for	O
2	O
min	O
.	O
The	O
cell	O
extracts	O
were	O
then	O
subjected	O
to	O
SDS	B-Chemical
-	O
PAGE	O
with	O
subsequent	O
Western	O
blot	O
analysis	O
with	O
antibodies	O
against	O
phospho	O
-	O
specific	O
MYPT	O
-	O
1	O
MYPT	O
-	O
1	O
RhoA	O
Rho	O
-	O
kinase	O
.	O
(	O
a	O
)	O
The	O
histogram	O
shows	O
the	O
quantitative	O
representations	O
the	O
levels	O
phosphorylated	O
MYPT	O
-	O
1	O
after	O
normalization	O
with	O
respect	O
to	O
MYPT	O
-	O
1	O
from	O
laser	O
densitometric	O
analysis	O
.	O
The	O
levels	O
were	O
expressed	O
as	O
the	O
fold	O
increase	O
to	O
the	O
basal	O
levels	O
presented	O
as	O
lane	O
1	O
.	O
(	O
b	O
)(	O
c	O
)(	O
d	O
)	O
The	O
histogram	O
shows	O
the	O
quantitative	O
representations	O
the	O
levels	O
MYPT	O
-	O
1	O
(	O
b	O
)	O
RhoA	O
(	O
c	O
)	O
and	O
Rho	O
-	O
kinase	O
(	O
d	O
)	O
after	O
normalization	O
with	O
respect	O
to	O
GAPDH	O
from	O
laser	O
densitometric	O
analysis	O
respectively	O
.	O
The	O
levels	O
were	O
expressed	O
as	O
the	O
ratio	O
to	O
the	O
levels	O
presented	O
as	O
lane	O
1	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
?ñ	O
S	O
.	O
E	O
.	O
M	O
.	O
triplicate	O
determinations	O
from	O
three	O
independent	O
cell	O
preparations	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
control	O
.	O
N	O
.	O
S	O
.	O
designates	O
no	O
significant	O
difference	O
between	O
the	O
indicated	O
pairs	O
.	O
Effect	O
PGF2?ñ	B-Chemical
the	O
phosphorylation	O
p38	O
MAP	O
kinase	O
in	O
HSP90	O
knockdown	O
MC3T3	O
-	O
E1	O
cells	O
To	O
further	O
investigate	O
whether	O
HSP90	O
affects	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
p38	O
MAP	O
kinase	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
we	O
examined	O
the	O
effect	O
HSP90	O
-	O
siRNA	O
the	O
phosphorylation	O
p38	O
MAP	O
kinase	O
induced	O
by	O
PGF2?ñ	B-Chemical
.	O
We	O
found	O
that	O
the	O
levels	O
HSP90	O
were	O
not	O
significantly	O
but	O
slightly	O
reduced	O
in	O
the	O
HSP90	O
-	O
siRNA	O
(#	O
1	O
and	O
#	O
2	O
)-	O
transfected	O
cells	O
(	O
Fig	O
7A	O
and	O
Fig	O
7B	O
).	O
The	O
levels	O
phosphorylated	O
p38	O
MAP	O
kinase	O
induced	O
by	O
PGF2?ñ	B-Chemical
in	O
the	O
HSP90	O
-	O
siRNA	O
transfected	O
cells	O
(#	O
1	O
and	O
#	O
2	O
)	O
were	O
significantly	O
amplified	O
compared	O
to	O
those	O
in	O
the	O
control	O
cells	O
(	O
Fig	O
7A	O
and	O
Fig	O
7B	O
).	O
Thus	O
it	O
seems	O
likely	O
that	O
HSP90	O
-	O
siRNA	O
has	O
little	O
effect	O
HSP90	O
protein	O
levels	O
but	O
reduces	O
HSP90	O
activity	O
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O
The	O
protein	O
levels	O
p38	O
MAP	O
kinase	O
were	O
not	O
affected	O
by	O
HSP90	O
-	O
siRNA	O
(#	O
1	O
and	O
#	O
2	O
).	O
Effect	O
PGF2?ñ	B-Chemical
the	O
phosphorylation	O
p38	O
MAP	O
kinase	O
in	O
HSP90	O
knockdown	O
MC3T3	O
-	O
E1	O
cells	O
.	O
(	O
A	O
)	O
The	O
cultured	O
cells	O
were	O
transfected	O
with	O
10	O
nM	O
negative	O
control	O
siRNA	O
(	O
Neg	O
)	O
10	O
nM	O
HSP90	O
-	O
siRNA	O
(#	O
1	O
).	O
(	O
B	O
)	O
The	O
cultured	O
cells	O
were	O
transfected	O
with	O
30	O
nM	O
negative	O
control	O
siRNA	O
(	O
Neg	O
)	O
30	O
nM	O
HSP90	O
-	O
siRNA	O
(#	O
2	O
).	O
Twenty	O
-	O
four	O
hours	O
after	O
transfection	O
the	O
cells	O
were	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
vehicle	O
for	O
10	O
min	O
.	O
The	O
cell	O
extracts	O
were	O
then	O
subjected	O
to	O
SDS	B-Chemical
-	O
PAGE	O
with	O
subsequent	O
Western	O
blot	O
analysis	O
with	O
antibodies	O
against	O
phospho	O
-	O
specific	O
p38	O
MAP	O
kinase	O
p38	O
MAP	O
kinase	O
HSP90	O
GAPDH	O
.	O
(	O
a	O
)	O
The	O
histogram	O
shows	O
the	O
quantitative	O
representations	O
the	O
levels	O
phosphorylated	O
p38	O
MAP	O
kinase	O
after	O
normalization	O
with	O
respect	O
to	O
GAPDH	O
from	O
laser	O
densitometric	O
analysis	O
.	O
The	O
levels	O
were	O
expressed	O
as	O
the	O
fold	O
increase	O
to	O
the	O
basal	O
levels	O
presented	O
as	O
lane	O
1	O
.	O
(	O
b	O
)(	O
c	O
)	O
The	O
histogram	O
shows	O
the	O
quantitative	O
representations	O
the	O
levels	O
(	O
b	O
)	O
total	O
p38	O
MAP	O
kinase	O
and	O
(	O
c	O
)	O
HSP90?ñ?ý	O
after	O
normalization	O
with	O
respect	O
to	O
GAPDH	O
from	O
laser	O
densitometric	O
analysis	O
respectively	O
.	O
The	O
levels	O
were	O
expressed	O
as	O
the	O
ratio	O
to	O
the	O
levels	O
presented	O
as	O
lane	O
1	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
?ñ	O
S	O
.	O
E	O
.	O
M	O
.	O
triplicate	O
determinations	O
from	O
three	O
independent	O
cell	O
preparations	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
control	O
.	O
**	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
PGF2?ñ	B-Chemical
alone	O
.	O
Effect	O
SB203580	B-Chemical
the	O
enhancement	O
by	O
HSP90	O
inhibitors	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
in	O
MC3T3	O
-	O
E1	O
cells	O
Furthermore	O
we	O
examined	O
the	O
effect	O
SB203580	B-Chemical
a	O
p38	O
MAP	O
kinase	O
inhibitor	O
[	O
34	O
]	O
the	O
enhancement	O
by	O
HSP90	O
inhibitors	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
.	O
We	O
found	O
that	O
SB203580	B-Chemical
which	O
by	O
itself	O
had	O
little	O
effect	O
IL	O
-	O
6	O
levels	O
truly	O
suppressed	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
IL	O
-	O
6	O
release	O
as	O
previous	O
report	O
[	O
25	O
]	O
(	O
Fig	O
8	O
).	O
SB203580	B-Chemical
markedly	O
reduced	O
the	O
amplification	O
by	O
geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
(	O
Fig	O
8	O
).	O
SB203580	B-Chemical
(	O
30	O
?¬M	O
)	O
caused	O
an	O
approximately	O
90	O
%	O
90	O
%	O
and	O
95	O
%	O
decrease	O
in	O
the	O
effect	O
PGF2?ñ	B-Chemical
with	O
geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
and	O
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
respectively	O
.	O
Effect	O
SB203580	B-Chemical
the	O
enhancement	O
by	O
geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
IL	O
-	O
6	O
release	O
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O
The	O
cultured	O
cells	O
were	O
preincubated	O
with	O
30	O
?¬M	O
SB203580	B-Chemical
vehicle	O
for	O
60	O
min	O
subsequently	O
pretreated	O
with	O
1	O
?¬M	O
geldanamycin	B-Chemical
1	O
?¬M	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
1	O
?¬M	O
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
vehicle	O
for	O
60	O
min	O
and	O
then	O
stimulated	O
by	O
10	O
?¬M	O
PGF2?ñ	B-Chemical
vehicle	O
for	O
48	O
h	O
.	O
IL	O
-	O
6	O
concentrations	O
the	O
conditioned	O
mediums	O
were	O
determined	O
by	O
ELISA	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
?ñ	O
S	O
.	O
E	O
.	O
M	O
.	O
triplicate	O
determinations	O
from	O
three	O
independent	O
cell	O
preparations	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
control	O
.	O
**	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
PGF2?ñ	B-Chemical
alone	O
.	O
***	O
p	O
<	O
0	O
.	O
5	O
compared	O
to	O
the	O
value	O
PGF2?ñ	B-Chemical
with	O
the	O
pretreatment	O
each	O
HSP90	O
inhibitor	O
.	O
Discussion	O
In	O
the	O
present	O
study	O
we	O
demonstrated	O
that	O
HSP90	O
inhibitors	O
including	O
geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
and	O
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
significantly	O
enhanced	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
release	O
IL	O
-	O
6	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
.	O
We	O
also	O
found	O
that	O
another	O
type	O
HSP90	O
inhibitor	O
[	O
31	O
]	O
amplified	O
the	O
IL	O
-	O
6	O
release	O
induced	O
by	O
PGF2?ñ	B-Chemical
in	O
these	O
cells	O
.	O
In	O
addition	O
we	O
showed	O
that	O
the	O
expression	O
levels	O
IL	O
-	O
6	O
mRNA	O
induced	O
by	O
PGF2?ñ	B-Chemical
were	O
markedly	O
amplified	O
by	O
geldanamycin	B-Chemical
and	O
.	O
Thus	O
it	O
seems	O
likely	O
that	O
the	O
amplifying	O
effect	O
HSP90	O
inhibitors	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
is	O
mediated	O
through	O
the	O
gene	O
transcription	O
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O
Based	O
findings	O
it	O
is	O
probable	O
that	O
HSP90	O
plays	O
an	O
inhibitory	O
role	O
in	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
.	O
To	O
the	O
best	O
knowledge	O
this	O
is	O
probable	O
the	O
first	O
report	O
showing	O
the	O
suppression	O
by	O
HSP90	O
IL	O
-	O
6	O
synthesis	O
in	O
.	O
Therefore	O
we	O
next	O
investigated	O
the	O
exact	O
mechanism	O
behind	O
the	O
suppression	O
by	O
HSP90	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
.	O
Regarding	O
the	O
intracellular	O
signaling	O
system	O
PGF2?ñ	B-Chemical
in	O
we	O
have	O
previously	O
shown	O
that	O
PGF2?ñ	B-Chemical
stimulates	O
the	O
synthesis	O
IL	O
-	O
6	O
through	O
p44	O
/	O
p42	O
MAP	O
kinase	O
and	O
p38	O
MAP	O
kinase	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
[	O
23	O
24	O
].	O
Additionally	O
in	O
previous	O
study	O
[	O
25	O
]	O
we	O
have	O
reported	O
that	O
Rho	O
-	O
kinase	O
positively	O
regulates	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
at	O
a	O
point	O
upstream	O
not	O
p44	O
/	O
p42	O
MAP	O
kinase	O
but	O
p38	O
MAP	O
kinase	O
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O
Thus	O
we	O
investigated	O
whether	O
HSP90	O
inhibitors	O
affect	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
activation	O
p44	O
/	O
p42	O
MAP	O
kinase	O
p38	O
MAP	O
kinase	O
in	O
these	O
cells	O
.	O
However	O
neither	O
geldanamycin	B-Chemical
nor	O
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
affected	O
the	O
phosphorylation	O
p44	O
/	O
p42	O
MAP	O
kinase	O
.	O
the	O
contrary	O
we	O
demonstrated	O
that	O
geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
and	O
significantly	O
enhanced	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
phosphorylation	O
p38	O
MAP	O
kinase	O
.	O
Therefore	O
it	O
is	O
probable	O
that	O
the	O
enhancement	O
by	O
HSP90	O
inhibitors	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
is	O
due	O
to	O
up	O
-	O
regulating	O
the	O
activation	O
p38	O
MAP	O
kinase	O
but	O
not	O
p44	O
/	O
p42	O
MAP	O
kinase	O
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O
In	O
addition	O
we	O
demonstrated	O
that	O
either	O
geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
failed	O
to	O
affect	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
MYPT	O
-	O
1	O
a	O
substrate	O
Rho	O
-	O
kinase	O
[	O
33	O
].	O
We	O
also	O
found	O
that	O
HSP90	O
inhibitors	O
had	O
no	O
effect	O
the	O
amounts	O
MYPT	O
-	O
1	O
RhoA	O
Rho	O
-	O
kinase	O
.	O
It	O
is	O
generally	O
recognized	O
that	O
Rho	O
and	O
the	O
down	O
-	O
stream	O
effector	O
Rho	O
-	O
kinase	O
play	O
crucial	O
roles	O
in	O
a	O
variety	O
cellular	O
functions	O
such	O
as	O
cell	O
motility	O
and	O
smooth	O
muscle	O
contraction	O
[	O
32	O
33	O
].	O
As	O
for	O
it	O
has	O
been	O
shown	O
that	O
the	O
inhibition	O
RhoA	O
-	O
Rho	O
-	O
kinase	O
signaling	O
influences	O
adhesion	O
differentiation	O
and	O
mineralization	O
[	O
35	O
].	O
In	O
the	O
present	O
study	O
we	O
showed	O
that	O
HSP90	O
inhibitors	O
failed	O
to	O
affect	O
the	O
phosphorylation	O
MYPT	O
-	O
1	O
a	O
target	O
Rho	O
-	O
kinase	O
.	O
Based	O
findings	O
it	O
seems	O
unlikely	O
that	O
the	O
amplification	O
by	O
HSP90	O
inhibitors	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
is	O
mediated	O
through	O
the	O
enhancement	O
RhoA	O
-	O
Rho	O
-	O
kinase	O
activity	O
.	O
findings	O
suggest	O
that	O
HSP90	O
might	O
function	O
as	O
a	O
negative	O
regulator	O
in	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
and	O
that	O
the	O
effect	O
HSP90	O
the	O
IL	O
-	O
6	O
synthesis	O
is	O
exerted	O
at	O
the	O
point	O
between	O
Rho	O
-	O
kinase	O
and	O
p38	O
MAP	O
kinase	O
.	O
In	O
to	O
further	O
elucidate	O
whether	O
HSP90	O
regulates	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
activation	O
p38	O
MAP	O
kinase	O
in	O
MC3T3	O
-	O
E1	O
cells	O
we	O
examined	O
the	O
effect	O
HSP90	O
-	O
siRNA	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
phosphorylation	O
p38	O
MAP	O
kinase	O
.	O
The	O
PGF2?ñ	B-Chemical
-	O
induced	O
levels	O
phosphorylated	O
p38	O
MAP	O
kinase	O
were	O
significantly	O
enhanced	O
by	O
HSP90	O
-	O
siRNA	O
.	O
Additionally	O
we	O
clearly	O
demonstrated	O
that	O
SB203580	B-Chemical
reduced	O
the	O
amplification	O
by	O
geldanamycin	B-Chemical
17	B-Chemical
-	I-Chemical
AAG	I-Chemical
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
release	O
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O
Taking	O
these	O
findings	O
into	O
account	O
it	O
is	O
most	O
likely	O
that	O
HSP90	O
limits	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
and	O
the	O
suppressive	O
effect	O
HSP90	O
is	O
exerted	O
at	O
the	O
point	O
between	O
Rho	O
-	O
kinase	O
and	O
p38	O
MAP	O
kinase	O
.	O
The	O
potential	O
mechanism	O
underlying	O
amplification	O
by	O
HSP90	O
inhibitors	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
in	O
is	O
summarized	O
as	O
Fig	O
9	O
.	O
Schematic	O
illustration	O
the	O
regulatory	O
mechanism	O
underlying	O
the	O
amplifying	O
effect	O
HSP90	O
inhibitors	O
the	O
PGF2?ñ	B-Chemical
-	O
induced	O
IL	O
-	O
6	O
synthesis	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
.	O
PGF2?ñ	B-Chemical
prostaglandin	B-Chemical
F2?ñ	I-Chemical
;	O
MAPK	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
;	O
HSP90	O
heat	O
shock	O
protein	O
90	O
;	O
IL	O
-	O
6	O
interleukin	O
-	O
6	O
.	O
In	O
bone	O
metabolism	O
it	O
has	O
been	O
generally	O
recognized	O
that	O
IL	O
-	O
6	O
acts	O
as	O
a	O
potent	O
bone	O
resorptive	O
agent	O
and	O
to	O
promote	O
formation	O
[	O
17	O
].	O
In	O
addition	O
to	O
the	O
IL	O
-	O
6	O
-	O
effect	O
bone	O
resorption	O
IL	O
-	O
6	O
is	O
currently	O
considered	O
as	O
an	O
factor	O
under	O
the	O
condition	O
increased	O
bone	O
turnover	O
and	O
is	O
inducible	O
even	O
bone	O
formation	O
[	O
19	O
].	O
Bone	O
resorption	O
is	O
the	O
primary	O
step	O
bone	O
remodeling	O
and	O
bone	O
formation	O
is	O
subsequently	O
initiated	O
[	O
36	O
].	O
To	O
the	O
quantity	O
bone	O
and	O
the	O
quality	O
the	O
adequate	O
handling	O
bone	O
remodeling	O
process	O
performed	O
by	O
and	O
is	O
essential	O
.	O
Although	O
there	O
is	O
no	O
doubt	O
that	O
IL	O
-	O
6	O
stimulates	O
bone	O
resorption	O
IL	O
-	O
6	O
is	O
recognized	O
to	O
act	O
as	O
a	O
bone	O
remodeling	O
mediator	O
from	O
the	O
viewpoint	O
whole	O
bone	O
metabolism	O
.	O
As	O
for	O
HSP90	O
in	O
we	O
have	O
shown	O
that	O
the	O
expression	O
levels	O
HSP90	O
protein	O
are	O
quite	O
high	O
in	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
[	O
37	O
].	O
Therefore	O
present	O
findings	O
showing	O
that	O
HSP90	O
inhibitors	O
could	O
function	O
as	O
an	O
up	O
-	O
regulator	O
with	O
regard	O
to	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
in	O
probably	O
provides	O
a	O
novel	O
insight	O
with	O
regard	O
to	O
HSP90	O
as	O
an	O
essential	O
regulator	O
bone	O
remodeling	O
.	O
Several	O
HSP90	O
inhibitors	O
including	O
geldanamycin	B-Chemical
have	O
been	O
recognized	O
as	O
an	O
anticancer	O
drug	O
and	O
the	O
effects	O
HSP90	O
inhibitors	O
have	O
been	O
tested	O
in	O
the	O
clinical	O
trial	O
[	O
38	O
].	O
Based	O
present	O
findings	O
it	O
is	O
probable	O
that	O
HSP90	O
inhibitors	O
in	O
addition	O
to	O
the	O
anticancer	O
chemotherapeutics	O
could	O
affect	O
bone	O
metabolism	O
as	O
a	O
bone	O
remodeling	O
modulator	O
through	O
the	O
enhancement	O
IL	O
-	O
6	O
synthesis	O
in	O
.	O
Therefore	O
HSP90	O
inhibitors	O
might	O
lead	O
a	O
new	O
therapeutic	O
strategy	O
for	O
acceleration	O
fracture	O
healing	O
and	O
bone	O
metabolic	O
diseases	O
such	O
as	O
.	O
Further	O
investigations	O
would	O
be	O
required	O
to	O
clarify	O
the	O
details	O
underlying	O
the	O
effects	O
HSP90	O
bone	O
metabolism	O
.	O
In	O
conclusion	O
results	O
strongly	O
suggest	O
that	O
HSP90	O
negatively	O
regulates	O
the	O
PGF2?ñ	B-Chemical
-	O
stimulated	O
IL	O
-	O
6	O
synthesis	O
in	O
and	O
that	O
the	O
effect	O
HSP90	O
the	O
IL	O
-	O
6	O
synthesis	O
is	O
exerted	O
through	O
regulating	O
p38	O
MAP	O
kinase	O
activation	O
.	O
References	O
Data	O
driven	O
polypharmacological	O
drug	O
design	O
for	O
lung	O
cancer	O
:	O
analyses	O
for	O
targeting	O
ALK	O
MET	O
and	O
EGFR	O
Drug	O
design	O
protein	O
kinase	O
inhibitors	O
is	O
now	O
greatly	O
enabled	O
by	O
thousands	O
publicly	O
available	O
X	O
-	O
ray	O
structures	O
extensive	O
ligand	O
binding	O
data	O
and	O
scaffolds	O
coming	O
patent	O
.	O
The	O
extensive	O
data	O
begin	O
to	O
enable	O
design	O
against	O
a	O
spectrum	O
targets	O
(	O
polypharmacology	O
);	O
however	O
the	O
data	O
also	O
reveal	O
heterogeneities	O
structure	O
subtleties	O
chemical	O
interactions	O
and	O
apparent	O
inconsistencies	O
between	O
diverse	O
data	O
types	O
.	O
As	O
a	O
result	O
incorporation	O
all	O
relevant	O
data	O
requires	O
expert	O
choices	O
to	O
combine	O
computational	O
and	O
informatics	O
methods	O
along	O
with	O
human	O
insight	O
.	O
Here	O
we	O
consider	O
polypharmacological	O
targeting	O
protein	O
kinases	O
ALK	O
MET	O
and	O
EGFR	O
(	O
and	O
its	O
drug	O
resistant	O
mutant	O
T790M	O
)	O
in	O
non	O
small	O
cell	O
lung	O
cancer	O
as	O
an	O
example	O
.	O
Both	O
EGFR	O
and	O
ALK	O
represent	O
sources	O
primary	O
lesions	O
while	O
drug	O
resistance	O
arises	O
from	O
MET	O
amplification	O
and	O
EGFR	O
mutation	O
.	O
A	O
drug	O
which	O
inhibits	O
these	O
targets	O
will	O
expand	O
relevant	O
patient	O
populations	O
and	O
forestall	O
drug	O
resistance	O
.	O
Crizotinib	B-Chemical
co	O
-	O
targets	O
ALK	O
and	O
MET	O
.	O
Analysis	O
the	O
crystal	O
structures	O
reveals	O
few	O
shared	O
interaction	O
types	O
highlighting	O
proton	O
-	O
arene	B-Chemical
and	O
key	O
CH	O
ƒ??	O
hydrogen	B-Chemical
bonding	O
interactions	O
.	O
These	O
are	O
not	O
typically	O
encoded	O
into	O
molecular	O
mechanics	O
force	O
fields	O
.	O
Cheminformatics	O
analyses	O
binding	O
data	O
show	O
EGFR	O
to	O
be	O
dissimilar	O
to	O
ALK	O
and	O
MET	O
but	O
its	O
structure	O
shows	O
how	O
it	O
may	O
be	O
co	O
-	O
targeted	O
with	O
the	O
addition	O
a	O
covalent	O
trap	O
.	O
This	O
suggests	O
a	O
strategy	O
for	O
the	O
design	O
a	O
focussed	O
chemical	O
library	O
based	O
a	O
pan	O
-	O
kinome	O
scaffold	O
.	O
Tests	O
model	O
compounds	O
show	O
these	O
to	O
be	O
compatible	O
with	O
the	O
goal	O
ALK	O
MET	O
and	O
EGFR	O
polypharmacology	O
.	O
Electronic	O
supplementary	O
material	O
The	O
version	O
this	O
article	O
(	O
doi	O
:	O
10	O
.	O
1186	O
/	O
s13321	O
-	O
17	O
-	O
229	O
-	O
8	O
)	O
contains	O
supplementary	O
material	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O
Background	O
The	O
importance	O
and	O
proven	O
druggability	O
protein	O
kinases	O
as	O
targets	O
in	O
cancer	O
[	O
]	O
inflammation	O
[]	O
and	O
disease	O
areas	O
have	O
transformed	O
antikinase	O
drug	O
discovery	O
into	O
an	O
information	O
driven	O
research	O
area	O
unprecedented	O
scale	O
[].	O
Public	O
and	O
proprietary	O
databases	O
contain	O
binding	O
data	O
for	O
hundreds	O
thousands	O
active	O
compounds	O
[].	O
Crystal	O
structures	O
are	O
publicly	O
available	O
for	O
some	O
3000	O
protein	O
kinase	O
inhibitor	O
complexes	O
in	O
the	O
Protein	O
Database	O
(	O
www	O
.	O
rcsb	O
.	O
)	O
[].	O
This	O
data	O
begins	O
to	O
enable	O
ƒ??	O
polypharmacological	O
ƒ?	O
targeting	O
multiple	O
kinases	O
[ƒ??]	O
which	O
may	O
more	O
effectively	O
modify	O
network	O
behavior	O
[]	O
forestall	O
drug	O
resistance	O
[	O
]	O
provide	O
broader	O
applicability	O
against	O
heterogeneous	O
cancers	O
larger	O
patient	O
groups	O
.	O
Such	O
approaches	O
[]	O
may	O
involve	O
ƒ??	O
retargeting	O
ƒ?	O
via	O
modification	O
known	O
compounds	O
simply	O
ƒ??	O
repurposing	O
ƒ?	O
known	O
compounds	O
to	O
new	O
applications	O
when	O
target	O
profiles	O
are	O
suitable	O
.	O
Practical	O
approaches	O
to	O
polypharmacological	O
design	O
include	O
both	O
experimental	O
and	O
computational	O
methods	O
[ƒ??].	O
There	O
is	O
however	O
no	O
single	O
strategic	O
approach	O
to	O
modify	O
such	O
starting	O
compounds	O
to	O
achieve	O
the	O
final	O
selectivity	O
profile	O
;	O
this	O
depends	O
the	O
availability	O
identification	O
and	O
understanding	O
the	O
essential	O
selectivity	O
determinants	O
the	O
relevant	O
targets	O
as	O
we	O
examine	O
with	O
example	O
this	O
paper	O
.	O
current	O
molecular	O
targets	O
in	O
advanced	O
/	O
metastatic	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
).	O
Protein	O
kinase	O
inhibitors	O
for	O
NSCLC	O
therapy	O
either	O
approved	O
in	O
advanced	O
clinical	O
trials	O
are	O
shown	O
in	O
green	O
boxes	O
;	O
antibodies	O
against	O
cytokine	O
targets	O
HGF	O
asnd	O
VEGF	O
are	O
gray	O
.	O
EGFR	O
MET	O
and	O
ALK	O
are	O
labeled	O
with	O
blue	O
circles	O
Non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
represents	O
a	O
collection	O
diverse	O
molecular	O
pathologies	O
.	O
Most	O
types	O
are	O
relatively	O
insensitive	O
to	O
chemotherapy	O
but	O
the	O
identification	O
genomic	O
abnormalities	O
in	O
subpopulations	O
NSCLC	O
patients	O
[ƒ??]	O
have	O
led	O
to	O
the	O
development	O
protein	O
kinase	O
inhibitors	O
against	O
EGFR	O
[	O
]	O
(	O
gefitinib	B-Chemical
2003	O
;	O
erlotinib	B-Chemical
2004	O
;	O
afatinib	B-Chemical
2013	O
)	O
and	O
ALK	O
(	O
crizotinib	B-Chemical
2011	O
;	O
ceritinib	B-Chemical
2014	O
;	O
alectinib	B-Chemical
2015	O
)	O
see	O
Fig	O
.	O
1	O
.	O
These	O
inhibitors	O
specifically	O
target	O
either	O
EGFR	O
ALK	O
but	O
not	O
both	O
;	O
cross	O
-	O
reactive	O
inhibitors	O
are	O
under	O
investigation	O
however	O
[].	O
Analogous	O
to	O
the	O
results	O
imatinib	B-Chemical
and	O
ABL	O
inhibition	O
as	O
therapy	O
for	O
CML	O
treatment	O
with	O
gefitinib	B-Chemical
and	O
erlotinib	B-Chemical
is	O
associated	O
with	O
acquired	O
resistance	O
[].	O
Unlike	O
ABL	O
inhibition	O
resistance	O
development	O
to	O
EGFR	O
inhibitors	O
seems	O
universal	O
.	O
The	O
most	O
common	O
resistance	O
mechanism	O
is	O
a	O
secondary	O
mutation	O
the	O
gatekeeper	O
residue	O
(	O
for	O
EGFR	O
predominantly	O
T790M	O
);	O
'	O
s	O
group	O
first	O
realized	O
a	O
unique	O
ƒ??	O
deracemization	O
ƒ?	O
reaction	O
upon	O
cycloaddition	O
chalcone	B-Chemical
with	O
racemic	O
??	B-Chemical
-	I-Chemical
methyl	I-Chemical
allenoates	I-Chemical
but	O
requisite	O
the	O
use	O
a	O
stoichiometric	O
amount	O
chiral	O
phosphine	B-Chemical
catalyst	O
A	O
(	O
Scheme	O
1a	O
).	O
Subsequently	O
Fu	O
and	O
co	O
-	O
workers	O
have	O
accomplished	O
the	O
cycloaddition	O
reaction	O
racemic	O
??	B-Chemical
-	I-Chemical
substituted	I-Chemical
allenoates	I-Chemical
with	O
heteroatom	O
-	O
bearing	O
with	O
the	O
use	O
a	O
catalytic	O
amount	O
chiral	O
phosphine	B-Chemical
B	O
furnishing	O
a	O
facile	O
access	O
to	O
functionalized	O
cyclopentenes	B-Chemical
with	O
two	O
adjacent	O
stereo	O
centers	O
(	O
Scheme	O
1b	O
).	O
Recently	O
Marinetti	O
and	O
coworkers	O
have	O
reported	O
a	O
highly	O
enantioselective	O
[	O
3	O
+	O
2	O
]	O
cycloaddition	O
??	B-Chemical
-	I-Chemical
substituted	I-Chemical
allenoates	I-Chemical
with	O
benzylidenemalononitrile	B-Chemical
by	O
utilizing	O
chiral	O
phosphahelicenes	B-Chemical
catalyst	O
C	O
(	O
Scheme	O
1b	O
).	O
Selected	O
natural	O
products	O
and	O
pharmaceuticals	O
contain	O
cyclopentene	B-Chemical
cyclopentane	B-Chemical
rings	O
.	O
[	O
3	O
+	O
2	O
]	O
cycloaddition	O
reaction	O
??	B-Chemical
-	I-Chemical
substituted	I-Chemical
allenoates	I-Chemical
and	O
.	O
Despite	O
this	O
progress	O
the	O
scope	O
??	B-Chemical
-	I-Chemical
substituted	I-Chemical
allenoates	I-Chemical
and	O
electron	O
-	O
deficient	O
partner	O
for	O
enantioselective	O
Lu	O
'	I-Chemical
s	I-Chemical
solution	I-Chemical
was	O
shown	O
to	O
be	O
around	O
0	O
.	O
6	O
pmol	O
/	O
min	O
/	O
mg	O
(	O
Linden	O
et	O
al	O
.	O
2008	O
2010	O
).	O
In	O
the	O
small	O
and	O
large	O
intestine	O
rat	O
the	O
basal	O
level	O
H2S	B-Chemical
was	O
reported	O
to	O
be	O
around	O
60	O
nmol	O
/	O
g	O
/	O
h	O
and	O
the	O
response	O
to	O
10	O
mmol	O
/	O
L	O
cysteine	B-Chemical
in	O
these	O
tissues	O
ranged	O
from	O
300	O
to	O
500	O
nmol	O
/	O
g	O
/	O
h	O
a	O
5	O
ƒ?	O
to	O
10	O
ƒ?	O
fold	O
increase	O
(	O
Martin	O
et	O
al	O
.	O
2010	O
).	O
Phosphorylation	O
serine	B-Chemical
19	O
the	O
20	O
ƒ?	O
kDa	O
regulatory	O
light	O
ƒ?	O
chain	O
myosin	O
II	O
(	O
MLC20	O
)	O
is	O
an	O
essential	O
step	O
in	O
smooth	O
muscle	O
contraction	O
(	O
Hartshorne	O
et	O
al	O
.	O
1998	O
;	O
Somlyo	O
and	O
Somlyo	O
2003	O
;	O
Murthy	O
2006	O
;	O
de	O
Godoy	O
and	O
Rattan	O
2011	O
).	O
Phosphorylation	O
MLC20	O
is	O
regulated	O
by	O
a	O
Ca2	O
+/	O
calmodulin	O
ƒ?	O
dependent	O
MLC	O
kinase	O
(	O
MLCK	O
)	O
which	O
initiates	O
phosphorylation	O
MLC20	O
and	O
MLC	O
phosphatase	O
(	O
MLCP	O
)	O
which	O
dephosphorylates	O
MLC20	O
.	O
MLCP	O
is	O
a	O
heterotrimer	O
with	O
an	O
110	O
ƒ?	O
to	O
130	O
ƒ?	O
kDa	O
regulatory	O
subunit	O
(	O
myosin	O
phosphatase	O
target	O
subunit	O
1	O
(	O
MYPT1	O
)	O
a	O
37	O
ƒ?	O
kDa	O
catalytic	O
subunit	O
type	O
1	O
phosphatase	O
(	O
PP1c??	O
)	O
and	O
a	O
20	O
ƒ?	O
kDa	O
subunit	O
unknown	O
function	O
(	O
Hartshorne	O
et	O
al	O
.	O
1998	O
).	O
The	O
RhoA	O
/	O
Rho	O
kinase	O
signaling	O
pathway	O
regulates	O
muscle	O
contraction	O
.	O
RhoA	O
is	O
a	O
small	O
G	O
protein	O
with	O
inherent	O
GTPase	O
activity	O
and	O
cycles	O
between	O
two	O
states	O
:	O
an	O
inactive	O
GDP	B-Chemical
ƒ?	O
bound	O
state	O
and	O
an	O
active	O
GTP	B-Chemical
ƒ?	O
bound	O
state	O
.	O
Activated	O
RhoA	O
binds	O
to	O
the	O
Rho	O
ƒ?	O
binding	O
domain	O
Rho	O
kinase	O
causing	O
the	O
enzyme	O
to	O
unfold	O
and	O
freeing	O
its	O
catalytic	O
activity	O
.	O
Phosphorylation	O
MYPT1	O
at	O
Thr696	B-Chemical
by	O
Rho	O
kinase	O
causes	O
its	O
dissociation	O
from	O
and	O
inhibition	O
the	O
catalytic	O
subunit	O
resulting	O
in	O
MLC20	O
phosphorylation	O
and	O
muscle	O
contraction	O
(	O
Hartshorne	O
et	O
al	O
.	O
1998	O
;	O
Somlyo	O
and	O
Somlyo	O
2003	O
;	O
Murthy	O
2006	O
;	O
de	O
Godoy	O
and	O
Rattan	O
2011	O
).	O
results	O
demonstrate	O
selective	O
expression	O
CSE	O
in	O
colonic	O
smooth	O
muscle	O
cells	O
rabbit	O
mouse	O
and	O
human	O
and	O
addition	O
l	B-Chemical
ƒ?	I-Chemical
cysteine	I-Chemical
NaHS	B-Chemical
causes	O
S	O
ƒ?	O
sulfhydration	O
RhoA	O
that	O
lead	O
to	O
inhibition	O
RhoA	O
and	O
Rho	O
kinase	O
activities	O
and	O
muscle	O
contraction	O
in	O
response	O
to	O
contractile	O
agonists	O
.	O
Materials	O
and	O
Methods	O
Reagents	O
Cystathionine	O
ƒ?	O
?ý	O
ƒ?	O
synthase	O
(	O
CBS	O
)	O
and	O
cystathionine	O
ƒ?	O
??	O
ƒ?	O
lyase	O
(	O
CSE	O
)	O
antibodies	O
were	O
purchased	O
from	O
Proteintech	O
(	O
Chicago	O
IL	O
);	O
[	O
32P	B-Chemical
]	O
ATP	B-Chemical
was	O
purchased	O
from	O
PerkinElmer	O
(	O
Cambridge	O
MA	O
);	O
HRP	O
ƒ?	O
conjugated	O
secondary	O
antibodies	O
were	O
from	O
Cell	O
Signaling	O
Technology	O
(	O
Danvers	O
MA	O
);	O
PVDF	B-Chemical
membranes	O
were	O
from	O
Millipore	O
(	O
Billerica	O
MA	O
);	O
Effectene	O
Transfection	O
Reagent	O
QIAEX	O
??	O
II	O
was	O
from	O
Qiagen	O
(	O
Germantown	O
MD	O
);	O
culture	O
medium	O
(	O
Dulbecco	O
'	O
s	O
medium	O
)	O
was	O
from	O
Fisher	O
Scientific	O
(	O
Ashville	O
NC	O
);	O
l	B-Chemical
ƒ?	I-Chemical
Cysteine	I-Chemical
and	O
dl	B-Chemical
ƒ?	I-Chemical
propargylglycine	I-Chemical
(	O
PPG	O
)	O
were	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
MO	O
).	O
All	O
reagents	O
were	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
MO	O
).	O
Rabbits	O
(	O
New	O
Zealand	O
white	O
male	O
)	O
weighing	O
4	O
ƒ??	O
5	O
lbs	O
were	O
purchased	O
from	O
RSI	O
Biotechnology	O
(	O
Clemmons	O
NC	O
)	O
and	O
mice	O
(	O
male	O
C57BL	O
/	O
6	O
strain	O
)	O
were	O
purchased	O
from	O
Jackson	O
Laboratories	O
(	O
Bar	O
Harbor	O
ME	O
).	O
Rabbits	O
and	O
mice	O
were	O
acclimatized	O
at	O
the	O
facility	O
administered	O
by	O
the	O
Division	O
Animal	O
Resources	O
Virginia	O
Commonwealth	O
University	O
.	O
The	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
Virginia	O
Commonwealth	O
University	O
approved	O
all	O
the	O
procedures	O
conducted	O
.	O
Colons	O
from	O
normal	O
human	O
subjects	O
were	O
from	O
a	O
nonprofit	O
known	O
as	O
National	O
Disease	O
Research	O
Interchange	O
(	O
NDRI	O
Philadelphia	O
PA	O
)	O
that	O
provides	O
human	O
and	O
tissue	O
.	O
The	O
studies	O
involving	O
human	O
tissues	O
are	O
approved	O
as	O
exempt	O
from	O
VCU	O
Institutional	O
Review	O
Board	O
.	O
Isolation	O
smooth	O
muscle	O
cells	O
The	O
colon	O
from	O
rabbit	O
mouse	O
and	O
human	O
were	O
dissected	O
and	O
after	O
emptying	O
the	O
contents	O
was	O
placed	O
in	O
Kreb	B-Chemical
'	O
s	O
essential	B-Chemical
amino	I-Chemical
acid	I-Chemical
mixture	O
0	O
.	O
1	O
%	O
collagenase	O
[	O
type	O
II	O
]	O
and	O
0	O
.	O
1	O
%	O
soybean	O
trypsin	O
inhibitor	O
).	O
After	O
the	O
30	O
ƒ?	O
min	O
digestion	O
period	O
tissues	O
were	O
washed	O
with	O
collagenase	O
ƒ?	O
free	O
medium	O
(	O
50	O
mL	O
)	O
and	O
muscle	O
cells	O
were	O
allowed	O
to	O
disperse	O
spontaneously	O
.	O
Cells	O
were	O
collected	O
by	O
filtration	O
through	O
500	O
?¬m	O
Nitex	O
followed	O
by	O
centrifugation	O
twice	O
at	O
350g	O
for	O
10	O
min	O
.	O
Smooth	O
muscle	O
cells	O
were	O
cultured	O
in	O
DMEM	B-Chemical
containing	O
10	O
%	O
fetal	O
bovine	O
serum	O
and	O
cells	O
passaged	O
after	O
attaining	O
confluence	O
.	O
For	O
experiments	O
muscle	O
cells	O
were	O
used	O
in	O
the	O
first	O
passage	O
.	O
Transfection	O
CSE	O
siRNA	O
The	O
eukaryotic	O
expression	O
vector	O
pcDNA3	O
was	O
used	O
to	O
subclone	O
CSE	O
siRNA	O
into	O
the	O
multiple	O
cloning	O
sites	O
(	O
EcoRI	O
).	O
Smooth	O
muscle	O
cells	O
in	O
culture	O
were	O
transiently	O
transfected	O
for	O
48	O
h	O
with	O
recombinant	O
plasmid	O
cDNAs	O
.	O
To	O
monitor	O
transfection	O
efficiency	O
muscle	O
cells	O
were	O
cotransfected	O
with	O
2	O
?¬g	O
pcDNA3	O
vector	O
and	O
1	O
?¬g	O
pGreen	O
Lantern	O
ƒ?	O
1	O
DNA	O
(	O
Rajagopal	O
et	O
al	O
.	O
2013	O
;	O
Nalli	O
et	O
al	O
.	O
2015	O
).	O
Western	O
blot	O
analysis	O
Expression	O
CSE	O
and	O
CBS	O
was	O
measured	O
by	O
western	O
blot	O
as	O
described	O
previously	O
(	O
Murthy	O
et	O
al	O
.	O
2003a	O
b	O
;	O
Rajagopal	O
et	O
al	O
.	O
2013	O
;	O
Nalli	O
et	O
al	O
.	O
2015	O
).	O
Smooth	O
muscle	O
cells	O
were	O
homogenized	O
in	O
lysis	O
buffer	O
containing	O
Triton	B-Chemical
X	I-Chemical
ƒ?	I-Chemical
100	I-Chemical
and	O
protease	O
and	O
phosphatase	O
inhibitors	O
.	O
The	O
lysates	O
were	O
centrifuged	O
at	O
20	O
000g	O
for	O
10	O
min	O
at	O
4	O
?ø	O
C	O
and	O
the	O
supernatants	O
were	O
collected	O
.	O
Aliquots	O
containing	O
an	O
equal	O
amount	O
protein	O
(	O
50	O
?¬g	O
)	O
were	O
resolved	O
10	O
%	O
SDS	B-Chemical
ƒ?	O
PAGE	O
and	O
the	O
proteins	O
were	O
transferred	O
to	O
PVDF	B-Chemical
membranes	O
.	O
The	O
membranes	O
were	O
incubated	O
with	O
CSE	O
CBS	O
antibodies	O
followed	O
by	O
incubation	O
with	O
appropriate	O
secondary	O
antibody	O
conjugated	O
with	O
horseradish	O
peroxidase	O
.	O
Enhanced	O
chemiluminescence	O
was	O
used	O
to	O
visualize	O
protein	O
bands	O
the	O
membrane	O
.	O
Assay	O
for	O
RhoA	O
GTPase	O
activation	O
RhoA	O
activation	O
was	O
evaluated	O
in	O
pull	O
ƒ?	O
down	O
assays	O
using	O
specific	O
anti	O
ƒ?	O
RhoA	O
ƒ?	O
GTP	O
antibody	O
and	O
protein	O
A	O
/	O
G	O
beads	O
(	O
Rajagopal	O
et	O
al	O
.	O
2013	O
).	O
In	O
brief	O
cultured	O
smooth	O
muscle	O
cells	O
were	O
incubated	O
with	O
carbachol	B-Chemical
(	O
CCh	B-Chemical
1	O
?¬mol	O
/	O
L	O
)	O
for	O
10	O
min	O
.	O
In	O
some	O
experiments	O
CCh	B-Chemical
was	O
added	O
after	O
treatment	O
with	O
l	B-Chemical
ƒ?	I-Chemical
cysteine	I-Chemical
(	O
10	O
mmol	O
/	O
L	O
)	O
NaHS	B-Chemical
(	O
1	O
mmol	O
/	O
L	O
)	O
for	O
10	O
min	O
.	O
In	O
some	O
cases	O
the	O
cells	O
were	O
preincubated	O
with	O
CSE	O
inhibitor	O
DL	B-Chemical
ƒ?	I-Chemical
PPG	I-Chemical
(	O
1	O
mmol	O
/	O
L	O
)	O
for	O
10	O
min	O
before	O
the	O
addition	O
CCh	B-Chemical
in	O
the	O
presence	O
absence	O
l	B-Chemical
ƒ?	I-Chemical
cysteine	I-Chemical
NaHS	B-Chemical
.	O
Cells	O
were	O
homogenized	O
in	O
the	O
lysis	O
buffer	O
and	O
GTP	B-Chemical
ƒ?	O
bound	O
RhoA	O
was	O
immunoprecipitated	O
using	O
monoclonal	O
antibody	O
(	O
NewEast	O
Biosciences	O
Malvern	O
PA	O
)	O
that	O
specifically	O
recognizes	O
RhoA	O
ƒ?	O
GTP	B-Chemical
.	O
RhoA	O
ƒ?	O
GTP	B-Chemical
bound	O
antibody	O
were	O
pulled	O
down	O
by	O
protein	O
A	O
/	O
G	O
washed	O
with	O
lysis	O
buffer	O
and	O
processed	O
for	O
separation	O
by	O
SDS	B-Chemical
ƒ?	O
PAGE	O
.	O
The	O
level	O
activated	O
RhoA	O
was	O
evaluated	O
by	O
western	O
blot	O
analysis	O
.	O
Biotin	B-Chemical
switch	O
assay	O
to	O
detect	O
S	O
ƒ?	O
sulfhydration	O
S	O
ƒ?	O
sulfhydration	O
was	O
measured	O
by	O
biotin	B-Chemical
switch	O
assay	O
as	O
described	O
previously	O
(	O
Jaffrey	O
and	O
Snyder	O
2001	O
;	O
Mustafa	O
et	O
al	O
.	O
2009	O
;	O
Kang	O
et	O
al	O
.	O
2015	O
)	O
with	O
modification	O
.	O
HEK293	O
cells	O
transfected	O
with	O
RhoA	O
cloned	O
pcDNA	O
3	O
vector	O
were	O
homogenized	O
in	O
a	O
medium	O
A	O
(	O
250	O
mmol	O
/	O
L	O
HEPES	B-Chemical
ƒ?	O
NaOH	B-Chemical
[	O
pH	O
7	O
.	O
7	O
]	O
1	O
mmol	O
/	O
L	O
EDTA	B-Chemical
2	O
.	O
5	O
%	O
SDS	B-Chemical
0	O
.	O
1	O
mmol	O
/	O
L	O
neocuproine	B-Chemical
)	O
containing	O
100	O
?¬mol	O
/	O
L	O
deferoxamine	B-Chemical
.	O
Protein	O
samples	O
(	O
250	O
?¬g	O
)	O
were	O
then	O
treated	O
in	O
the	O
presence	O
absence	O
NaHS	B-Chemical
(	O
0	O
.	O
1	O
mmol	O
/	O
L	O
and	O
1	O
mmol	O
/	O
L	O
)	O
for	O
15	O
min	O
and	O
then	O
incubated	O
at	O
50	O
?ø	O
C	O
for	O
20	O
min	O
with	O
blocking	O
buffer	O
(	O
medium	O
A	O
adjusted	O
to	O
2	O
.	O
5	O
%	O
SDS	B-Chemical
and	O
20	O
mmol	O
/	O
L	O
methyl	B-Chemical
methane	I-Chemical
thiosulfonate	I-Chemical
)	O
with	O
frequent	O
vortexing	O
.	O
Proteins	O
were	O
precipitated	O
using	O
acetone	B-Chemical
and	O
incubated	O
at	O
37	O
?ø	O
C	O
for	O
3	O
h	O
in	O
medium	O
A	O
adjusted	O
to	O
1	O
%	O
SDS	B-Chemical
with	O
4	O
mmol	O
/	O
L	O
biotin	B-Chemical
ƒ?	I-Chemical
HPDP	I-Chemical
(	O
N	B-Chemical
ƒ?[	I-Chemical
6	I-Chemical
ƒ?(	I-Chemical
biotinamido	I-Chemical
)	I-Chemical
hexyl	I-Chemical
]ƒ?	I-Chemical
3	I-Chemical
ƒ?ýƒ?(	I-Chemical
2	I-Chemical
ƒ?ýƒ?	I-Chemical
pyridyldithio	I-Chemical
)ƒ?	I-Chemical
propionamide	I-Chemical
)	O
in	O
dimethyl	B-Chemical
formamide	I-Chemical
.	O
The	O
biotinylated	O
proteins	O
were	O
precipitated	O
by	O
streptavidin	O
ƒ?	O
agarose	B-Chemical
beads	O
washed	O
with	O
medium	O
A	O
and	O
resolved	O
by	O
SDS	B-Chemical
ƒ?	O
PAGE	O
.	O
After	O
the	O
transfer	O
proteins	O
PVDF	B-Chemical
membranes	O
RhoA	O
was	O
analyzed	O
by	O
western	O
blot	O
.	O
Assay	O
for	O
Rho	O
kinase	O
activity	O
Rho	O
kinase	O
activity	O
was	O
measured	O
by	O
immunokinase	O
assay	O
as	O
previously	O
described	O
(	O
Murthy	O
et	O
al	O
.	O
2003a	O
b	O
;	O
Rajagopal	O
et	O
al	O
.	O
2013	O
;	O
Nalli	O
et	O
al	O
.	O
2015	O
).	O
Smooth	O
muscle	O
cells	O
were	O
treated	O
with	O
different	O
concentrations	O
NaHS	B-Chemical
l	B-Chemical
ƒ?	I-Chemical
cysteine	I-Chemical
for	O
10	O
min	O
and	O
then	O
with	O
CCh	B-Chemical
for	O
10	O
min	O
.	O
The	O
cells	O
were	O
homogenized	O
in	O
medium	O
containing	O
50	O
mmol	O
/	O
L	O
Tris	B-Chemical
ƒ?	O
HCl	B-Chemical
(	O
pH	O
7	O
.	O
5	O
)	O
0	O
.	O
1	O
%	O
SDS	B-Chemical
0	O
.	O
5	O
%	O
sodium	B-Chemical
deoxycholate	I-Chemical
1	O
%	O
Nonidet	B-Chemical
P	I-Chemical
ƒ?	I-Chemical
40	I-Chemical
150	O
mmol	O
/	O
L	O
NaCl	B-Chemical
1	O
mmol	O
/	O
L	O
PMSF	B-Chemical
10	O
?¬g	O
/	O
mL	O
aprotinin	B-Chemical
10	O
?¬g	O
/	O
mL	O
pepstatin	B-Chemical
A	I-Chemical
and	O
10	O
?¬g	O
/	O
mL	O
leupeptin	B-Chemical
.	O
Aliquots	O
containing	O
an	O
equal	O
amount	O
protein	O
(	O
50	O
?¬g	O
)	O
were	O
incubated	O
at	O
4	O
?ø	O
C	O
with	O
Rho	O
kinase	O
ƒ?	O
2	O
antibody	O
and	O
protein	O
A	O
/	O
G	O
agarose	B-Chemical
.	O
The	O
immunoprecipitates	O
collected	O
by	O
centrifugation	O
were	O
washed	O
twice	O
with	O
a	O
medium	O
containing	O
10	O
mmol	O
/	O
L	O
MgCl2	B-Chemical
and	O
40	O
mmol	O
/	O
L	O
HEPES	B-Chemical
(	O
pH	O
7	O
.	O
4	O
)	O
followed	O
by	O
incubation	O
for	O
5	O
min	O
at	O
4	O
?ø	O
C	O
with	O
myelin	O
basic	O
protein	O
(	O
MBP	O
)	O
(	O
1	O
mg	O
/	O
mL	O
).	O
The	O
reaction	O
was	O
initiated	O
by	O
the	O
addition	O
10	O
?¬Ci	O
[	O
32P	B-Chemical
]	O
ATP	B-Chemical
(	O
3000	O
Ci	O
/	O
mmol	O
)	O
and	O
20	O
?¬mol	O
/	O
L	O
ATP	B-Chemical
at	O
37	O
?ø	O
C	O
and	O
terminated	O
after	O
10	O
min	O
by	O
spotting	O
the	O
reaction	O
mixture	O
phosphocellulose	B-Chemical
disks	O
to	O
capture	O
phosphorylated	O
MBP	O
.	O
The	O
disks	O
were	O
washed	O
with	O
75	O
mmol	O
/	O
L	O
phosphoric	B-Chemical
acid	I-Chemical
to	O
remove	O
free	O
radioactivity	O
.	O
Phosphorylation	O
MBP	O
was	O
determined	O
from	O
the	O
radioactivity	O
disks	O
by	O
liquid	O
scintillation	O
.	O
Measurement	O
contraction	O
in	O
muscle	O
strips	O
Rabbit	O
colonic	O
muscle	O
strips	O
cut	O
in	O
the	O
direction	O
circular	O
muscle	O
layer	O
from	O
rabbit	O
colon	O
were	O
rinsed	O
immediately	O
in	O
Kreb	B-Chemical
'	I-Chemical
s	I-Chemical
medium	I-Chemical
(	O
pH	O
7	O
.	O
4	O
)	O
at	O
37	O
?ø	O
C	O
.	O
The	O
isometric	O
force	O
generated	O
by	O
circular	O
muscle	O
was	O
measured	O
by	O
mounting	O
the	O
tissue	O
between	O
a	O
glass	O
rod	O
and	O
isometric	O
transducer	O
(	O
Grass	O
Technologies	O
Quincy	O
MA	O
)	O
connected	O
to	O
a	O
computer	O
recording	O
system	O
.	O
A	O
resting	O
tension	O
1	O
g	O
was	O
given	O
and	O
the	O
muscle	O
strips	O
were	O
allowed	O
to	O
equilibrate	O
.	O
Muscle	O
strips	O
were	O
contracted	O
with	O
10	O
?¬mol	O
/	O
L	O
CCh	B-Chemical
in	O
the	O
presence	O
absence	O
different	O
concentrations	O
l	B-Chemical
ƒ?	I-Chemical
cysteine	I-Chemical
NaHS	B-Chemical
pretreatment	O
for	O
10	O
min	O
.	O
In	O
some	O
experiments	O
muscle	O
strips	O
were	O
pretreated	O
with	O
10	O
?¬mol	O
/	O
L	O
glibenclamide	B-Chemical
(	O
a	O
KATP	O
channel	O
blocker	O
)	O
before	O
the	O
addition	O
NaHS	B-Chemical
l	B-Chemical
ƒ?	I-Chemical
cysteine	I-Chemical
.	O
Tissue	O
weight	O
was	O
recorded	O
after	O
the	O
experiment	O
and	O
contraction	O
was	O
calculated	O
as	O
area	O
under	O
the	O
curve	O
in	O
response	O
to	O
CCh	B-Chemical
alone	O
and	O
compared	O
with	O
CCh	B-Chemical
with	O
l	B-Chemical
ƒ?	I-Chemical
cysteine	I-Chemical
NaHS	B-Chemical
(	O
Nalli	O
et	O
al	O
.	O
2015	O
).	O
Measurement	O
contraction	O
in	O
muscle	O
cells	O
Contraction	O
in	O
dispersed	O
muscle	O
cells	O
was	O
determined	O
by	O
scanning	O
micrometry	O
as	O
described	O
previously	O
(	O
Murthy	O
et	O
al	O
.	O
2003a	O
b	O
;	O
Rajagopal	O
et	O
al	O
.	O
2013	O
;	O
Nalli	O
et	O
al	O
.	O
2015	O
).	O
An	O
aliquot	O
muscle	O
cells	O
(	O
0	O
.	O
4	O
mL	O
containing	O
104	O
/	O
cell	O
mL	O
)	O
was	O
preincubated	O
with	O
a	O
different	O
concentration	O
l	B-Chemical
ƒ?	I-Chemical
cysteine	I-Chemical
NaHS	B-Chemical
for	O
10	O
min	O
and	O
then	O
with	O
CCh	B-Chemical
for	O
another	O
for	O
10	O
min	O
.	O
A	O
final	O
concentration	O
1	O
%	O
acrolein	B-Chemical
was	O
used	O
to	O
terminate	O
the	O
reaction	O
and	O
a	O
drop	O
cell	O
suspension	O
was	O
placed	O
a	O
slide	O
under	O
a	O
cover	O
slip	O
.	O
In	O
some	O
experiments	O
muscle	O
cells	O
were	O
pretreated	O
with	O
10	O
?¬mol	O
/	O
L	O
glibenclamide	B-Chemical
(	O
a	O
KATP	O
channel	O
blocker	O
)	O
before	O
the	O
addition	O
NaHS	B-Chemical
l	B-Chemical
ƒ?	I-Chemical
cysteine	I-Chemical
.	O
Cell	O
length	O
was	O
measured	O
by	O
scanning	O
micrometry	O
.	O
Cell	O
length	O
in	O
the	O
absence	O
any	O
treatment	O
was	O
taken	O
as	O
resting	O
cell	O
length	O
.	O
Contraction	O
was	O
expressed	O
as	O
a	O
decrease	O
in	O
mean	O
cell	O
length	O
from	O
control	O
cell	O
length	O
.	O
Statistical	O
analysis	O
Data	O
are	O
expressed	O
as	O
mean	O
?ñ	O
SEM	O
.	O
ƒ??	O
n	O
ƒ?	O
represents	O
average	O
values	O
sample	O
run	O
in	O
duplicate	O
triplicate	O
from	O
animal	O
.	O
Comparisons	O
between	O
groups	O
were	O
analyzed	O
by	O
Student	O
'	O
Emmanuele	O
diVilla	O
Bianca	O
et	O
al	O
.	O
2009	O
;	O
Bucci	O
et	O
al	O
.	O
2012	O
).	O
These	O
concentrations	O
have	O
been	O
considered	O
to	O
be	O
physiologic	O
as	O
several	O
reports	O
suggest	O
that	O
the	O
tissue	O
H2S	B-Chemical
concentration	O
normally	O
ranges	O
from	O
high	O
?¬M	O
to	O
low	O
mM	O
range	O
(	O
30	O
?¬mol	O
/	O
L	O
to	O
>	O
100	O
?¬mol	O
/	O
L	O
)	O
(	O
Yang	O
et	O
al	O
.	O
2012	O
).	O
The	O
free	O
H2S	B-Chemical
concentrations	O
in	O
GI	O
smooth	O
muscle	O
and	O
the	O
significance	O
H2S	B-Chemical
at	O
low	O
?¬M	O
concentration	O
as	O
a	O
messenger	O
molecule	O
are	O
yet	O
to	O
be	O
determined	O
.	O
studies	O
also	O
showed	O
that	O
the	O
effect	O
H2S	B-Chemical
is	O
not	O
dependent	O
the	O
activation	O
KATP	O
channels	O
but	O
dependent	O
the	O
S	O
ƒ?	O
sulfhydration	O
RhoA	O
.	O
In	O
the	O
present	O
study	O
we	O
have	O
identified	O
RhoA	O
as	O
S	O
ƒ?	O
sulfhydration	O
target	O
H2S	B-Chemical
in	O
mediating	O
the	O
inhibitory	O
effect	O
muscle	O
contraction	O
.	O
Like	O
S	O
ƒ?	O
nitrosylation	O
by	O
nitric	B-Chemical
S	O
ƒ?	O
sulfhydration	O
by	O
H2S	B-Chemical
appears	O
to	O
be	O
the	O
common	O
post	O
ƒ?	O
translational	O
mechanism	O
to	O
alter	O
the	O
function	O
proteins	O
(	O
Mustafa	O
et	O
al	O
.	O
2009	O
;	O
Wang	O
2012	O
).	O
S	O
ƒ?	O
sulfhydration	O
several	O
proteins	O
including	O
receptors	O
ion	O
channels	O
and	O
enzymes	O
have	O
been	O
described	O
in	O
previous	O
studies	O
(	O
Mustafa	O
et	O
al	O
.	O
2009	O
;	O
Wang	O
2012	O
).	O
Initially	O
it	O
was	O
suggested	O
that	O
S	O
ƒ?	O
sulfhydration	O
always	O
results	O
in	O
the	O
increase	O
protein	O
activity	O
;	O
however	O
the	O
inhibitory	O
effect	O
sulfhydration	O
was	O
also	O
demonstrated	O
(	O
Mustafa	O
et	O
al	O
.	O
2009	O
;	O
Wang	O
2012	O
).	O
Previous	O
studies	O
in	O
gastric	O
muscle	O
strips	O
demonstrate	O
regulation	O
MLC	O
phosphatase	O
activity	O
by	O
H2S	B-Chemical
(	O
Dhaese	O
and	O
Lefebvre	O
2009	O
).	O
In	O
GI	O
smooth	O
muscle	O
activation	O
RhoA	O
by	O
contractile	O
agonists	O
causes	O
sustained	O
contraction	O
via	O
phosphorylation	O
the	O
regulatory	O
subunit	O
MLCP	O
(	O
MYPT1	O
)	O
and	O
inhibition	O
MLC	O
phosphatase	O
leading	O
to	O
an	O
increase	O
in	O
MLC20	O
phosphorylation	O
and	O
muscle	O
contraction	O
(	O
Murthy	O
et	O
al	O
.	O
2003a	O
;	O
Murthy	O
2006	O
).	O
H2S	B-Chemical
exerts	O
an	O
inhibitory	O
effect	O
RhoA	O
activity	O
causing	O
attenuation	O
Rho	O
kinase	O
activity	O
and	O
disinhibition	O
Rho	O
kinase	O
ƒ?	O
mediated	O
MLCP	O
activity	O
augmentation	O
MLC20	O
dephosphorylation	O
and	O
inhibition	O
sustained	O
contraction	O
.	O
Blockade	O
l	B-Chemical
ƒ?	I-Chemical
cysteine	I-Chemical
effect	O
by	O
DL	B-Chemical
ƒ?	I-Chemical
PPG	I-Chemical
in	O
dispersed	O
muscle	O
cells	O
and	O
CSE	O
siRNA	O
in	O
cultured	O
muscle	O
cells	O
provides	O
evidence	O
for	O
the	O
involvement	O
CSE	O
activation	O
.	O
In	O
summary	O
studies	O
demonstrated	O
the	O
selective	O
expression	O
CSE	O
in	O
colonic	O
smooth	O
muscle	O
cells	O
and	O
identified	O
the	O
molecular	O
mechanism	O
by	O
which	O
H2S	B-Chemical
inhibits	O
muscle	O
contraction	O
via	O
S	O
ƒ?	O
sulfhydration	O
RhoA	O
and	O
inhibition	O
RhoA	O
and	O
Rho	O
kinase	O
activities	O
.	O
Author	O
Contributions	O
K	O
.	O
S	O
.	O
M	O
.	O
A	O
.	O
N	O
.	O
and	O
H	O
.	O
W	O
.	O
participated	O
in	O
research	O
design	O
;	O
A	O
.	O
N	O
.	O
H	O
.	O
W	O
.	O
S	O
.	O
B	O
.	O
B	O
.	O
B	O
.	O
and	O
K	O
.	O
S	O
.	O
M	O
.	O
conducted	O
experiments	O
;	O
K	O
.	O
S	O
.	O
M	O
.	O
and	O
A	O
.	O
N	O
.	O
performed	O
data	O
analysis	O
;	O
K	O
.	O
S	O
.	O
M	O
.	O
A	O
.	O
N	O
.	O
and	O
S	O
.	O
B	O
.	O
wrote	O
contributed	O
to	O
the	O
writing	O
the	O
manuscript	O
.	O
None	O
contributed	O
to	O
new	O
reagents	O
analytical	O
tools	O
.	O
Disclosure	O
None	O
declared	O
.	O
References	O
Are	O
boat	O
transition	O
states	O
likely	O
to	O
in	O
Cope	O
rearrangements	O
?	O
A	O
DFT	O
study	O
the	O
biogenesis	O
germacranes	B-Chemical
It	O
has	O
been	O
proposed	O
that	O
elemanes	B-Chemical
are	O
biogenetically	O
formed	O
from	O
germacranes	B-Chemical
by	O
Cope	O
sigmatropic	O
rearrangements	O
.	O
Normally	O
this	O
reaction	O
proceeds	O
through	O
a	O
transition	O
state	O
with	O
a	O
chair	O
conformation	O
.	O
However	O
the	O
transformation	O
schkuhriolide	B-Chemical
(	O
germacrane	B-Chemical
)	O
into	O
elemanschkuhriolide	B-Chemical
(	O
elemane	B-Chemical
)	O
may	O
through	O
a	O
boat	O
transition	O
state	O
due	O
to	O
the	O
final	O
configuration	O
the	O
elemanschkuhriolide	B-Chemical
but	O
this	O
transition	O
state	O
is	O
questionable	O
due	O
to	O
its	O
high	O
energy	O
.	O
The	O
possible	O
mechanisms	O
this	O
transformation	O
were	O
studied	O
in	O
the	O
density	O
functional	O
theory	O
frame	O
.	O
The	O
mechanistic	O
differences	O
between	O
the	O
transformation	O
(	B-Chemical
Z	I-Chemical
,	I-Chemical
E	I-Chemical
)-	I-Chemical
germacranes	I-Chemical
and	O
(	B-Chemical
E	I-Chemical
,	I-Chemical
E	I-Chemical
)-	I-Chemical
germacranes	I-Chemical
were	O
also	O
studied	O
.	O
We	O
found	O
that	O
(	B-Chemical
Z	I-Chemical
,	I-Chemical
E	I-Chemical
)-	I-Chemical
germacranolides	I-Chemical
are	O
significantly	O
more	O
stable	O
than	O
(	B-Chemical
E	I-Chemical
,	I-Chemical
E	I-Chemical
)-	I-Chemical
germacranolides	I-Chemical
and	O
elemanolides	B-Chemical
.	O
In	O
the	O
specific	O
case	O
schkuhriolide	B-Chemical
even	O
when	O
the	O
boat	O
transition	O
state	O
is	O
not	O
energetically	O
favored	O
a	O
previous	O
hemiacetalization	O
lowers	O
enough	O
the	O
energetic	O
barrier	O
to	O
allow	O
the	O
formation	O
a	O
very	O
stable	O
elemanolide	B-Chemical
that	O
is	O
even	O
more	O
stable	O
than	O
its	O
(	B-Chemical
Z	I-Chemical
,	I-Chemical
E	I-Chemical
)-	I-Chemical
germacrane	I-Chemical
.	O
Introduction	O
Germacranes	B-Chemical
are	O
biogenetic	O
precursors	O
elemanes	B-Chemical
[ƒ??]	O
because	O
germacranes	B-Chemical
can	O
be	O
easily	O
transformed	O
into	O
elemanes	B-Chemical
by	O
heating	O
through	O
a	O
Cope	O
rearrangement	O
.	O
In	O
some	O
cases	O
these	O
transformations	O
are	O
so	O
favorable	O
that	O
it	O
has	O
been	O
mentioned	O
that	O
the	O
elemanes	B-Chemical
are	O
artifacts	O
produced	O
at	O
the	O
extraction	O
[ƒ??].	O
It	O
is	O
known	O
that	O
1	B-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
dienes	I-Chemical
suffer	O
Cope	O
rearrangements	O
at	O
temperatures	O
between	O
200	O
and	O
300	O
?ø	O
C	O
but	O
some	O
structural	O
changes	O
in	O
the	O
diene	B-Chemical
such	O
as	O
the	O
anionic	O
-	O
Cope	O
transformation	O
allows	O
the	O
reactions	O
to	O
happen	O
at	O
temperatures	O
below	O
0	O
?ø	O
C	O
[].	O
The	O
Cope	O
rearrangement	O
is	O
a	O
[	O
3	O
3	O
]-	O
sigmatropic	O
reaction	O
and	O
in	O
general	O
through	O
a	O
single	O
transition	O
state	O
(	O
TS	O
)	O
which	O
has	O
normally	O
a	O
chair	O
conformation	O
due	O
to	O
the	O
higher	O
energy	O
the	O
boat	O
conformation	O
[ƒ??].	O
In	O
this	O
mechanism	O
the	O
electron	O
density	O
the	O
TS	O
is	O
delocalized	O
into	O
the	O
six	O
carbon	B-Chemical
atoms	O
[ƒ??].	O
However	O
if	O
the	O
diene	B-Chemical
contains	O
free	O
radical	O
stabilizing	O
groups	O
this	O
mechanism	O
could	O
have	O
significant	O
contributions	O
from	O
mechanisms	O
that	O
involve	O
radical	O
species	O
[ƒ??].	O
Detailed	O
discussions	O
about	O
Cope	O
rearrangements	O
can	O
be	O
found	O
in	O
several	O
studies	O
and	O
reviews	O
that	O
have	O
been	O
published	O
previously	O
[ƒ??].	O
The	O
configuration	O
elemanes	B-Chemical
formed	O
via	O
a	O
Cope	O
rearrangement	O
from	O
germacranolides	B-Chemical
depends	O
the	O
configuration	O
the	O
most	O
stable	O
germacrane	B-Chemical
conformer	O
since	O
it	O
is	O
mainly	O
a	O
concerted	O
reaction	O
[].	O
It	O
is	O
accepted	O
that	O
the	O
conformers	O
that	O
normally	O
carry	O
a	O
Cope	O
rearrangement	O
are	O
the	O
that	O
have	O
crossed	O
double	O
bonds	O
as	O
they	O
can	O
generate	O
a	O
chair	O
TS	O
.	O
The	O
configuration	O
the	O
final	O
elemanolide	B-Chemical
is	O
also	O
affected	O
by	O
the	O
substituents	O
in	O
the	O
germacranolides	B-Chemical
the	O
pseudo	O
-	O
equatorial	O
position	O
is	O
preferred	O
the	O
pseudo	O
-	O
axial	O
position	O
[ƒ??].	O
These	O
are	O
the	O
factors	O
that	O
dictate	O
that	O
specific	O
germancranes	B-Chemical
will	O
rearrange	O
to	O
yield	O
potentially	O
two	O
elemanolide	B-Chemical
configurations	O
.	O
The	O
schkuriolide	B-Chemical
(	O
1	O
Scheme	O
1	O
)	O
is	O
a	O
sesquiterpene	B-Chemical
lactone	I-Chemical
specifically	O
a	O
(	B-Chemical
Z	I-Chemical
,	I-Chemical
E	I-Chemical
)-	I-Chemical
germacranolide	I-Chemical
named	O
melampolide	B-Chemical
that	O
coexists	O
in	O
the	O
same	O
natural	O
source	O
with	O
the	O
elemanschkuhriolide	B-Chemical
(	O
3	O
)	O
which	O
is	O
an	O
elemanolide	B-Chemical
with	O
a	O
stereochemistry	O
structurally	O
similar	O
to	O
1	O
(	O
C14?ñH5?ý	B-Chemical
).	O
In	O
to	O
know	O
if	O
1	O
and	O
3	O
have	O
biogenetic	O
relation	O
1	O
was	O
transformed	O
into	O
3	O
by	O
heating	O
1	O
for	O
10	O
minutes	O
at	O
200	O
?ø	O
C	O
.	O
This	O
suggests	O
that	O
1	O
is	O
a	O
biogenetic	O
precursor	O
3	O
[].	O
It	O
is	O
important	O
to	O
mention	O
that	O
1	O
suffers	O
a	O
hemiacetalization	O
in	O
addition	O
to	O
a	O
Cope	O
rearrangement	O
to	O
form	O
3	O
.	O
The	O
non	O
-	O
hemiacetaled	O
compound	O
3	O
was	O
found	O
in	O
neither	O
the	O
natural	O
source	O
nor	O
the	O
products	O
the	O
biomimetic	O
transformation	O
1	O
into	O
3	O
.	O
This	O
transformation	O
is	O
very	O
interesting	O
since	O
in	O
to	O
explain	O
the	O
stereochemistry	O
elemane	B-Chemical
3	O
a	O
boat	O
-	O
like	O
TS	O
is	O
necessary	O
(	O
path	O
M	O
Scheme	O
1	O
)	O
[ƒ??].	O
This	O
is	O
the	O
few	O
reported	O
cases	O
elemane	B-Chemical
ƒ??	O
s	O
biogenetic	O
formations	O
where	O
a	O
boat	O
TS	O
can	O
be	O
proposed	O
instead	O
the	O
normal	O
chair	O
TS	O
[ƒ??].	O
In	O
a	O
second	O
proposed	O
mechanism	O
for	O
the	O
transformation	O
1	O
into	O
3	O
the	O
(	B-Chemical
Z	I-Chemical
,	I-Chemical
E	I-Chemical
)-	I-Chemical
germacranolide	I-Chemical
isomerizes	O
into	O
(	B-Chemical
E	I-Chemical
,	I-Chemical
E	I-Chemical
)-	I-Chemical
germacranolide	I-Chemical
and	O
in	O
a	O
second	O
step	O
a	O
Cope	O
rearrangement	O
forms	O
the	O
elemane	B-Chemical
.	O
In	O
this	O
case	O
a	O
normal	O
chair	O
TS	O
is	O
proposed	O
to	O
generate	O
the	O
correct	O
elemane	B-Chemical
configuration	O
(	O
path	O
N	O
Scheme	O
1	O
)	O
[ƒ??].	O
It	O
is	O
possible	O
that	O
an	O
enzyme	O
is	O
responsible	O
to	O
allow	O
reactions	O
that	O
happen	O
in	O
the	O
flask	O
at	O
very	O
high	O
temperatures	O
in	O
two	O
ways	O
stabilizing	O
the	O
transition	O
state	O
destabilizing	O
the	O
ground	O
states	O
energy	O
the	O
reactants	O
.	O
An	O
antibody	O
-	O
catalyzed	O
Oxy	O
-	O
Cope	O
reaction	O
has	O
already	O
been	O
described	O
[]	O
as	O
well	O
as	O
a	O
proposed	O
reaction	O
mechanism	O
[].	O
In	O
the	O
study	O
presented	O
in	O
this	O
paper	O
we	O
performed	O
density	O
functional	O
theory	O
(	O
DFT	O
)	O
calculations	O
the	O
possible	O
mechanisms	O
for	O
the	O
transformation	O
1	O
into	O
3	O
to	O
elucidate	O
which	O
mechanism	O
is	O
more	O
likely	O
and	O
to	O
determine	O
if	O
the	O
Cope	O
TS	O
with	O
a	O
boat	O
conformation	O
during	O
the	O
transformation	O
is	O
energetically	O
favorable	O
.	O
The	O
study	O
will	O
also	O
help	O
to	O
understand	O
the	O
structural	O
factors	O
that	O
determine	O
the	O
energetic	O
evolution	O
germacranolides	B-Chemical
ƒ??	O
Cope	O
transformations	O
.	O
Biogenetic	O
hypothesis	O
for	O
the	O
transformation	O
schkuhriolide	B-Chemical
(	O
1	O
)	O
into	O
elemanschkuriolide	B-Chemical
(	O
3	O
).	O
Computational	O
methods	O
DFT	O
has	O
been	O
proved	O
to	O
be	O
a	O
good	O
method	O
for	O
the	O
study	O
reaction	O
mechanisms	O
natural	O
products	O
Of	O
Of	O
Org	O
Oxidation	O
One	O
Of	O
Oxygen	I-Chemical
Oxidative	O
Of	O
Or	O
Ontological	O
Oxidoreductases	O
Oxidative	O
Of	O
Oxidative	O
Of	O
Of	O
Oxidation	O
Oxidation	O
Only	O
Of	O
Oxidative	O
Of	O
Of	O
Of	O
O2	B-Chemical
Oxygen	B-Chemical
Oxidation	O
Of	O
Oxygen	I-Chemical
Of	O
Of	O
Only	O
Of	O
Other	O
Of	O
Organisms	O
Oxidative	O
Of	O
Oxidative	O
Of	O
Oxidative	O
Oxidative	O
Oxidation	O
Of	O
Of	O
Of	O
Oxidation	O
Of	O
Oxidation	O
Of	O
Overall	O
Oxidation	O
Of	O
Oxidative	O
Often	O
On	O
Or	O
Of	O
Of	O
Of	O
Of	O
Of	O
On	O
Oxidative	O
Of	O
Originating	O
Of	O
Oxidative	O
Of	O
Organelles	O
Oxidative	O
Of	O
Oxidative	O
Oxidative	O
Of	O
Of	O
Of	O
Oxidation	O
Of	O
Of	O
Oxidative	O
Of	O
On	O
Our	O
Of	O
Oxidative	O
Of	O
Of	O
Of	O
Of	O
Of	O
Oxido	O
Of	O
Oxidoreductases	O
Or	O
Oxidoreductases	O
Observations	O
On	O
Of	O
One	O
Oxidation	O
Oxido	O
Oxidative	O
Of	O
Of	O
Of	O
Open	O
Of	O
Oxidation	O
Of	O
Of	O
Of	O
Occurred	O
Oxidation	O
Oxidation	O
Oxidation	O
Of	O
Oxidation	O
Oxidation	O
Of	O
Over	O
Of	O
Observed	O
Of	O
Occurred	O
Oxidized	O
Of	O
Oxidized	O
Oxidized	O
Of	O
Oxidation	O
Other	O
Oxidized	O
Oxidation	O
Of	O
Of	O
Oxidations	O
Of	O
Oxidation	O
Oxidation	O
Of	O
Oxidized	O
Oxidation	O
Oxidized	O
Observed	O
Other	O
Oxidation	O
Oxidized	O
Of	O
Of	O
Oxidized	O
Oxidized	O
Of	O
Oxidized	O
Of	O
Oxidation	O
Oxidized	O
Oxidation	O
Of	O
Oxidations	O
Oxidation	O
Oxo	I-Chemical
Oxidized	O
Oxidatively	O
Oxidized	O
Oxidized	O
Oxidized	O
Of	O
Oxidative	O
Oxidation	O
Oxidation	O
Of	O
Oxidized	O
Or	O
Oxidizes	O
Oxidized	O
Of	O
Of	O
Of	O
Oxidation	O
Of	O
Of	O
Of	O
Oxidized	O
Of	O
Oxidized	O
Of	O
Of	O
Of	O
Of	O
Of	O
Oxidation	O
Oxidation	O
Oxidation	O
Only	O
Oxidation	O
Of	O
Oxidation	O
Oxidation	O
Oxidation	O
Of	O
Of	O
Of	O
Of	O
Observation	O
Of	O
Of	O
On	O
Of	O
Or	O
Of	O
Of	O
Or	O
Of	O
Oxidized	O
Of	O
Of	O
Open	O
Oxidative	O
On	O
One	O
Of	O
Oxidized	O
Our	O
Oxidized	O
Observed	O
Oxidation	O
Occurred	O
Our	O
Oxidized	O
Oxidation	O
Or	O
Of	O
Oxidized	O
Observations	O
Only	O
Oxidized	O
On	O
Of	O
Of	O
Or	O
Of	O
Oxidation	O
Of	O
Oxidized	O
Or	O
On	O
Of	O
Observations	O
Of	O
Oxidative	O
Of	O
Oxidative	O
Our	O
Oxidized	O
Oxidation	O
Of	O
Of	O
Of	O
Of	O
Oxidation	O
Oxidation	O
Of	O
Oxidation	O
Oxidation	O
Of	O
Of	O
Oxidative	O
Our	O
Overexpression	O
Oxidation	O
Of	O
Of	O
Of	O
Of	O
Of	O
On	O
Of	O
Of	O
Operated	O
Of	O
Of	O
Of	O
Oxidation	O
On	O
On	O
Of	O
Of	O
Orbitrap	O
Of	O
Of	O
Oxidation	O
Of	O
Or	O
Of	O
Open	O
Or	O
Of	O
Oxidation	O
Of	O
Of	O
Of	O
Of	O
Of	O
Oxidized	O
Of	O
Oxidized	O
Of	O
Of	O
Oxidized	O
Of	O
Of	O
Of	O
Of	O
On	O
Of	O
Of	O
Of	O
Or	O
On	O
On	O
Occurrence	O
On	O
Odyssey	O
On	O
Of	O
Oxidase	O
Of	O
Of	O
Our	O
Oxidative	O
Oxidative	O
Or	O
Of	O
Our	O
Of	O
Of	O
Of	O
Of	O
Oxidative	O
Oxidoreductases	O
Or	O
Or	O
Oxidation	O
Oxidoreductase	O
Of	O
Of	O
Oxidation	O
Oxidation	O
Only	O
Of	O
Of	O
Of	O
Of	O
Of	O
On	O
Orbitrap	O
Of	O
Original	O
Of	O
Oxidized	O
Of	O
Of	O
Oxidized	O
Of	O
Oxidized	O
Of	O
Oxidation	O
Of	O
Oxidation	O
Of	O
Of	O
Of	O
Oxidation	O
Of	O
Of	O
Oxidative	O
Oxidation	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Oxidized	O
Ox	O
Oxidation	O
Oxidized	O
Oxidation	O
Oxidation	O
Of	O
Of	O
On	O
Of	O
Of	O
On	O
Of	O
Of	O
Of	O
On	O
Of	O
One	O
Of	O
OR	O
Other	O
Of	O
Other	O
Of	O
Other	O
On	O
Of	O
On	O
Of	O
Of	O
Of	O
Of	O
On	O
Of	O
Of	O
Of	O
Of	O
Or	O
Of	O
Or	O
On	O
On	O
Of	O
Of	O
On	O
On	O
Of	O
Or	O
Of	O
Of	O
Or	O
On	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Or	O
Of	O
Of	O
Or	O
Order	O
Of	O
One	O
Of	O
Of	O
Originally	O
Of	O
Obtained	O
Of	O
Or	O
Of	O
Of	O
Of	O
Obtained	O
Or	O
Out	O
Of	O
Of	O
On	O
Obtained	O
Of	O
Of	O
Only	O
On	O
Outcomes	O
Obtained	O
Out	O
Of	O
Of	O
Of	O
Of	O
Objective	O
Of	O
Once	O
Or	O
Once	O
Of	O
Of	O
On	O
Of	O
On	O
Of	O
Only	O
Of	O
Observations	O
Or	O
Of	O
Of	O
On	O
Of	O
Of	O
Of	O
Osteoblasts	O
Of	O
Osteoblast	O
Of	O
Of	O
Of	O
Other	O
Onalespib	B-Chemical
Onalespib	B-Chemical
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Or	O
Of	O
Our	O
Osteoblasts	O
Of	O
Of	O
Or	O
Or	O
Of	O
Of	O
Of	O
Overexpressed	O
Of	O
Of	O
Of	O
One	O
Our	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Osteoblasts	O
Osteoclasts	O
Osteoblastic	O
Osteoclastic	O
Of	O
Osteoporosis	O
On	O
Osteoclast	O
Osteolytic	O
Of	O
Of	O
Of	O
On	O
Of	O
Of	O
Of	O
Osteoclast	O
Of	O
Osteotropic	O
Of	O
On	O
Other	O
Osteoblast	O
Of	O
Osteoblast	O
Osteoblast	O
Osteoblasts	O
Of	O
Osteoblasts	O
Of	O
Of	O
Of	O
Of	O
Osteoblasts	O
Osteoblast	O
Obtained	O
Onalespib	B-Chemical
Obtained	O
Obtained	O
Other	O
Obtained	O
Onalespib	B-Chemical
Of	O
Or	O
Or	O
Osteoblast	O
Of	O
Or	O
Osteoblast	O
Or	O
Or	O
Of	O
Or	O
Of	O
Or	O
Of	O
Of	O
Or	O
Of	O
Or	O
Of	O
Or	O
Of	O
Of	O
Of	O
Onalespib	B-Chemical
Of	O
Or	O
Omniscript	O
Or	O
Of	O
Of	O
Or	O
Of	O
Or	O
Of	O
Or	O
Of	O
Of	O
Onto	O
On	O
On	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
On	O
Of	O
Order	O
Of	O
Of	O
Osteoblast	O
Of	O
On	O
Of	O
Of	O
Observed	O
Of	O
On	O
Of	O
Of	O
On	O
Of	O
Or	O
Of	O
Or	O
Of	O
Of	O
Or	O
Of	O
Of	O
Of	O
Of	O
Of	O
Or	O
Of	O
Of	O
Or	O
Of	O
Or	O
Of	O
Of	O
Or	O
Of	O
Of	O
Of	O
Of	O
Onalespib	B-Chemical
Of	O
Of	O
Osteoblast	O
Onalespib	B-Chemical
On	O
Of	O
Onalespib	B-Chemical
Of	O
Or	O
Of	O
Order	O
Of	O
Or	O
Of	O
Or	O
Onalespib	B-Chemical
On	O
Of	O
Of	O
Of	O
Or	O
Of	O
Of	O
Onalespib	B-Chemical
Or	O
Of	O
Or	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
On	O
Of	O
Of	O
Osteoblasts	O
Osteoblast	O
Of	O
On	O
Of	O
Of	O
On	O
Of	O
Of	O
Or	O
On	O
Of	O
Of	O
Or	O
Of	O
Or	O
Or	O
Of	O
Of	O
Obtained	O
Of	O
Of	O
Of	O
On	O
Of	O
Our	O
Osteoblast	O
Order	O
Of	O
Of	O
Of	O
On	O
Of	O
On	O
Of	O
Of	O
Of	O
On	O
Onalespib	B-Chemical
Of	O
Of	O
Of	O
Or	O
Of	O
Of	O
Or	O
Or	O
Of	O
Or	O
Or	O
Of	O
Of	O
Obtained	O
Of	O
Of	O
Of	O
Of	O
On	O
Of	O
Of	O
Our	O
Osteoblast	O
Of	O
Of	O
Of	O
Of	O
On	O
Of	O
Of	O
Of	O
Of	O
Or	O
Or	O
On	O
Of	O
Of	O
Or	O
Of	O
Or	O
On	O
Of	O
Of	O
Of	O
Or	O
Of	O
Or	O
Or	O
Of	O
Of	O
Obtained	O
Of	O
Of	O
Obtained	O
Of	O
Of	O
Of	O
On	O
Of	O
Of	O
Osteoblast	O
Of	O
On	O
Of	O
Of	O
Of	O
On	O
Of	O
Of	O
On	O
Of	O
Or	O
Or	O
Or	O
Or	O
Of	O
Of	O
Obtained	O
Of	O
Of	O
Obtained	O
Of	O
Of	O
Of	O
Of	O
On	O
Of	O
Of	O
On	O
Of	O
Osteoblast	O
On	O
Our	O
Or	O
Of	O
Of	O
Of	O
On	O
Or	O
Of	O
Of	O
Or	O
Of	O
Of	O
Of	O
Or	O
Of	O
Or	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Osteoblast	O
Onalespib	B-Chemical
Of	O
Onalespib	B-Chemical
Of	O
On	O
On	O
Osteoblast	O
Of	O
Of	O
Osteoblasts	O
Of	O
Osteoblast	O
Of	O
Osteoblasts	O
Of	O
Osteoblast	O
Our	O
Of	O
Of	O
Or	O
Of	O
On	O
Onalespib	B-Chemical
Of	O
Of	O
Of	O
Or	O
Of	O
Of	O
Of	O
Of	O
Or	O
Of	O
Osteoblasts	O
Of	O
Osteoblast	O
Of	O
Of	O
On	O
Of	O
Of	O
Our	O
Osteoblast	O
Of	O
On	O
Order	O
Of	O
Of	O
On	O
Of	O
Of	O
Or	O
Of	O
Osteoblast	O
Of	O
Of	O
Osteoblasts	O
Of	O
Of	O
On	O
Osteoblast	O
Osteoclast	O
On	O
Osteotropic	O
Of	O
Of	O
Obtain	O
Of	O
Of	O
Osteoclasts	O
Osteoblasts	O
Osteoclastic	O
Of	O
Osteoblasts	O
Of	O
Osteoblast	O
Our	O
Osteoblasts	O
Of	O
Of	O
On	O
Of	O
Osteoblasts	O
Of	O
Osteoporosis	O
Of	O
On	O
Our	O
Osteoblasts	O
Of	O
On	O
Of	O
Of	O
Optimized	O
Off	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Oncogenic	O
Of	O
O	O
Of	O
Of	O
Of	O
On	O
Of	O
Of	O
Online	O
Of	O
Of	O
Other	O
Of	O
Of	O
Of	O
Org	O
Of	O
Or	O
Or	O
Or	O
Of	O
Or	O
On	O
Of	O
Of	O
Of	O
Overview	O
Or	O
Of	O
Of	O
Of	O
Of	O
Or	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Olefins	B-Chemical
Of	O
Of	O
Of	O
Or	O
Of	O
Olefins	B-Chemical
Of	O
Olefin	B-Chemical
Of	O
Of	O
Of	O
On	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Our	O
Of	O
Of	O
Of	O
Or	O
Of	O
Of	O
Obtained	O
Obtained	O
Other	O
Of	O
Of	O
Obtained	O
Organization	O
Organs	O
Of	O
Out	O
Oxygenated	O
Once	O
Of	O
Of	O
Of	O
Of	O
On	O
Overnight	O
Or	O
On	O
Or	O
Of	O
Or	O
Of	O
Or	O
Of	O
Or	O
Of	O
Of	O
Onto	O
Of	O
Or	O
Of	O
Overnight	O
Of	O
Of	O
Onto	O
Of	O
On	O
Of	O
Of	O
Of	O
Of	O
Or	O
Of	O
Of	O
Or	O
Of	O
Or	O
Or	O
Of	O
Of	O
Of	O
Or	O
Of	O
Of	O
On	O
Of	O
Or	O
Of	O
Of	O
Or	O
One	O
Of	O
Our	O
Of	O
On	O
Of	O
On	O
Of	O
Of	O
On	O
Oxide	I-Chemical
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
On	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Our	O
Of	O
Of	O
Of	O
Or	O
Of	O
Or	O
Occur	O
Of	O
Of	O
Of	O
Occur	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Observed	O
Only	O
Oxy	O
Occurs	O
Of	O
Of	O
Other	O
Of	O
Only	O
On	O
Of	O
Out	O
Ones	O
Of	O
Over	O
Only	O
One	O
Order	O
Of	O
Of	O
Of	O
Order	O
Of	O
One	O
Of	O
Of	O
Of	O
Or	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Of	O
Or	O
Occurs	O
Oxidative	O
Our	O
Ontological	O
Of	O
Oxidation	O
Oxidized	O
Only	O
Of	O
Oxidized	O
Oxidation	O
Oxidation	O
Oxidation	O
Of	O
Observations	O
Of	O
Of	O
Oxidation	O
Oxidized	O
Oxidized	O
Or	O
Or	O
Oncogenic	O
Of	O
Or	O
Osteosarcoma	O
Onalespib	B-Chemical
Or	O
Onalespib	B-Chemical
Onalespib	B-Chemical
Onalespib	B-Chemical
Onalespib	B-Chemical
Onalespib	B-Chemical
Onalespib	B-Chemical
Onalespib	B-Chemical
Onalespib	B-Chemical
Onalespib	B-Chemical
Onalespib	B-Chemical
Onalespib	B-Chemical
Our	O
Our	O
Our	O
Our	O
Of	O
One	O
Or	O
Of	O
Of	O
On	O
	
On	O
	
On	O
On	O
On	O
On	O
On	O
